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SUMMARY
Butylated Hydroxytoluene (BHT), an antioxidant used as a food additive, has been 
reported to increase the incidence of hepatocellular adenomas and carcinomas in rats 
in a two generation feeding study although no such increases have been found in 
several one generation studies.
BHT was fed to groups of 7 male and 50 female Wistar Albino rats (Fo generation) 
at doses of 0, 25, 100 or 500mg/kg body weight/ day prior to and throughout mating. 
Male pups from these matings (FI generation) were weaned onto diets of 0, 25, 100 
or 250mg/kg body weight/day BHT until 22 months post weaning. The effect BHT 
had on rat liver was examined both histologically and biochemically at various key 
stages in the animals development in an attempt to identify any changes which could 
account for the development of tumours.
The results showed that pups bom to and suckled by dams fed 500mg/kg body 
weight/day BHT showed a marked failure to gain weight throughout weaning and 
there is indirect biochemical evidence which suggests that during this period these 
animals had significantly lower growth hormone levels than controls. Consistently 
lighter body weights were noted in high dose BHT fed animals when compared to 
age-matched controls.
Biochemically, there were dose related increases in the induction of phase I and n  
metabolism enzymes throughout development, a similar spectmm being induced to 
that of Phenobarbitone. Histologically there was proliferation of smooth endoplasmic 
reticulum, centrilobular enlargement of the hepatocytes and an increase in the 
incidence of altered hepatic foci in animals at 22  months post weaning.
Biochemical and histological examination of the BHT fed dams indicated that 
metabohc stress was clearly caused by the dual demands of lactation and BHT 
metabolism and that good quality milk production was probably sacrificed in 
preference to maintaining the dams detoxification system. General malnourishment 
and choline deficiency have been shown to increase the incidence of cancer in 
laboratory animals.
Hence malnourishment of pups receiving high doses of BHT provides one possible 
explanation for the difference in cancer incidence between one and two generation 
studies.
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CHAPTER 1 
INTRODUCTION
Butylated hydroxytoluene, BHT (2,6,-bis(l,l,-dimethylethyl)-4-methyl phenol), has been 
reported to increase the incidence of liver tumours in a two generation rat study when fed at high 
concentrations in the diet. The dosing regimen was 25, 100, or 500 mg/kg body weight (B.wt.) 
to the FO generation and 25, 100, and 250 mg/kg B.wt. to the offspring, FI generation. A statis­
tically significant increase in hepatic adenomas and carcinomas was observed in the highest dose 
group. (Olsen et al 1986.) However no such carcinogenic effects have been found in one gener­
ation studies in rats, ( N.C.I, 1979, Hirose et al 1981, Williams et al 1990) although BHT has 
been shown to increase the incidence of lung cancer in mice in several independent studies, and 
increase the incidence of liver tumours in only one strain of mouse (C3H), when administered at 
doses of lOOmg/kg B.wt. or above. (Witschi et al 1978, Anon, 1978, Lindenschmidt et al 1986, 
Inai et al, 1988 ).
BHT is used as an antioxidant in the food industry to prolong the "freshness" o f many food­
stuffs. Therefore, it is obvious that large numbers of people will be consuming the compound on 
a daily basis. While the estimates of human intake from food have varied it is agreed that it is 
unlikely that the maximum combined intake of BHT and BHA (Butylated hydroxyanisole) the 
other widely used phenolic antioxidant, will exceed 0.25mg/kg B.wt. per day (Verhagen 1989). 
In the past some authorities have suggested that at these low doses, BHT may have a protective 
action, as seen in studies of chemically induced carcinogenesis (Reddy et al 1983, Williams et al 
1983, Cohen et al 1984, Maeura et al 1984). The results of Olsen and his colleagues, (1986), 
have raised questions about the possible risk to humans and has prompted an investigation into 
the safety and carcinogenic potential of BHT by the Joint Experts Committee for Food Additives 
(JECFA). The work to be presented in this thesis was designed to attempt to solve some of the 
questions.
Diagram 1. BHT.
BH T:
OH
(CH3) 5
CH
♦ nom enc la tu re :
Chemical Abstract Service Reg. No: 
names:
128-37-0
butylated hydroxytoluene
2.6-bis( 1,1 -dimethylethy I)-4-methylphenol
2 .6 -di-re/t-butyl-para-cresol 
butyl hydroxytoluene 
dibutylated hydroxytoluene 
di-rerr-butyl-para-cresol 
ortho,ortho'di-fm -butyl-para-cresol 
1,3-di-rerf-butyl-2-hydroxy-5- 
methylbenzene
3.5-di-rerr-butyl-4-hydroxytoluene
2.6-di-ferr-butyl-4-methylphenol 
4-methyl-2,6-di-rm-butylphenol 
dibunol
E 321
and numerous trade names
♦chem ical an d  physical data :
molecular weight: 
melting point: 
boiling point: 
state:
solubility:
♦use:
reg u la to ry  sta tus:
220.36 [C 15H 24O]
70 T
265 °C
white, crystalline solid 
practically insoluble in water 
soluble in many organic solvents
a n t io x id a n t fo r  fo o d , an im al feed, 
pharm aceuticals, food packaging materials, 
cosm etics, fat soluble vitam ins, synthetic 
rubber, plastics, gasoline, diesel fuel, etc... 
♦G RA S sta tu s  (US Food and D rug 
Administration);
♦temporary ADI o f 3 mg BHT/adult in EEC 
countries (Anonymous, 1987);
♦tem porary ADI o f 0-0.125 mg BHT/kg 
b o d y  w e ig h t  ( JE C F A , 1 9 8 6 ^  ) ; 
♦ p e rm itte d  as a food  a d d itiv e  in 
reportedly 40 countries.
1.2 Chemical Carcinogenesis
Any substance shown to be a hepatocarcinogen in animals must be suspected as having the 
potential to cause liver cancer in man. However, not all of the large number of agents identified 
as rodent hepatocarcinogens will necessarily be associated with human liver cancer because it is 
generally accepted that most animal models have only limited predictive value for human risk 
assessment with agents such as BHT (Grasso and Cramp ton 1972). Many factors affect the 
incidence of cancer in laboratory animals such as nutritional, hormonal and immunological 
status as well as dose and duration of chemical administration. There are, in addition, marked 
differences between the response of different species and even within strains of the same spe­
cies, for example, phénobarbital treatment of C3H mice resulted in an increase in liver tumours 
after 12 months, but no tumours were observed in the C57BL mouse treated at the same dose as 
the C3H strain for 18 months (Becker 1984). However these animal models allow some insight 
into the possible mechanisms of human carcinogenesis. Although it is a complex process, 
chemical carcinogenesis can be divided into three distinct stages termed initiation, promotion 
and progression and broadly speaking chemical carcinogens can be assigned to one o f two 
mechanistic groups i.e. genotoxic or non-genotoxic, only the genotoxics exhibiting all three 
stages clearly.
Diagram 2.
Schematic Representation of the Stages of Carcinogenesis.
Initiation P rom otion Progression Metastasis ;
G enetic
ONA d a m a g e  H y p erp las ia  instability Invasion
Genotoxic- Growth I actors Gene ampldicaiion
chemicals Hormones Loss ot normal oncogene allele
FladialkxVUV Non-genotoxx:- Suppressor gene loss
Viruses chemicals Chromosomal rea'taogements
Error-pfone- Additional mutations
ONA synthesis
1.2.1 Initiation
Initiation of hepatocarcinogenesis involves a genotoxic agent or its metabolite(s) binding direct­
ly to nucleophilic groups in DNA, RNA or proteins. This binding can result in the deletion of 
bases, the insertion of incorrect bases, (point mutations), increase in DNA synthesis/repair, 
chromosomal breaks or translocation of sections of one chromosome to another. This genetic
damage/mutation is then fixed within a particular cell population by several rounds of cell cy­
cling. If the mutation is detrimental to the cells’ viability it will not result in initiated cells but 
will cause the cells to die. However, if the alterations in the genes confer a selective advantage to 
that population then they have the potential for clonal expansion under the influence of one or 
more promoting agents. The genotoxic agent may be what is termed a complete carcinogen 
which not only initiates mutation but can promote and progress the cells to a tumour, while 
incomplete carcinogens require a promoting agent. At low doses complete carcinogens also 
require promotion if they are to display their carcinogenic potential. Many short term tests exist 
for the detection of genotoxins both in vivo and in vitro. As the details of these tests lie out with 
the scope of this thesis, a short list of the most frequently employed ones will be included.
Table 1.
1.Point mutation detection assays.
a. Ames Test (bacterial and yeast systems).
b. Sex linked recessive lethal test (non-mammalian eucaryotics).
c. Mouse lymphoma test.
d. Adult rat liver epithelial cells (mammalian cells in vitro)
e. Mouse specific-locus test (Germ cells in vivo ).
2. Chromosome aberrations
a. Chinese hamster ovary and lung cells in vitro.
b. Micronucleus test (mouse) and Bone marrow (rat).
3. DNA damage
a. Rec-assay (bacterial and yeast).
b. Sister chromatid exchange (mammalian cells in vitro)
c. Unscheduled DNA synthesis {in vitro and in vivo.)
(For a list of references the reader is referred to Bomhard et al 1992).
Studies of hepatic changes prior to tumour formation have shown that the earliest changes are 
focal and about the size of a liver lobule. These foci may consist of cells which stain heavily with 
eosin (eosinophilic foci) or with hadmatoxylin (basophilic), or they may be made up of clear 
cells (glycogen foci) or fat cells. Some of the foci may consist of large cells, others small cells, 
but the m ajority are normal in size. These foci are usually surrounded by normal adjacent 
parenchyma but in some cases the surrounding parenchyme is compressed and shows signs of 
p re ssu re  a trophy . W hen th is stage is reach ed  the foci arem ore a p p ro p ria te ly  ca lled  a 
nodule.(Grasso, personal communication).
The initiated preneoplastic lesions/ foci of cells may be detected immunohistochemically by 
virtue o f their increased or decreased expression of a number o f enzymes. For example the 
increased expression of the placental isozyme of glutathione S-transferase (GST-p) has been 
employed as a useful marker, (Moore et al 1987 and Satoh et al 1989) and histochemically and 
biochem ically by the enzyme g-glutam yltranspeptidase (gGT), (Hanausek et al 1991). It is 
generally accepted that more than one marker should be used in studies of hepatocarcinogenesis. 
Studies in mouse skin have indicated that initiated cells have many potential fates that may 
depend upon the type and extent of the genetic damage sustained (Shubik 1950). Similarily in 
the liver only a small fraction of such cells are capable of developing into altered hepatic foci 
(AHF) (Pitot,1989) .If the genetic damage is in the growth control genes (Proto-oncogenes) or in 
tumour suppressor genes, for example in the p53 gene, then these alterations would be sufficient 
to drive the normal cell along the route to malignancy. For example, the activation of ras proto­
oncogenes by many genotoxic carcinogens has been identified as playing an important initiating 
role in the development of many chemical-induced rodent tumours. (Anderson et al 1992). 
However, it is generally believed that several distinct mutations are required to transform  a 
normal cell to a frankly malignant one. Proto-oncogenes are known to be expressed during 
regulated growth, such as embryogenesis, wound healing and regeneration of damaged liver (as 
seen in partial hepatectomy) and in several cases have been identified with growth factors, their 
receptors or the intracellular proteins which transduce the signal from the plasma membrane to 
the nucleus. Diagram 3 shows the possible sites of oncogene activation.
Diagram 3.
Potential Sites of Oncogene Action
Reference: Alberts  at a l , Molecular Biology of the Cell .
grow th factors 
e.g. PDGF / sis
plasma m em brane
ras proteins 
e.g. H-ras
membrane-associated 
protein kinases 
e.g. src, C-kinase
grow th-factor
receptors
e.g. PDGF receptor, 
EG F receptor / erbB
cytoplasm ic protein
kinases
e.g. ra f
transcription regulators 
e.g. jun
DNA
GENE ACTIVATION
transcrip tion regulators 
e.g. foscell proliferation proteins
A ten ta tive  ou tlin e  ot 
th e  re la tio n sh ip s  of th e  m ajo r classes of 
p ro to -o n co g e n es  in th e  in trace llu la r 
co n tro l ne tw o rk  th ro u g h  w h ich  external 
s igna ls s tim u la te  cell p ro liferation . A 
sing le  rep re sen ta tiv e  p ro to -o n co g en e  is 
in d ic a te d  for each  class. .'\n a rro w  from 
A to B in d ica te s  th a t in  a norm al cell 
th e  acti\ ation  of A exerts its effect by 
activating  3 id irectly  o r  indirectly). The 
d iag ram  is b a se d  p a rtly  on  s tu d ies  of 
th e  m o lecu les  in cell-free system s an d  
p a rtly  on  s tu d ie s  of cells in w h ich  
p a r tic u la r  c o m p o n e n ts  are  activated  by 
in tro d u c in g  o n co g en es  o r  inactivated  by 
m ic ro in jec tin g  a p p ro p ria te  an tibod ies. 
N ote th a t each  of the  c lasses of 
reg u la to ry  m o lecu le s  h a s  m any  
m em ber's, so th a t e ac h  a rro w  in the  
d iag ram  p o ten tia lly  s ta n d s  for m any  
p aralle l a iro w s linking th e  individual 
m em b e rs  of o n e  c lass to th o se  of 
a n o th e r . M oreover, th e  m em b ers of a 
g iven c lass in  m an y  in s tan c es  can  
in te ra c t w ith  o n e  a n o th e r— for exam ple, 
by  m u tu a l phosphorylation— as well as 
w ith  the  m em b e rs  of th e  c lasses 
u p s tre a m  a n d  d o w n s tre a m  from  them . 
T h e  ex is ten ce  o f m u ltip le  paralle l 
in te rc o n n e c te d  p a th w ay s  p resu m ab ly  
h e lp s  to m ake th e  cell fail-safe, so th at a 
sing le  o n co g en ic  m u ta tio n  will no t 
no rm allv  suffice to tu rn  it in to  a can cer 
cell; bu t th is  com plex ity , a n d  th e  
p re se n c e  of feedback  loops, m akes the 
system  h a rd  to analyze  experim entally.
1.2.2.Promotion
Promotion has been defined as the reversible clonal expansion of initiated cells, and is normally 
associated with cellular hyperplasia. "Pure" promoters have very weak or no carcinogenic effect 
on their own, but markedly enhance tumour yield following administration of an initiator. They 
do not bind to DNA but produce their effects at the epigenetic level, hence many non-genotoxic 
carcinogens have been classed as and act as promoters. An increase in focal proliferation of 
hepatocytes is one of the characteristics seen in hepatocarcinogenesis. Phenotypically there is a 
decrease in canalicular adenosine triphosphatase (ATPase) and glucose 6 -phosphatase (G6Pase) 
both of which can be measured histochemically. The continued presence of at least a threshold 
level of the promoting agent has been shown to be necessary for the maintenance of promotion 
as removal has resulted in a decrease in the number of histochemically detectable AHF. (Hen- 
drich et al 1986). There are no short-term tests available for identifying potential non-genotoxic 
hepatocarcinogens, they are defined negatively as agents which increase the incidence of cancer 
in experimental animals but do not induce DNA repair or mutations. Promoting agents have 
diverse m echanism s o f action. Am ongst the many known prom oting agents are steroids 
(Ochs, 1986), phorbolesters, (Blumberg,1988, Schmidt and Hecker,1989), choline-deficient diets 
(Yokoyama et al 1985), peroxisome-proliferating agents (Rao et al 1987), dietary factors such as 
high fat diets, (Glauert et al 1991, M isslbeck et al 1984), and high levels o f dietary protein 
(Dunaif et al 1987). BHT has also been shown to enhance the development of AHF in rats treat­
ed with N-2-fluorenylacetamide (Maeura et al 1984) and hence has been termed a promoting 
agent. It shares, in common with phénobarbital and DDT, the ability to induce liver metabolic 
enzyme systems such as the mixed function oxidase system.( See section 2.3.1 BHT Toxicity: 
Liver). In most cases, these same chemicals co-administered with hepatocarcinogens decrease 
their effect because they induce phase II metabolism enzymes,leading to conjugation and inacti­
vation of the proximate carcinogenic metabolite. The reader is referred to section 2.3.1. Liver 
for a summary of phase I and II metabolism and the role of cytochrome P^^q (CYP450) activa­
tion in chemical carcinogenesis.
1.2.3. Progression
Progression is a phenomenon best characterised in human disease. For example in colo-rectal 
cancer, examination of "at risk" patients often all show benign intestinal polyps. If these are not 
removed then there is a significant risk of the patient developing malignant tumours whereas if 
they are removed the risk falls to that of patients with no polyps. Hence it would seem likely that 
the benign polyps could be influenced to progress to a malignant and life-threatening tumour. A 
similar progression appears to occur in rodent hepatocarcinogenesis. With weak liver carcino­
gens A.H.F. are slow growing, well differentiated and show little if any tendency to metastasise. 
More potent carcinogens produce tumours that are poorly differentiated, rapidly growing and 
rapidly metastatic. However, it is thought that these more "aggressive" tumours pass through a 
phase like those produced by weak carcinogens.
1.2.4 The role of persistent growth stimuli in carcinogenesis
In addition to proto-oncogenes and tumour suppressor genes, a third "element", growth factors, 
have been examined in relation to the control of tumour growth. In hepatocarcinogenesis an 
insulin-like growth factor (insulin-like growth factor II, IGF II) has been identified (Yang et al 
1991). Although IGF-II is normally highly expressed in the fetal liver, it is rapidly turned off 
shortly after birth, being present in the adult liver at low or undetectable levels (Soares et al 
1985). It has been shown to be highly expressed in chemically induced rat hepatocarcinogenesis 
(Uneo et al 1988), in the latter stages of liver carcinogenesis in four independent transgenic 
mouse lines (Schirm acher et al 1992) and also in many human hepatocellu lar carcinom as 
(Cariani et al 1988). Itsbelieved that IGF-II mediates its mitogenic effect through a receptor 
which has been shown to be linked to an intracellular G-protein signalling pathway (Okamoto et 
al 1990).
A second growth factor, which may play a role in hepatocarcinogenesis is transforming growth 
factor alpha (TGFa). This growth factor is structurally related to epidermal growth factor (EGF) 
and binds to the EGF receptor. In the normal rat liver TGFa is present at low levels and is 
thought to be one of the key factors in liver regeneration (Mead & Fausto 1989). The EGF recep­
tor is highly expressed in rodent liver and abundant and constitutive TGFa expression during 
hepatocarcinogenesis may establish a permanent auto-activation circuit. (Dunn & Hubbard, 
1984).Thus, if a chemical has the ability to bring about the re-expression of a normally quiescent 
gene encoding a growth factor, then the tissue in question could be sent into "auto-drive", thus 
persistently stimulating a tumour to grow. Regenerative hyperplasia and augmentative hepato­
megaly are two types of chemically induced hepatocyte proliferation which have been associated 
with carcinogenesis. Regenerative hyperplasia is triggered by chemicals that are toxic to hepato­
cytes and is associated with continuous loss of hepatic parenchyma. This leads to continual 
hepatocyte proliferation ( and, therefore, increased DNA synthesis), proportionate to the amount 
of hepatocyte loss. Thus a cycle of cell death and regeneration is established, which could in­
crease the number of altered hepatic foci present and hence lead to tumour formation. In aug­
mentative hepatomegaly the hepatic mass increases from normal to an additional 60-100% 
depending on the chemical and duration of exposure. An increase in hepatocyte number is also 
seen with chemicals that induce augmentative hepatomegaly (Michalopoulos et al 1987). Most 
have been shown to induce cytochrome P4 5 0  isozymes and increase the membranes o f the 
smooth endoplasmic reticulum. Phénobarbital exemplifies these compounds. Others of different 
structure but similar effects include the antiepileptic drug phenytoin, and the muscle relaxant 
diazepam. Another group is composed of compounds that induce peroxisome proliferation. All 
of these compounds strongly promote carcinogenesis in the liver (Michalopoulos 1991).
Having outlined the stages of carcinogenesis and briefly reviewing the mechanisms of hepato­
cyte proliferation, attention is now turned towards BHT. A review of the known toxicity of the 
compound is presented along with metabolism studies. Based on this information and the results 
of Olsen, the protocol to investigate the carcinogenic mechanism of BHT in the second genera­
tion animal is then proposed.
CHAPTER 2 
BHT TOXICITY
The following is a review of the data available on the toxicity/carcinogenicty of BHT at the time 
o f starting this research. It was hoped that this information would make clear the possible 
mechanism(s) of action of BHT in view of the study carried out by Olsen et al. One point that is 
clear is that the rat and mouse have very different responses to the carcinogenic action of BHT, 
the rat requiring exposure over two generations inorder to produce cancer.
2.1 Acute Toxicity
A number of oral LD50 tests and other acute toxicity tests have been carried out in hamsters, 
rabbits, guinea pigs, rats and mice of various strains and of both sexes. (McOmie et al 1948, 
Deichmann et al 1955, Karplyuk 1959,Ichikawa et al 1967, Anon 1973 and Bikbulatov 1976.) A 
typical example of one of these acute tests, carried out according to EEC guidelines, indicated 
that the LD50 in rats is greater than 2g/kg B.wt. a value which most investigators agreed with. 
(Hazleton 1988). There is very little variation in the LD50 value between species or sex.
Reports of human toxicity following oral exposure to high doses of BHT is limited. However 
from the data that is available it would appear that the effects are similar to those observed in 
experimental animals with human patients having the additional effect of a light headed "high" 
feeling.(Greenberg et al 1978 and Grogan 1986).
2.2 Irritation and Sensitisation
BHT has been administered to the eyes of rabbits as a 40% solution (Mcomie et al 1948), and 
applied to the skin of rabbits (Dooley 1963) and the skin of guinea pigs (M allette et al 1952, 
Deichmann et al 1955). The compound was found to be slightly irritating to the skin and eyes 
and not to cause skin sensitisation following patch-testing. Fifteen black male volunteers ap­
plied BHT at a concentration of 3% in an "innocuous proprietary cosmetic cream" twice daily to
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the skin for 7 weeks. At the end o f this period some of the patients had irritation of the skin. 
Mild irritation was also reported in 9/50 black men and women following 48hr patch tests with 
creams o f BHT at concentrations of 0.5 or 3%. Thus it would appear that repeated and pro­
longed skin contact with a cream of BHT may cause skin irritation. (Bentley et al 1974). Sensiti­
sation to BHT has been examined in several studies. In one study, patch tests using various 
potential allergens, including BHT, were conducted on patients presenting with skin problems. 
Out of 112 people exhibiting eczematous dermatitis only 3 gave a positive result when treated 
with 2% BHT in "petrolatum" while all 83 people patch tested with 5% BHT in ethanol gave 
negative results.(Roed-Petersen 1976). Seven cases of facial eczema were found to be caused by 
antioxidants in cosmetics or toiletries but only 1 out of these 7 gave a positive result when chal­
lenged with a 1% BHT in a petrolatum preparation. (White 1984). BHT has been applied to the 
back of volunteers for 48hrs as a diluted material. 71% of those studied gave a negative re­
sponse. A second challenge 14 days later did not change the "intensity" of the response (Malette 
et al 1952).Other studies have shown that BHT sensitisation may present itself as allergic reac­
tions of the skin and as allergic responses of the respiratory tract. (W eber 1979, Juhlin 1981, 
Hannuksela 1986 and Monteret-Vautrin 1986a & 1986b). These responses do not appear to be 
very common in the general population which is exposed to various amounts of BHT over long 
periods and therefore can be classed as idiosyncratic. Thus, BHT may be regarded as having a 
low sensitising potential in humans.
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2.3 Subchronic and Chronic Toxicity.
BHT has been found to cause liver enlargement and induce various hepatic enzymes. It has also 
been shown to cause thyroid hyperactivity in rats but not mice, while lung damage was only 
found in mice. There may also be some effects on the kidney and on blood clotting parameters. 
These will now be discussed in detail.
2.3.1 Liver
A.Gross Effects of BHT on the Liver
In all of the studies carried out to investigate the effect of BHT on the liver, the most consistent 
finding has been liver enlargement (irrespective of route of dosing). Gilbert et al,(1965), showed 
liver enlargement in female rats treated with 500mg/kg body weight BHT by stomach tube daily 
for 84 days and could demonstrate hepatomegaly by day 2 of dosing male rats with 125mg 
BHT/kg body weight/ day for 6  days. A similar effect was also reported in female mice also 
dosed by stomach tube for 18 days with 750 mg/kg body weight /day. A no effect level of 25 
mg/kg body weight/day was established in the rat. Feuer et al (1965) found similar effects in rats 
dosed by stomach tube with graded doses ranging from 50-500 mg/kg and showed that in 
comparison with known hepatotoxins, the hepatomegaly was readily reversible. In a long term 
feeding study to examine chemically induced liver enlargement in the rat, Crampton et al (1977), 
showed that dietary administration of BHT at 0.4% of the diet for 1 week increased the relative 
liver weight (RLW) of dosed animals over controls by 35%. Phenobarbitone at 0.25% in the diet 
had a similar effect on the R.L.W.(34% greater than controls). At 32 weeks of dosing with BHT, 
the R.L.W. was 50% greater than controls whilst at 30 days post cessation of dosing this value 
dropped to 95% of co n tro ls . The authors showed that after 7 days of this dosing regimen the 
hepatocytes of the centrilobular region were greatly enlarged. They concluded that, the observed 
hepatomegaly and associated induction of drug-metabolising enzymes, was a reversible adaptive 
response to administration of either BHT or Phenobarbitone and did not result in hepatic dam­
age.
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B. Histological Changes
Histological examination of the livers from rats treated with BHT at 0.4% in the diet for 1 week, 
showed centrilobular depression of glucose 6 -phosphate and accompanying increases in rela­
tive liver weight.(Crampton et al 1977). The enlarged cells showed an increase in the histologi­
cally determined levels of aniline hydroxylase but a normal pericanalicular distribution of lysos­
omal acid phosphatase was maintained through out the course of dosing. Powell et al (1986) 
showed that orogastric gavage of doses of BHT of 500mg/kg body weight/day for 28 days 
caused progressive periportal hepatocyte necrosis which was associated with proliferation of bile 
ducts, persistent fibrous and inflammatory cell reactions, hepatocyte hyperplasia and hepatocel­
lular and nuclear hypertrophy. As in the study of Crampton et al (1977), Powell et al also found 
that G6Pase was reduced.
C. Induction of the Smooth Endoplasmic Reticulum
Closely associated with the hepatomegaly reported in the previous studies was hypertrophy of 
the smooth endoplasmic reticulum (s.e.r.). Induction of the hepatic drug activating and detoxify­
ing enzymes located in the membranes of the s.e.r, in particular the mixed function oxidase 
system, was therefore also influenced by BHT administration. (Gilbert et al 1965& 1969, Gaunt 
et al 1965 , Crampton 1977 and Powell 1986).
D. Induction of Phase I and II Metabolism Enzymes
The major function of the liver is to make water insoluble endogenous and exogenous com­
pounds soluble, and thus facilitate their excretion. The liver achieves this by a two step process: 
firstly a hydroxyl group is inserted into the compound to be excreted and secondly the hydroxy- 
lated compound is conjugated with other hydrophilic compounds and then excreted. These two 
stages make up phase I and phase II metabolism. The mixed function oxidases are perhaps the 
most important example of the systems that are involved in phase I metabolism, and in particular 
the Cytochrome P4 5 QS (CYP450). The hepatic m.f.o.s have been shown to consist of cyto­
chrome P4 5 0 . (a haemoprotein), cytochrome reductase and lipid and play a central role in the
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oxidative metabolism of many endogenous steroids and fatty acids to more polar derivatives. (See 
diagram 4).
Diagram 4
Schematic representation of the Cytochrome P450 system.
(1) addition of substrate to the enzyme;
(2) donation of an electron;
(3) addition o f oxygen and rearrangement;
(4) donation of a second electron and loss of water.
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In addition to endogenous compounds, the microsomal P4 5 0 S can hydroxylate drugs and envi­
ronmental chemicals (Waxman 1988) thus leading to their deactivation and elimination via 
phase II metabolism. Phase II reactions generally result in detoxication of reactive intermediates 
by conjugation with glucuronic acid, glutathione, amino acids or sulphate. Some of the P 4 5 0 S 
have been isolated and characterised into families with specific substrates, some of which are 
highly specific, others displaying substrate overlap with different subfamilies. (loannides and 
Parke 1989). (Table 2 -adapted from Nebert et al 1991).
Table 2
N O M EN C LA TU R E OF SO M E O F THE M O RE IM PO R TA N T FO RM S O F CYTO CH RO M E P450
Systematic Trivial names Species Inducers M odel enzyme assays
lA l P448, c, (3NF-B rat PAHs, 3MC, ER O-dééthylation
P I, c, form 6 human TCDD BP hydroxylation
form 6 rabbit
PI mouse
IA2 P-448, d. rat isosafrole MR O-demethylation
P3, d, form 4 human phenacetin 0-dethyIation
L M j rabbit
P ^ æ mouse
2A1 a l,a ,3 ,U T -F rat ethylmorphine N -déméthylation
2A2 a2. RLM2 rat coumarin 7a-hydroxylation
2A6 P 450(l) human
281 b. P 8 -4 .P B -8 rat phenobarbitone PR 0-depeniylation
2 8 2 e,P B -5 ,P B -D rat Benzpheiamine N -déméthylation
2 84 LM rabbit Methoxycoumarin déméthylation
2 8 6 LM2 human
2C7 f rat phenobarbitone mephenytoin 4-hydroxylation
2C8 1, mp-12, mp-20 human mephenytoin N-dcmihylation
2C10 mp, mp-8 human
2C11 h, 16a, 2c, UT-A male rat
2C12 i, Isp , 2d, UT-I female rat
2D 6 dbl human - debrisoquine 4-hydroxylation
2E1 j human, rat ethanol. aniline hydroxylation
mouse isoniazid activation of nitrosamines
3a rabbit
3A1 pcnl rat glucocorticoids erythromycin N-demthylation
3A2 pcn2 rat nifedipine oxidase
3A4 hPCNl human cyclosporin oxidase
3A5 hPCN3 human
3A6 3c rabbit
4A1 P452 rat peroxisome laurate 12-hydroxylation
proliferators
481 lung P450 human
form 5 rat, rabbit
101 Ps putida
Abbreviations PAH ; polycyclic aromatic hydrocarbon; 3MC : 3-methylcholanthrene; 
TCDD : 2,4,6,8-tctrachlorodibenzodioxine; ER : cthoxyresorufin; BP : benzo(a)pyrene; 
MR : mcthoxyrcscrnfin; PR : pentoxyresorufin
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The P4 5 0  isozyme composition of the hepatic e.r. has been shown to vary between species and 
to be greatly affected by exposure to xenobiotics as well as to endogenous compounds. For 
example treatment of rats with 3-methylcholanthrene (3-MC) results in a marked increase in the 
activity of the cytochrome P 4 ^Ql family and in particular the A1 isoform. (Burke et al 1989). 
Treatment with phénobarbital however, results in the increased expression of the P4 5 0 2  family 
specifically the B1 isoenzyme.(Lubet et al 1985). Steroid hormones regulate the expression of 
both male and female specific forms and age-related forms,(Waxman 1984 & 1988, Peck et al 
1985, Yamazoe et al 1987, Lemonie et al 1988, Maenpaa et al 1993) whilst starvation (Imaoka et 
al 1990) and diabetes (Barnett et al 1993) also regulate the expression of different isoforms.
E. The Role of P450 Induction in Chemical Carcinogenesis
Whilst the primary role of the cytochrome P4 5 0S is the bioinactivation of chemicals, it has been 
shown that they are the major group of enzymes involved in the activation of a large number of 
chemical carcinogens to their proximate or ultimate carcinogenic/mutagenic form.(loannides and 
Parke 1987).
Diagram 5.
PHASC 1 
METABOLISM
phase 2
METABOLISM
E*cf«tlon
noo-hindered
o*y9cn* tio r*
C h e m ic a l — —  —  ~
h in d ered
oxygénation
conjoçations
Metabolites
Reactive 
Inter mediates
GSH, proteins, 
thiol cnzymca, OHA
C ovaU ot Binding 
T oxicity and C arcinogenicity
-h  C o n jo g a tcJ
OG TOXICA TION 
ACTIVATION
16
The CY Pl family of proteins,(specifically the CYPIA subfamily) has been identified as the 
principal m ediator with respect to the activation of the polycyclic aromatic hydrocarbons 
(PAHs) to their carcinogenic forms (loannides and Parke 1987), whilst the CYP2E family is 
associated with the activation of many nitrosamines (Garro et al 1981). Thus the metabolic fate 
of many chemicals may depend on constitutive levels of particular isozymes of CYP450 as well 
as their ability to induce a particular family.
F. Induction of Specific P450s by BHT
Gilbert et al (1965 and 1969) have shown that the oral administration of BHT at 500mg/kg body 
weight causes an increase in the activity of five hepatic microsomal activities, namely aniline 
hydroxylase, hexabarbitone oxidase, nitroanisole demethylase, codeine demethylase and amino- 
pyrine demethylase. Crampton et al (1977) also showed enhanced activities of ethylmorphine N- 
demethylase, aniline 4-hydroxylase, biphenyl 4-hydroxylase and NADPH-cytochrome c reduc­
tase one week after treatment with 0.4% BHT in the diet. He also showed that treatment with 
phenobarbitone induced a similar profile of isoenzymes but the induction was greater with 
phenobarbitone. Other workers e.g. Gaunt et al 1965a, 1965b, Feuer et al 1965, and 1969, 
Botham et al 1970, Saheb et al 1977 and Powell et al 1986 have all observed changes in the 
hepatic activating and detoxifying enzyme profiles, (see list below) the spectrum  of which 
would place BHT in the class of inducers that induce the CYP2B fam ily. Below are some 
examples of the activities reported to be effected by BHT administration.
References can be found in source of list i.e. Review of Toxicology, lonol CP, Shell Internation­
al, The Hague.
ACTIVITY
Aminopyrine demethylase 
Aniline hydroxylase 
Biphenyl 4-hych'oxylase 
Codeine demethylase 
Cytochrome P450 
Ethylmorphine N-demethylase 
Hexabarbitone oxidase 
NADPH-cytochrome c reductase 
p-Nitroanisole demethylase
EFFECT SPECIES
Increased Rat/Mouse
Increased Rat/Mouse
Increased Rat
Decreased Rat
Increased Rat/Mouse
Increased Rat
Increased Rat
Increased Rat
Increased Rat/Mouse
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2.3.2 Thyroid
Thyroid hyperactivity induced by a compound can be related to either a direct acting effect on 
the gland or an indirect action via a secondary organ such as the liver. The studies presented 
here, examine what effect dietary composition has on the uptake of iodine by the rat thyroid.
Male rats were fed various amounts of BHT in commercial or semi-synthetic diets at doses of 
500 parts per million (ppm) or 5000ppm for periods up to 90 days. The aim was to investigate 
the effect of BHT on iodine uptake by the thyroid.(Sondergaard 1982). It was found that rats 
receiving 5000ppm BHT had a significantly increased ^^^I uptake by the thyroid after 8 days on 
the diet compared to controls. This increased uptake fell with time but was still greater than 
controls at day 90.
The authors examined both a standard rodent diet and a semisynthetic diet supplemented with 
different amounts of radiolabelled Iodine and BHT in order to investigate how the composition 
of the diets influenced the effects of BHT on iodine uptake. The standard diet had an iodine 
content of 150ug/100g before supplement while the semisynthetic diet contained 12ug/100g. 5 
diets were examined.dl Semisynthetic diet with iodine supplement of 12ug/100g.(2) Semisynthet­
ic diet with supplement of 300ug iodine/1 OOg diet and 5000ppm BHT. (3). Semisynthetic diet, 
iodine supplement of 300ug iodine/1 OOg diet, no BHT. (4) Standard diet with no iodine supple­
ment and 5000ppm BHT.(5) Standard diet, no supplement of iodine, no BHT.
The authors found the ratio of radioactivity in the thyroid to radioactivity in serum was increased 
in rats receiving BHT and 300ug iodine in the diet. They also observed increases in the relative 
weights of liver and thyroid in both the 500 and the 5000 ppm BHT groups and an increase in 
the apparent biological half-life of thyroxine. These increases in organ weight would suggest an 
adaptive hypertrophy in response to the demands of BHT metabolism. It could be via a liver- 
thyroid axis, whereby the liver has increased its metabolising activities which would in turn feed 
back onto the thyroid to produce more thyroxine.The authors suggest that this increase indicated 
a delayed peripheral metabolism of thyroxine that regressed with time. However, they could not 
correlate this delayed metabolism with the thyroid changes induced by BHT in this study nor 
could they say what toxicological importance these findings had.
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2.3.3 Kidney
Studies examining BH T’s effects on the kidney have produced conflicting and more often 
inconclusive results. Meyer et al (1978) found marked differences in the incidence of nephropa­
thy between rats fed commercial chow and semisynthetic diets. Females of both strains fed 1% 
BHT in the semisynthetic diet showed a greater degree of damage than the males on the same 
diet. The kidney lesions were not found in animals receiving the unadulterated or BHT spiked 
chow. Pathologically the damage progressed from empty dilated tubules, mainly in the outer 
medullary zone, to hyperplastic epithelial cells with mild fibrosis and cell infiltration in the 
cortical zone. However, as lesions of the same type were observed in the groups fed only semi­
synthetic diets, these changes could not be definitely attributed to the action of BHT. A sex 
difference in the route of excretion of BHT and nephrocalcinosis, a common finding in female 
rats fed semisynthetic diet, has to be considered in connection with the observed kidney damage. 
The only noticeable differences between the chow and semisynthetic diets are : 1. lower protein 
content in the semisynthetic diet (s.s); 2.1ower vit.A , vit.D2 and vit.E in the s.s. diet; 3. 10 fold 
lower iron in the s.s. diet and 2 fold greater sodium in the s.s. diet. (Most of these values were 
well within the acceptable range of requirements for laboratory animals). The authors concluded, 
" the results ... stress the influence of the feed on the reaction of the animal to experimental 
procedures."
2.3.4 Lung
Experiments employing oral and intraperitoneal administration of BHT at doses ranging from 
0.004-2.5g/kg B.wt. have shown the mouse lung to be more sensitive to BHT than that of the rat. 
(Marino et al 1972, Witschi et al 1974, 1976 & 1978, Sahabs et al 1975, Adamson et al 1977, 
Larsen et al 1978,). Thickening of the interalvelor s?uta, inflam m ation, an increase in the 
numbers of pyknotic nuclei, hyperplasia, hypertrophy and a generalised disorganisation of cellu­
lar components were some of the major effects observed in the two strains of mouse used in 
these studies. The effects were apparently reversible . A threshold value for the effects was 
shown to be 0.04g per kg B.wt.
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Using several different strains of mice and i.p. doses of BHT upto 500mg/kg B.wt. the most 
consistently observed changes were a dose dependent increase in lung weight and increases in 
total DNA, RNA and protein levels. Mechanistically, it would appear that the toxicity of BHT 
in the mouse lung is due to a reactive metabolite rather than the parent compound. (Omaye et al 
1977, Kehier et al 1980 and Mizutani et al 1984). Administration of cysteine protected the lung 
from these toxic effects while treatments that reduced cellular glutathione levels enhanced it. 
Further studies indicated that the active metabolite was probably BHT-quinone-methide. (Mizu­
tani et al 1983). (See diagram 6 ).
D iagram  6. BHT-quinone-methide metabolite.
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2.3.5 Blood
Repeated oral administration of BHT in the diet at doses ranging from 436 to 876mg/kg B.wt. to 
rats, resulted in Vitamin K antagonism with increased excretion of vitamin K in the faeces. The 
activities of the vitamin K dependent clotting factors II, VII and X were markedly decreased as 
were platelet factor 3 and plasma prothrombin time in BHT fed rats.(Suzuki et al 1979,Taka- 
hashi et al 1981 ).This decrease in the activities of the clotting factors resulted in haemorrhagic 
lesions in many organs and haemorrhage into the various body cavities. Addition of phylloqui- 
none (vit.K) prevented death, haemorrhage and hypoprothrombinemia when administered at 
doses of 10mg/kg,i.p. ( Suzuki et al 1979 and Takahashi et al 1979). It was also shown that i.p. 
doses of Vitamin K^, K2  or Kg corrected the increased prothrombin time in rats previously fed 
diets containing 1.5% BHT. The authors concluded that the haemorrhagic action of BHT and its 
metabolites although due to Vitamin K antagonism, differed in mechanism from that caused by
20
dicoumarol, as the administration of Vit.K .2 Qj.3 could not overcome the prolonged prothrombin 
time in rats treated with 17mg/kg dicoumarol, while Vit.K^ could.(Suzuki et al 1979).
It has been suggested that BHT could act by inhibiting intestinal absorption of Vitamin K, re­
sulting in increased excretion of vit.K into the faeces. This would result in decreased Vit.K 
levels in the livers of rats. Alternatively, BHT could inhibit the uptake of Vit.K by the liver 
which would affect the synthesis and/or release of the clotting factors into the circulation. 
(Suzuki et al 1983). It is not yet clear which of these hypotheses is correct.
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CHAPTER 3
BHT and GENOTOXICITY DATA
3.1 Mutagenesis
The g en o to x ic  p o te n tia l o f BH T has been  ex am in ed  in in v itro  s tu d ie s  such as the 
Salmonella/microsome assay (Ames Test) using several strains of Salmonella tvphimuriium in 
the presence and absence of metabolic activation (Adamson et al 1977, Omaye et al 1977, Joner 
1977 and M izutani et al 1984). In simple terms this assay system employs bacteria that are 
phenotypically lacking the gene(s) for Histidine synthesis. The test examines the reversion to the 
wild type by plating the bacteria in culture media lacking histidine. Under normal conditions 
there is a spontaneous reversion rate back to the wild type of 200-300 bacteria per 10^. In the 
presence of a genotoxic chemical this rate is increased by at least two fold and should show a 
dose dependent response before the compound is classified as a mutagen. In all cases the results 
with BHT have been negative. Negative results have also been obtained in the standard Recom­
bination assay using Bacillus subtilis and no mutagenic activity was detected for BHT using 
Saccharomvces cerevisiae.(Anon 1975, Anon 1984,Kawachi et al 1980). In mammalian cells in 
culture, BHT gave negative results when used in a primary hepatocyte DNA repair assay system 
,in an adult rat HGPRT ( hypoxanthine-guanine phosphoribosyltransferase) mutation assay and 
did not cause any detectable chromosomal damage in Chinese hamster ovary cells. (Anon 1984). 
Two separate studies have shown BHT inhibited the excision repair of u.v. damaged human 
peripheral lymphocytes in culture (Mizutani et al 1983 ) and induced chromosome aberrations in 
human embryonic lung cells WI-38 (Anon 1975) at the highest dose used. The significance of 
these findings are unclear as all of the data was not reported.
The results of in vivo mutagenicity studies with BHT are somewhat less clearcut. BHT at Ig/kg 
B.wt. was given to male CD-I mice intraperitoneally prior to mating with virgin females. No 
dominant lethal mutations were observed. (Epstein et al 1968). Other in vivo studies using male 
Sprague-Dawley rats and BHT either given in single oral doses of 30, 900, or 14(X)mg/kg B.wt 
or continuously in the diet at concentrations of 400ppm, 1333ppm or 4000ppm for 10 weeks 
prior to mating, showed there were significant increases in the number of dead implants per
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pregnant female. This was found in the mid and high dose diet exposed animals, while no consist­
ent responses could be attributed to BHT when given in single oral doses. (Masubuchi et al 
1976, Anon 1972 & 1977). Chromosomal analysis of bone marrow cells harvested from mice 
and rats fed BHT at doses of 1.5% in the diet revealed no significant increase in chromosomal 
aberrations.(Masubuchi et al 1976). Thus the results of both in vitro and in vivo assay systems 
do not indicate that BHT is genotoxic at the doses employed. However, some concern over the 
"apparent" dominant lethal effects on spermatazoa reported by the above authors remains, even 
when others have not shown any statistically significant differences from control levels (Ep­
stein et al 1968 & Masubuchi et al 1976).
The authors of the study whereBHT was fed to male Sprague-Dawley rats prior to mating with 
non treated females , concluded that BHT may be a mutagen at 1333 and 4000ppm in the diet. 
(Anon, 1977).
3.2Teratogenesis
3.2.1 Rats
Early studies involving BHT administration to Norway Hooded rats at 0.1% or 0.5% for five 
months prior to mating found three out of thirty litters produced had a 10% incidence of anop- 
thalmic young. (Brown et al 1959). However, subsequent studies conducted in male Tuck 
Albino rats at doses of 750mg BHT/kg B.wt. for 70 days prior to mating with non dosed females 
showed no abnormal foetuses were born to these animals (Clegg 1965).The same authors also 
dosed 3 week old Porton strain specific pathogen free (s.p.f.) albino rats with 500mg BHT/kg 
B.wt./day for 7 weeks prior to mating and during gestation and a second group of the same strain 
dosed from week 7. In both groups the level of foetal abnormalities were below those observed 
in controls. It may be that the Norway Hooded strain are more sensitive than other strains used 
or it is more likely to be an improvement in animal husbandry since 1959 which has resulted in 
better genetic stock and overall animal health in the latter studies.
No teratogenic effects, including anophthalmia, were found in a multigeneration study conduct-
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ed in groups of male and female Sprague-Dawley rats fed diets containing 0.03, 0.1 or 0.3% BHT 
for 79 days. Two litters per generation for 3 generations were also fed on the same BHT contain­
ing diets but no positive teratogenic effects were found. (Greenberg et al 1978, Frawley et al 
1965a). A teratology study employing male and female W istar outbred S.P.F. rats, fed on a 
semi-synthetic diet containing BHT of 500mg/kg B.wt./day, was carried out by Meyer et al 
(1980). After 13 weeks the animals were mated. The litter size was reduced at 24hrs and half of 
each litter were crossfostered so that offspring of both treated and non-treated groups were 
nursed by treated and non-treated dams. The authors found that some of the developm ental 
stages were slightly delayed of the groups exposed to BHT both in utero and during lactation 
and pups nursed by treated dams exhibited hyperactivity during the first week of lactation. They 
concluded that these effects were indicators of a toxic rather than a teratogenic effect on the 
pups.
BHT has been shown to cross the placenta.(Shipp et al 1970). An i.p. dose of 150mg/kg B.wt. 
(^"^C) BHT was given to pregnant Charles River CD rats on day 10 of gestation. A rapid distri­
bution throughout the tissues showed a time course deposition. The highest levels of radioactivi­
ty being associated firstly with the body fat, later less radioactivity than found in the fat was seen 
in the liver, with kidney, muscle and finally blood, all having some trace of radioactivity. The 
level of radiolabelled BHT in the foetus at 2hrs post dosing of dams was 10.2mg/kg tissue. Thus 
it seems that BHT is transferred via the placenta. It is therefore possible that the neonate could 
be exposed to BHT at two very critical time points in terms of m.f.o. development, i.e. in utero 
via placental transfer and during weaning/ lactation in the dams, when BHT stored in the fat 
could be transferred to the pups via the milk. These are important times in the expression of 
constitutive enzymes and the presence of BHT could alter the spectrum of hepatic detoxifying 
enzymes and hence alter the toxicity of BHT. These findings will be considered later in the 
discussion section.
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3.2.2 Other Species
Teratology studies have been carried out in mice (Clegg et al 1965, Hiraga et al 1977, Anon 
1972b, Stokes et al 1974 and Johnson 1965), hamsters, rabbits (Anon 1972) and in monkeys 
(Allen et al 1976) but in none of the studies were teratogenic effects, like those reported in rats 
by Brown et al, reproduced. In a study by Stokes (Stokes et al 1974) to investigate the effect of 
BHT on behavioural development, groups of pregnant Swiss-Webster mice were fed a diet of
0.5% BHT during the entire gestational and lactational periods. The pups were fed a similar diet 
for 6  weeks post weaning. The authors found that pups from 4 dams exposed to BHT showed 
increased social and isolation-induced aggression, decreased sleeping and learning ability.
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CHAPTER 4 
BHT M ETABOLISM ,DISTRIBUTION and EXCRETION.
4.1 Non-Rodent Species.
4.1.1 Rabbit
The urinary excretion of BHT administered orally as either a single dose of 0.8g/kg B.wt. or five 
consecutive daily doses of 0.28 - 0.65g has been monitored in female New Zealand white rab­
bits. A number of metabolites were identified at the end of excretion, (the end of excretion was 
calculated to be 3-4 days after the last dose administered). The major urinary metabolites were 
the glucuronides of 3,5,-di-tert-buty 1-4-hydroxy benzoic acid and beta-(3-tert-butyl-2-hydroxy-5- 
methylphenol) beta, beta dimethyl ethanol and free 3,5,-di-tert-butyl-4-hydroxybenzoic acid 
(Dacre et al 1961). Other metabolites included 3,5,di-tert-butyl-4-hydroxybenzylalcohol, 3,5,-di- 
tert-butyl-4-hydroxy-benzoic acid and 4 ,4 ’-ethylene-bis(2,6-di-tertbutylphenol).(Akagi et al 
1962).
4.1.2 Chicken
(^^C)BHT was fed to male and female chicks in a 10% lard diet containing 0.02% BHT for 1,2 
or 10 weeks. (Frawley et al 1965b). The authors found that the highest levels of radioactivity 
were associated with fat, skin and the digestive organs, while in a second study by the same 
authors, the eggs from young adult laying hens fed 0 .0 2 % (^^C)BHT were examined for radio­
activity at days 1,3,7,14,21 & 28, and shown to accumulate the radioactivity with time. The 
authors did not identify any metabolites in this study.
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4.1.3 Monkey
Individual Rhesus monkeys were given (^"^C)BHT dissolved in corn oil at doses of 0.5,50 or 
500mg/kgB.wt. by gastric intubation. Faeces and urine were collected for 6  days. In a second 
part of this study 2 further monkeys were given a single oral dose of 0.5mg/kg B.wt. of radio­
labelled BHT followed by unlabelled BHT at the same dose for 6  days. They were then given a 
further oral dose of radiolabelled BHT at 0.5mg/kg B.wt.(Chang et al 1983). The authors found 
the excretion of radioactivity in the urine and faeces was not altered by the feeding of unlabelled 
BHT, urinary excretion was faster in male monkeys than in females and most of the oral dose 
was excreted within the first 24hrs post dosing. The major metabolite was identified by HPLC 
analysis as 3,5,-di-tert-butyl-4-hydroxy-benzoic acid and its conjugates.
4.1.4 Humans
Human metabolism of BHT has been monitored by several workers since the earliest reports 
appeared in 1966. In a study carried out by Gage, volunteers were given an oral dose of 
(^'^C)BHT which was labelled in the tert-butyl groups. W ithin 24hrs more than 50% of the 
radioactivity was eliminated in the urine. The author found that the rate of excretion fell rapidly 
after the first 24hrs and that enterohepatic circulation did not appear to occur. He identified the 
major metabolite as a glucuronide of an oxidation product of BHT. (Gage 1966).
Two male subjects were given an oral dose of 40mg of labelled and unlabelled BHT (0.5mg/kg 
B.wt). The radioactive label (^^C) was randomly bound to the methyl groups o f the two tert- 
butyl groups. One subject received 98 microcuries/40mg BHT while the other received 5 micro­
curies. Both men excreted approximately 50% of the dosed radioactivity in the urine in the first 
24hrs of the study, the rate of urinary elimination slowing down in both over the next few days. 
This route accounted for an estimated 75% of the total dose. The rate of faecal excretion was 
found to be about half of that of the urinary excretion rate. The authors calculated that approxi­
mately 2 0 % of the administered doses were retained in the body and were released with a half- 
life of 5 days (Daniel et al 1967). Controversy exists about the identity o f the major urinary 
metabolite that Daniel et al identified as an ester glucuronide of 4-carboxy-2-( 1 -carboxy-1 - 
methyl-ethyl)-6 -( 1 -formyl-1-methylethyl)phenol.(Daniel et al 1982). Holder et al (Holder et al
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1970) and Ryan (Ryan 1971) repeated the same study as Daniel but were unable to detect this 
metabolite in 8 male volunteers even using the same procedures. They identified the major 
urinary metabolite as 3,5-di-tert-butyl-4-hydroxy-benzoic acid and its ester conjugate. Daniel 
disagreed with this finding.
A third investigation carried out by Wiebe (Wiebe et al 1978), found the major urinary metabo­
lite in a single volunteer was indeed that which Daniel found with small amounts of the metabo­
lite that Holder and Ryan identified. However further analysis indicated that the metabolite was 
a dicarboxylic acid hemiacetal, 5-carboxy-7-(l-carboxy-l-m ethylethyl)-3,3-dim ethyl-2-hy- 
droxy-2,3-dihydrobenzofuran.
4.2 Rodent Species.
4.2.1 Mouse
In a study carried out by Matsuo (Matsuo et al 1984) using male Swiss-W ebster mice orally 
dosed with 400mg/kg B.wt (^^C) BHT, it was found that the radioactivity associated with BHT 
and/or its metabolites rapidly accumulated in the liver, lung and kidney. The time course for 
peak level measurement showed the kidney to be the first organ to be "targeted" at one hour post 
dosing with the liver at two hours and the lung at two and a half hours post dosing. Peak levels 
in the liver, at 2 hours post dosing, were 4-5 times higher than those peak levels in the lung or 
kidney but the rate of decrease of radioactivity was greater in the liver. Thus, by 10 days post 
administration all three organs had 3.5, 3.8 and 3.4 ug/BHT equivalent/g tissue, respectively. 
Similar findings were obtained using male and female BALB/c mice receiving a single oral dose 
of 55mg (^^C)BHT/kg B.wt. The radioactivity was associated with both the nuclear and cyto­
plasmic fractions of the tissues examined. The principal route of excretion was via the kidneys 
with up to 90% of the dose excreted in the urine within 120hrs. (Daugherty et al 1980). The 
authors were able to show that two pathways of metabolic oxidation existed in the male and 
female DDY/SLC mouse. 20mg or 500mg/kg B.wt (^^C) BHT were administered as oral doses. 
In the low dose group mouse (of both sexes), oxidation of one or both tertiary butyl groups was
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the major metabolic route while in the higher dose group oxidation of the para-methyl group to 
the carboxylic acid was the preferred route. The metabolite was excreted as the glucuronide. The 
authors concluded that the metabolic pathway via oxidation of the tertiary butyl groups was 
saturable at doses of 500mg/kg B.wt and this difference in metabolism could in part explain 
species differences in BHT toxicity.
4.2.2 Rat
The metabolic handling of BHT by male and female rats of various strains has been extensively 
studied. (C older et al 1962, Landom ery 1963 & 1967,D aniel et al 1965 and Tye et al 
1965).Daniel and co-workers found that both male and female Wistar rats excreted approximate­
ly 90% of the radioactivity given within 4 days and that females favoured urinary excretion , 
with 40% of the dose being eliminated by this route whilst males only removed 25% of the same 
dose by this path. Pre-loading the animals for 3 weeks with "cold" BHT then administering 
radioactive (^"^C)BHT led to a more rapid excretion in both sexes. The same authors also 
showed that males preferred biliary excretion of radio-labelled BHT when given as a single oral 
dose of 1.75mg/kg B.wt.(Daniel et al 1965). Similar findings confirming the sex differences in 
the route of excretion of (^"^C)BHT and or its metabolites have also been reported by the authors 
referenced earlier.
One study clearly demonstrated enterohepatic re-circulation was operative by introducing the 
bile from a rat dosed intravenously with (^^C)BHT into the duodenum of a second rat. By lOhrs 
approximately 30% of the radioactivity given to the first rat was recovered from the bile of the 
second rat. (Landomery et al 1967). As with other species studied a number of metabolites of 
BHT have been identified in the rat; the major biliary and urinary metabolites are 3,5-di-tert- 
butyl-4-hydroxybenzoic acid and its glucuronide.(Hathway et al 1966 and Daniel et al 1968). 
Studies have shown that BHT fed in the diet quickly accumulates in the body fat.(Tye et al 
1965). Male and female Alderley Park Wistar rats were fed diets containing either 1% BHT for 
50 days or 0.5% BHT for 35 days. At day 50, the 1% BHT fed animals had 49 ppm and 34 ppm 
in the abdominal fat in males and females respectively. 18 days of a BHT "free" diet reduced the 
BHT concentrations in fat to 3 ppm and 4.2 ppm. At day 35, animals receiving 0.5% BHT in the
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diet showed a similar profile to the above with 30ppm and 45ppm for males and females.
G ilbert and co. workers found that despite continued adm inistration of BHT at 500mg/kg 
B.wt./day to male and female Porton rats.(G ilbert et al 1965), once the initial peak value of 
265ppm BHT in the abdominal fat was reached, the level fell and plateaued out at lOOppm by 
day 7 of the study. There appeared to be a "threshold" level of 75mg/kg B.wt./day BHT where 
the levels in fat rose sharply in direct proportion to this dose but at values greater than this only a 
slow accumulation was observed. The significance of this accumulation in the fat is unclear. 
However, the accumulation of a compound in fat will always give cause for concern in multi­
generation studies. For example a fat soluble substance such as DDT can be rapidly mobilised 
during lactation from its fat storage site, passed into milk and taken in by the neonate at toxic 
doses. Whether this is important in the case of BHT remains uncertain.
The subcellular distribution of (^^C)BHT in male rat liver showed that the maximum radioactiv­
ity peaked at 6hrs, accounting for 5.1% of the dose (5mg/rat). (Nakagawa et al 1979)? Between 6 
and 12hrs post dosing the maximum level was reached in the serum, this decreased with time as 
in the liver. At 48hrs, 2% of the administered radioactivity was still associated with the liver. 
Subcellular fractionation of the livers also detected maximal radioactivity in the nuclear, heavy 
mitochondrial and supernatant fractions at 6 hrs post dosing, while the microsomal and light 
mitochondrial fractions reached a maximum at 12hrs. The r^te of decrease in radioactivity was 
slower in the microsomal fraction than that of the supernatant fraction (cytosol). The distribution 
of radioactivity between subcellular fractions seemed to parallel the distribution of glucose 6- 
phosphatase activity, possibly indicating an association with the e.r.
Further studies on the binding of BHT to the microsomal fraction of liver have shown that this 
binding is covalent and that pretreatment of the rats with phénobarbital (a known microsomal 
enzyme inducer), further increased the binding and that there was an interaction of 2 ,6-di-tertbu- 
tyl-4-m ethylene 2,5-cyclohexadienone (quinone methide) with the thiol group of cysteine. 
(Nakagawa et al 19795^1981 & 1983).
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In summary the metabolism of BHT in all species studied is as follows:
1. It is rapidly absorbed from the alimentary tract.
2. The major metabolite in most of the species studied, appears to be 3,5-di-tert-butyl-4-hy- 
droxybenzoic acid and its glucuronide conjugates.
3. Humans may produce a metabolite not found in other species, i.e. a dicarboxylic acid alde­
hyde or hemiacetal which is excreted in the urine. Small amounts of the BHT acid have also 
been found.
4. The mouse may have two pathways of metabolic oxidation; one saturable at low doses of 
BHT oxidises one or both tertiary butyl groups, the second oxidises the para-methyl group of 
BHT at doses of 500mg per kg body weight and above and produces the carboxylic acid.
5. Male rats prefer biliary excretion of BHT metabolites while females favour urinary.
6 . BHT accumulates in the body fat.
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Table 3
Metabolites of BHT Identified in Laboratory Animals.
Reference: Review of Toxicology, lonol CP, (BHT), Shell International, The Hague.
Metabolite species source
3,5-di-tert-butyl-4-hydroxybenzyl alcohol 
(BHT-CH OH)
rat
rat
liver 
bile, urine
3,5-di-tert-butyl-4-hydroxybenzaldehyde 
(B H T -C H O )
rat
rat
rat
rabbit
liver
urine
bile
urine
3,5-di-tert-butyl-4-hydroxybenzoic acid 
(B H T -C O O H )
rat
rat
rabbit
dog
monkey
liver
bile,
faeces
urine
faeces
urine
urine,
, urine
4 -hydroxy-4-me thyl- 2,6-di-tert-butyl 
2,5-cyclohexadienone (B H T -O H )
rat
mouse
liver 
urine 
liver, lung
2,6-di-tert-butyl-4-hydroperoxy-4 -methyl- 
2,5-cyclohexadienone (B H T -O O H )
rat urine
2,6-di-tert-butyl-4-methylene-2,5 - 
cyclohexadienone
mouse
rat
liver, 
liver
lung
3,5-di-tert-butyl-4-hydroxy-benzoyl-beta- 
D-glucosidutonic acid
rabbit
rat
monkey
urine 
bile, 
urine
urine
S-(3,5-di-tert-butyl-4-hydroxybenzyl)-N- 
acetylcystine
rat bile, urine
2,6-di-tert-butyl-4 (methyl-thio)methyl 
phenol
rat urine
2,6-di-tert-butyl-p-benzoquinone rat urine
2,6-di-tert-butyIhydroxyquinone rat urine
alpha-hydroxy-2,6-di-tert-butyl-p-cresol rabbit urine
4,4'-ethylene-bis(2,6-di-tert-butyl 
phenol)
rabbit
rat
urine
bile, urine
beta-(3-tert-butyl-2-hydroxy-5-methyl- 
phenyl-beta beta-dimethyl-ethyl-beta-D- 
glucosiduronic acid
rabbit urine
3,5 -di- tert-butyl-4-hydroxy-hippur ic acid rabbit urine
5-carboxy-7-(1-carboxy-1-methylethyl)- 
3,3-dimethyl-2-hydroxy-2,3-dihydro- 
benzofuran
monkey urine
2,6-di-tert-butyl-4-methylene-2,5-cyclo- rat bile
hexadiene-l-one (BHT-raethide)
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CHAPTER 5 
BHT AND CARCINOGENICITY
As is clear from the previous sections, pathological alterations in animals treated acutely or 
chronically with BHT, are only observed at very high doses. There are, however, indications that 
BHT may increase the incidence of some tumours and it is now necessary to examine these 
studies in some detail.
5.1 Mouse
The carcinogenic potential of BHT has been examined in various strains of mouse. Groups of 50 
male and 50 female B6C3F1 mice were fed BHT in the diet at concentrations of 200, 1000 or 
5000ppm for 96 weeks followed by a basal diet for 8 weeks. (Shirai et al 1982). There was no 
difference in the lifespan of the animals fed BHT and those that were not. Food consumption 
showed no differences between treated and controls throughout the 104 weeks of the study. Both 
males and females exposed to 5000ppm and lOOOppm and above, respectively, failed to gain 
weight at the same rate as control animals. BHT treatment had no effect on haematological and 
clinical chemistry parameters such as clotting time or cholesterol levels. However, many organs 
were observed to have tumours, in particular the lungs (adenoma and adenocarcinoma), liver 
(hepatocellular carcinoma), lymph nodes (malignant lymphoma) and spleen (malignant lym­
phoma). As these were found in both the treated and control populations, the authors concluded 
that no correlation between BHT treatment and tumour incidence could be shown. Lindensch- 
midt et al (1986) fed groups of 10 male and 10 female C3H mice diets containing 0.05% or
0.5% BHT for 10 months. Other groups were fed the BHT containing diet for 1 month and then 
control diet for 10 months. The authors noted only minor effects on body weight gain through­
out the study but found BHT treatment to cause a statistically significant increase in the inci­
dence of hepatocellular adenomas. The males showed a greater increase in adenoma incidence 
than the females and this was most pronounced in those males receiving 0.05% BHT in the diet. 
The authors could not find any difference in the incidence of lung tumours between treated and 
non-treated animals of either sex. Inconclusive evidence of BHT’s carcinogenic potential was
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found when groups of 12 or 24 male and female CFl mice were fed BHT for upto 2 years. The 
dosing regime was as follows: one group were fed a diet containing 0.1% BHT for 2 years; a 
second group were fed 0.1% for 4 weeks then 0.25% BHT for 100 weeks. a third group received 
BHT at 0.1% for 4 weeks followed by 0.5% for 100 weeks, while a fourth group were fed 0.1% 
for 8 weeks followed by 0.5% for 100 weeks. The authors found significant increases in the 
incidence o f lung tumours in all treated animals at termination of the studies.(67.4%, 53.2%, 
73.9% and 75% respectively. Control incidence was 46.8%). They also noted a dose related 
increase in benign ovarian tumours. Histological examination of the liver showed increases in 
centrilobular cytomegaly and karyomegaly in both sexes. The authors reported that these latter 
changes were not accompanied by any histopathological indications of tissue damage or any 
increase in the incidence of liver tumours (Brook and Hunt 1975). It was claimed that the results 
of this study were inconclusive as to the carcinogenic potential of BHT, due to the fact that 
aflatoxins B1 and B2 were found to be contaminants of the diet. Thus no clear correlation 
between BHT and the increased incidence of lung tumours in this strain of mouse can be made 
(Anon, 1978). An increase in the incidence of lung tumours was found in male BALB/c mice 
exposed to BHT in the diet at 0.75% for 16 months. This increase was noted at 18 months whilst 
animals exam ined after 12 months exposure to BHT showed no such increase. Also at 12 
months there was a 33% incidence of bile-duct hyperplasia in the liver of dosed animals com­
pared to controls but this change was not present in animals examined at 18 months, 2  months 
after dosing stopped. The liver did not show any sign of tumours (Clapp et al 1974). Groups of 
male and female B6C3F1 mice were given diets containing BHT at 3000 or 6000 ppm for 107- 
108 weeks. (National Cancer Institute 1979). In this study the males showed an increased inci­
dence in a number of non-neoplastic lesions, including hepatocytomegaly, peliosis, cytoplasmic 
vacuolation, hepatocellular degeneration and necrosis. The authors also noted an increased 
incidence in the num ber of areas of focal hepatocellular proliferation, which they termed 
"hepatocellular adenomas". This seemed to be greatest in the 3000ppm dose group. Female mice 
o f this strain, dosed at 3000 ppm, exhibited a significant increase in the incidence o f lung 
adenomas and alveolar/ bronchiolar carcinomas.
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In summary:
1.Male mice of B6C3F1 strain and C3H strain show an increased incidence in hepatocellular 
adenomas as a result of long-term exposure to BHT.
2.B ALB/c males do not show an increased incidence of liver tumours with BHT but do show an 
increase in lung tumours at 18 months.
3.C Fl strain of mice of either sex do not clearly show a correlation between BHT and an in­
crease in tumour incidence.
4.Female B6C3F1 show the lung to be the target organ, with a significant increase in the inci­
dence of adenomas and alveolar/bronchiolar carcinomas at doses of 3000ppm.
5.C3H females do not show as significant increases in hepatocellular adenomas as the males.
The lung response appeared to be strain related and may have resulted from  tissue damage 
produced in this organ by a metabolite of BHT.
5.2 Rat
The National Cancer Institute examined the possible carcinogenicity of BHT in groups of male 
and female F344 rats fed diets containing BHT at concentrations of 3000 or 6000 ppm for 105 
weeks. The authors found that non-neoplastic lesions were not induced in either sex of the F344 
rats nor was there an increase in the incidence of tumours. They did note a dose related focal 
histocytosis which was more prominent in the treated females than in the treated males.(National 
Cancer Institute 1979). A second long term feeding study was conducted in Wistar rats which 
were exposed to BHT in the diet at 0.25% or 1% for 104 weeks. (Hirose et al 1981). Both males 
and females receiving BHT showed a reduced body weight gain compared to control animals, 
even though there was no persistent reduction in mean food intake between the groups. The 
authors noted that the relative liver weights and the total blood cholesterol values were in­
creased in all rats receiving BHT, while increases in red cell count and gamma-glutamyl-transfer- 
ase activity in the liver were only found in the exposed females. Histopathological examination
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of the liver and the haematopoietic system did not show any significant changes between treated 
and control animals of either sex. Increases in the incidence of spontaneous tumours were found 
in the liver (hyperplastic nodule), pancreas (adenoma and carcinoma), mammary gland (fibr­
oadenoma) and adrenal glands (adenoma). The authors found these increases to be slight, not 
statistically significant and non-dose related. Females fed BHT at 0.25% were found to have a 
statistically significant increase in pituitary adenomas but this was not found in the high dose 
BHT females. In the multi generation study conducted by Olsen et al, (1986) FO generation male 
and female rats received semi synthetic diets containing BHT at 25, 100 or 500mg/kg b.wt./day 
for 13 weeks. After this time they were mated and the F I generation pups weaned onto diets 
containing BHT at 25, 100 and 250mg/kg b.wt./day. This second generation group of animals 
were maintained on these diets for 141-144 weeks when surviving animals were killed. 44% of 
males and 39% of females on the highest dose survived untill the end of the experiment com­
pared to 16% and 17% male and female control animals respectively. Liver tumours were re­
ported in rats more than 115 weeks old. The following were noted :
Males:
1 adenoma, 1 carcinoma : controls
1 adenoma : 25mg/kg b.wt.
5 adenomas, 1 carcinoma : lOOmg/kg b.wt.
18 adenomas, 8 carcinomas, 1 haemangiosarcoma : 250mg/kg b.wt.
Females:
2 adenomas : controls
3 adenomas : 25mg/kg b.wt.
5 adenomas : lOOmg/kg b.wt.
12 adenomas, 2 carcinomas : 250mg/kg b.wt.
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5.3 BHT - ITS PROTECTIVE ROLE IN CHEMICALLY INDUCED CANCER 
The anticarcinogenic properties of this synthetic phenolic antioxidant were discovered by 
Wattenberg (1972). He showed that BHT and BHA inhibited polycyclic aromatic hydrocarbon- 
induced forestomach tumours in mice and mammary tumours in rats, when fed in the diet at 
5000 ppm. Other workers have also shown this inhibitory effect,(with doses o f 5000 ppm or 
above) against a number of chemical carcinogens( Williams, 1992). At these high levels, phenol­
ic antioxidants are inducers of carcinogen biotransformation systems and there is considerable 
evidence that their anticarcinogenic effects at these doses are due to a blocking action resulting 
from increased carcinogen detoxification (Williams, 1992 and W attenberg, 1985). Williams 
examined the anticarcinogenic effects of BHT and BHA at low doses, which may be more rele­
vant to cancer prevention in humans where the A.D.I. for BHT is 0.5mg/kg body weight per day. 
He found that concurrent feeding of 300 ppm of BHT with 200 ppm of acetylaminofluorene 
(AAF), produced a dose dependent reduction in the numbers of altered foci in male F344 rats. In 
a second experiment AAF was fed at 50 ppm and BHT at doses as low as 100 ppm for upto 76 
weeks to male F344 rats. By the end of the study AAF fed alone resulted in a 100% incidence 
of liver neoplasms, but simultaneous feeding of BHT inhibited the induction in a dose related 
manner. The author concluded that at this low dose BHT may have caused the inhibition by 
trapping reactive metabolites.
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5.4 AIMS OF WORK
Before an outline of the aims of the work is given, it is worth noting what problems have been 
posed as a result of Olsen’s work.
Firstly, from a safety point of view, the question is raised as to how real the risks of tumour 
development are in man especially as exposure will be mulitigenerational?
Secondly, can the results of mice carcinogenicity studies be disregarded on the grounds that they 
are a species of animal with a high degree of sensitivity to carcinogens? Some have been special­
ly crossbred with strains that carry a high genetic burden of spontaneously developing tumours.
Thus, the aim of this work was two fold i.e.
1.To follow the experimental design outlined by Olsen et al (1986) to reevaluate the hepatocar- 
cinogenic action of BHT.
2 .T0  characterise the hepatic changes in both the Dams and FI generation pups inorder to identi­
fy a possible mechanism of action of BHT which would account for its carcinogenic response. If 
BHT causes changes in a lifetime study what are they and how could these alterations predispose 
the second generation animal to cancer whilst having no such apparent carcinogenic effect in the 
first generation animal.
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CHAPTER 6 
MATERIALS and METHODS 
6.1 Test Material
Butylated hydroxytoluene (BHT) of defined purity (99.96%) and composition was provided by 
Bayer AG (Germany).
6.2 Other Chemicals
Pentobarbital (SAGATAL) was from May and Baker Ltd.
NADPH, Bovine Serum Albumin (BSA), Glucose 6 -phosphate, l-Chloro-2,4-dinitro- 
benzene, (CDNB), 5,5’dithio-bis-2-nitro-benzoic acid (DTNB), reduced Glutathione,Glutathione 
Reductase and 5-Bromo-2-Deoxyuridine were from Sigma Chemical Co.,Dorset.(UK) 
7-ethoxyresorufin, 7-pentoxyresorufin and resorufm were from Molecular Probes,
Oregon (USA).
7- H-styrene oxide was obtained from Amersham (UK).
T^ Kits were from the Kodak Co. (UK).
Mini-Osmotic Pumps were from Charles River Ltd.
Antibodies to the various P4 5 Q isoenzymes were kindley donated by Prof. Gordon Gibson and 
Dr. Costas loanides. School of Biological Sciences, Surrey University, Dr C.R Wolfe, Depart­
ment of Biochemistry, I.C.R.F. Lab., University of Edinburgh and Dr D. Koop, School of 
Medicine, Clevland, Ohio, U.S.A.
Peroxidase-linked second antibodies (to the various P450 antibodies) were obtained from the 
Sigma Chemical Co., U.K.
"Thrombotest" kit from Nycomed, Birmingham, U.K.
All other compounds of analytical grade were obtained from British Drug Houses (BDH) or the 
Aldrich Chemical Co.
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6.3 Rodent Diet
A standard rodent breeding (CRM) and a standard rodent maintenance diet (RMM) were pur­
chased from SDS, Manea, Cambridge, UK. Manufacturers analysis of the unadulterated CRM 
diet gives a crude oil content of 2.4%, a crude protein content of 17.9% and a combined thiol 
amino acid (cysteine + methionine) content of 5.9g per kg diet. The quoted analysis of the RMM 
diet gives a crude oil content of 2.1%, a crude protein content of 14.6% and a combined thiol 
amino acid content of 0.5g per kg diet. The RMM diet has been specifically designed for long 
term studies such as this one and formulated to minimise renal stress and obesity.
6.3.1 Diet Preparation and Analysis for BHT
Prior to incorporation into the rodent diet, the BHT was finely ground in an atmosphere of nitro­
gen, to prevent oxidation by atmospheric oxygen. A new batch of diet was prepared every two 
weeks with the concentration of BHT being adjusted according to the body weights of the 
animals in each dose group (See below) and their food consumption. The diet was analysed on 
the day of mixing (day 0) and then at day 14 following storage at 4°C, to check the homogeneity 
and stability of BHT in the diet. This analysis was carried out in this way in the initial stages 
only. After the FI generation reached maturity the diet was analysed once every three months.
6.4 Animals and Dietary Administration of BHT
6.4.1 Animals.
Virgin male and female W istar albino rats, purchased from Bantin and Kingman Ltd.(Hull 
U.K.), and of defined microbiological status were used in both the current study and an earlier 
aborted one. Male rats were approximately eight weeks of age [250g body weight] and females 
were four weeks of age [60g body weight]. All animals were examined upon receipt and any 
showing signs of ill-health or injury were rejected. The maximum tolerated body weight varia­
tion for each sex was +/- 2 0 % of the mean weight.
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6.4.2 Randomisation and Acclimatisation
The animals were randomly assigned to treatment groups and weighed. All animals were al­
lowed to acclimatise for three weeks and were housed in polypropylene cages with sterilised 
sawdust. The temperature was maintained at 20° +/- 3° and humidity in the range of 30-70%. 
Lighting was artificial, with a 12h light/12h dark cycle. They were allowed unrestricted access to 
tap water and to a standard rodent breeding diet. Average food consumption for each sex and 
group were monitored.
6.4.3 Dose Groups - FO Generation
The doses for both an earlier aborted study and the definitive study were chosen as a result of the 
findings from: 1. a dose ranging study carried out by both supervisors of this study (See Appen­
dix 1) and 2. following doses used by Olsen et al 1986 and were as follows :
Group A : CRM diet only (Control)
Group B : CRM diet containing 25mg/kg body weight BHT (Low)
Group C : CRM diet containing lOOmg/kg body weight BHT (Mid)
Group D : CRM diet containing 500mg/kg body weight BHT (High)
6.4.4 Mating Schedule.
During the three week period of compound administration each male rat was allowed access to 3 
virgin females who were not part of the main study as virgin male rats do not mate readily with 
virgin females. Mating "proper" consisted of one male rat being transferred to a cage of 8 fe­
males of the same treatment group. Since male and female rats were receiving different amounts 
of BHT according to their body weights, it was necessary to remove the diet pots from the cages
during the 15 hour mating period. Upon confirm ation of pregnancy ( i.e. palpation of the
abdomen for confirmation of implantation sites, by an experienced worker) the female was 
housed singly and maintained on a diet containing BHT at the same concentration as that admin­
istered immediately prior to confirmation of pregnancy. After 21 days, the males, and any non­
pregnant females were removed from the study. Groups B and C as defined above, were termi­
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nated without autopsy. The remaining females formed part of a study which examined the 
hepatic differences between pregnant and non-pregnant females fed either control diets or 
BHT diets at 500mg/kg body weight. These diets had been administered for the same length 
of time to each group. A further group of animals, which had been pregnant and had 
received either control diet or BHT in the diet at a nominal 500mg/kg body weight/day prior 
to and through out mating, pregnancy and weaning, were given control diets for 14 days after 
the end of weaning. Those animals that had been fed BHT in the diet and then fed control 
diet for 14 days were termed the "reversed" group and their livers were examined 
biochemically to investigate whether any changes caused by the feeding of BHT and or 
pregnancy were reversible or permanent.
It should be noted that two identical studies were conducted and that the results from the 
second study (the definitive study) are presented and discussed in great detail in this thesis. 
Where differences between both studies were found these have been discussed. This earlier 
study is referred to as either the "first" study or "the earlier terminated study".
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6.5 STUDY DESIGN-BHT EXPOSURE 
STUDIES ON THE Fo GENERATION.
1.Males.
No biochemical or histopathological examinations were carried out on the males of this study. 
M ales from the dose ranging study (Appendix 1) had been exam ined and showed hepatic 
changes similar to those reported by other workers.( Hinton, R.H. and Price, S.C., personal 
communication).
2. Females.
Those females that became pregnant were either sacrificed after 20 days gestation or sacrificed 
after weaning (21 days post partum). Sections of liver were taken from those dams sacrificed at 
day 2 0  of gestation and were examined by light microscopy.
As outlined above some of the females in both the control and test groups failed to become 
pregnant. Four non-pregnant females from the control group and four non-pregnant females 
from the group receiving 500mg/kg body weight BHT per day, were age matched with control 
and BHT treated females that had under gone pregnancy and lactation. Twenty-one days after 
giving birth the dams and the nulliparus females were given an overdose of pentobarbital, the 
livers removed, homogenised and subjected to differential ultracentrifugation to obtain micros­
omal fractions. Biochemical analysis was carried out as described in 6.6.3. Sections of the liver 
were taken for both light and electron microscope examination and also for measurement of 
nuclear size alterations.(Results not presented).
STUDIES ON THE FI GENERATION.
Time point 1 : In Utero Exposure
On the 19th or 20th day of gestation, 5 female rats from each dose group were anaethetised and 
the pups delivered by Caesarian section. The following examinations were performed :
1. A count of the num ber of im plantation sites and resorption sites was made as was the 
number and weight of foetuses.
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2. The weights of the maternal livers were recorded and sections were taken for light 
microscopy.
3. Sections of four foetal livers/dam were taken for both light and electron microscopy 
(See 6.6.2)
4. The livers of four foetuses/dam were pooled, homogenised, fractionated and analysed bio­
chemically as described in 6.7
Time point 2 : In Utero and During Lactation Exposure
Four to six days after littering the pups were examined, weighed and the litter number either 
increased or reduced where possible to a maximum of 8 , leaving the maximum number of males 
in each litter. Cross fostering of males was done within the same dose group. Twenty one days 
post-partum, five dams and their litters were chosen randomly form each dose group and killed. 
The following examinations were carried out on male pups :
1.Terminal body and liver weights were recorded.
2.Sections of the livers, kidneys, adrenals and thyroids were taken for light microscopy.
3.Sections of the liver of one pup/dam/dose group were taken for electron microscopy. 
4.Subcellular fractionation of livers was carried out prior to biochemical analysis (See 6.7)
Dose Groups - FI Generation.
In both studies the remaining male pups were divided into five groups which were sacrificed at 
various sampling times post weaning. Tables 4a and 4b shows how these experimental groups 
were set up for 1. the terminated study (table 4a ) and 2. the definitive study (table 4b) from 
which most of the results to presented have been taken from.
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Tables 4a and 4b : Protocol of Experimental Sampling Times.
f  The numbers o f animals studied at each time point were as follow s*:
Table 4a Dose Group mg/kg bw/day
25 100 250 or 
500
Notes
Sam ple Tim es 
[1] 20  days 5 
gestation
Pregnant 
fe in kes &  
foetuses
[2] 21 days 5 
after delivery 20
5
20
5
20
5
20
Mothers
Pups
[3] 4  weeks 15 
after weaning
15 15 15 Male pups
[4] 6  months 15 
after weaiting
15 15 15 Male pups
[5] 11 months 15 
after weaning
15 15 15 Male pups
[6] 16 months 10 
after weaning
11 9 10 Male pups
[7] Termination 12 11 11 9 Male pups
The numbers o f  animals studied at each time point were as follows*:
Dose Group 0 
mg/kg bw/day
25 100 250 or 
500
Notes
Sample Times.
[1] 20 days 5 
gestation
5 5 5 Pregnant 
females & 
foetuses
[2] 21 days 5 
after delivery 20
5
20
5
20
5
20
Mothers
Pups
[3] 4 weeks 5 
after weaning
5 5 . . 5 Male pups
[4] 6 months 5 
after weaning
5 5 4+ Male pups
[5] 11 months^ 10 
after weaning (10)
10
(8)
10
(8)
10
(10)
Male pups
[6] 16 months^ 10 
after weaning (10)
10
(9)
10
(9)
15
(13)
Male pups
[7] 22 months^ 18 
after weaning (10) 
Termination
19
(13)
19
(11)
25
(19)
Male pups
* Animals were allocated randomly to groups intended for killing at time points 3 to 6  a: 
weaning. Any adjustments to these groups were made only after consultation with the 
Sponsor.
a Due to a number of unscheduled deaths the number o f animals-cülJed arc found in ( ).
+ One animal died following pump insertion.
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All groups, except the "high" dose group, were fed diets containig BHT at the same levels as 
their parents. The "high " dose was reduced to 250mg BHT/kg body weight as adverse effects on 
the kidney at the higher dose were reported (Meyer et al 1978). This is identical to the dosing 
regimen followed by Olsen et al 1986 and are as follows:
Group A : RMM diet only (Control group)
Group B : RMM diet containing 25mg/kg body weight BHT (Low)
Group C : RMM diet containing lOOmg/kg body weight BHT (Mid)
Group D : RMM diet containing 250mg/kg body weight BHT (High)
Time point 3 : In Utero, D uring Lactation & 1 month post weaning
Five rats from each dose group were given an overdose of pentabarbitone (Sagatal) four weeks 
after weaning (approximately 7 weeks old) at which time the following examinations were car­
ried out :
1. The terminal body and liver weights were recorded
2. Sections of livers, kidneys, adrenals and thyroids from all animals were fixed for L.M.
3. Samples from the livers of all animals were fixed for electron microscope examination.(E.M.).
4. Biochemical analysis was carried out as described in section 6.6.3, after preparation of the 
various liver fractions as outlined in 6.6.3.1.
Time point 4 : In Utero, During Lactation & 6 months post weaning
Six months after weaning five rats per dose group were killed and examinations similar to time 
point 3 were carried out.
Time point 5 : In Utero, During Lactation & 11 months postweaning
10 rats per dose group were examined histologically and biochemically as outlined above in time 
point 3.
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Time point 6 : In Utero, During Lactation & 16 months postweaning
The same procedure as above was carried out at this time point with the exception that the
number of animals in the high dose group was increased to 15. (See Table 4b).
Cell proliferation was measured by the insertion of mini osmotic pumps containing 5-Bromo-2- 
Deoxyuridine, into the back of the necks of the animals. This differed from the first study were 
^H-Thymidine was injected into the animals 24 hours prior to termination.
Time Point 7: Termination of Study
Those animals surviving until 22 months post weaning ( 2 year old rats) were treated in the same 
manner as outlined above. A minimum of 10 animals per dose group were used for biochemical 
analysis. Cell proliferation was measured as outlined above.
* It should be noted that the first study was terminated between time points 6  and 7 due to a 
malfunction in the temperature control mechanism which resulted in the death of many of the 
animals from over heating. It was felt that those animals that survived these excessive tempera­
tures, ( >30^c) could not give reliable results.
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6.6 STUDIES CARRIED OUT AT EACH TIME POINT.
6.6.1 Gross Observations
All animals were examined carefully for signs of ill health every day. W eekly body weights 
were recorded from the time of birth onwards for the FI generation as it had been carried out for 
the Fo generation. Daily food consumption of each dose group was calculated. From time point 
5 onwards the animals were closely observed for tumor development and were palpated monthly 
from time point 6 . At each autopsy, all animals were examined upon opening for any organs 
showing abnormalities. Terminal body weights and liver weights were recorded.
6.6.2 Pathology
The reader is referred to the appendix section for the methods of sample preparation for light and 
electron microscopy and immunohistochemistry. The following is a brief summary of both 
methods.
6.6.2.1 Preparation of Tissues for Light Microscopy
At autopsy all samples were placed in 10% neutral buffered formalin, pH 7.4 and left in this 
fixative for one week. The tissues were then dehydrated and embedded as described in Appendix 
2 , prior to being stained with haematoxylin and eosin.
6.6.2.2. Preparation of Tissues for Electron Microscopy
At autopsy sections of liver and thyroid were placed in 4% gluteraldehyde in O.IM cacodylate 
buffer: HNOg, pH 7.4 for 4-6 hours. The samples were then washed and counterfixed in 2% 
osmic acid /O.IM cacodylate: HNOg, pH 7.4 and dehydrated through graded alcohols and pro­
pylene oxid prior to embedding in EPON 812. Details of the procedure have been given else­
where ( Mann et al, 1985).
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6.6.2.3. Preparation of Unfixed Frozen Tissue for 
Immunohistochemistry *
At autopsy sections of liver from the median lobe were cut into small cubes and rapidly frozen in 
hexane which was cooled to a temperature of -80°c by immersion in a Cardice/ethanol "bath". 
When required the sections were removed from a -80°c freezer and cut in a cryostat, transferred 
to slides and stained as required for the particular enzyme activity of interest. ( See Appendix 3 
for preparation of unfixed samples).
6.6.2.4 Histochemistry *
Immunohistochemical staining of the liver sections was carried out to identify the following 
enzymes :
1. Glucose 6 -phosphatase
2. gamma-Glutamyl Transpeptidase 
(See Appendix 3 for both methods)
6.6.2.5 Measurement of Cell Proliferation *
Unscheduled DNA synthesis was measured as an indicator of cell proliferation by monitoring 
the incorporation of 5-Bromo-2-Deoxyuridine into DNA. Mini osmotic pumps were filled with 
200ul of a 250mg/10ml solution of BrDU in NaHCOg buffer. The pumps were then inserted into 
the back of the neck area of an anaesthetised rat. (See Appendix 4). After autopsy the samples 
were processed as detailed in Appendix 4 and labelled nuclei counted using the Quantimet 
(image analyser) to identify areas of incorporation of BrDU. (See Appendix 4 for method).
* These techniques were not carried out by the writer personally.
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6.6.3. Biochemistry
6.6.3.1 Preparation of Large Particulate Fraction , Cytosols 
and Microsomes from Liver Homogenate.
The preparation of organelle fractions from liver homogenates is achieved by differential ultra­
centrifugation. Following homogenisation of the liver in a volume of 20mM Tris-HCl/ 250mM 
sucrose buffer pH 7.4, such that 5ml of homogenate contains Ig of liver, the sample is diluted 
1:1 with buffer and spun at lOOOOg for 15 min. This produces the large particulate fraction and 
a supernatant (S9) which is recentrifuged at an equivalent of 105,000g for 1 hour. The superna­
tant from this spin is the cytosolic fraction which can be poured off leaving the microsomal 
pellet, highly enriched in endoplasmic reticulum. The pellet is resuspend in a small volume of 
buffer containing 20mM Tris HCl/ 250mM sucrose/1.15% Potassium Chloride, pH 7.4, then 
topped up and spun as above. Following this "washing" the resultant pellet is resuspended in a 
small volume of buffer containing 20mM Tris HCl/ 250mM sucrose/ 5.4mM disodium ethylene 
diamine tetra-acetic acid ( EDTA), pH 7.4 then stored in small aliquots at -80^C.
(See flow diagram 7).
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DIAGRAM 7. STAGES IN THE PREPARATION OF HEPATIC MICROSOMES.
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Microsomal Pellet -^D iscard SUPERNATANT
Resuspend
I
Microsomal Pelle^(Store at either -20°C
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Enzymes Used as Indicators of Hepatotoxicity 
6.Ô.3.2 Glucose 6 -phosphatase
Glucose 6 -phosphate is broken down by glucose 6 -phosphatase in the liver to yield glucose and 
inorganic phosphate. (The inorganic phosphate can be measured using an autoanalyser). A 1/40 
dilution o f the homogenate fraction is added to a volume of buffer containing 0.03M 3,3 di- 
methylglutaric acid, 0.025M disodium ethylene diamine tetra-acetic acid and 0.3M Na-h tartrate, 
pH 6.5. with 0.2M sodium hydroxide. The reaction is initiated in test samples by the addition of
0.05M glucose 6 -phosphate substrate while a series of blanks , reagent blank, substrate blank 
and tissue blank are treated in the same manner as samples. Incubation at 37^C for a period 
between 20 mins and 2hrs is terminated by the addition of ice-cold 6% Trichloroacetic acid. 
Centrifugation of the samples is required prior to estimation of inorganic phosphate using an 
autoanalyser (see below).This is based on the method of Hinton et al (1970) as adapted by 
Prospero et al (1973).
1.Determination of inorganic phosphate using an autoanalyser.
The phosphate released by a wide range of liver phosphatase enzymes is estimated by its reac­
tion with ammonium molybdate followed by reduction of the resulting phospho-molybdate 
complex with ascorbic acid to form molybdenum blue. The absorbance o f this complex is 
measured at 721nm (red end of spectrum). The autoanalyser manifold essentially mixes the 
correct amounts of molybdate reagent, ascorbic acid and water. ( Diagram 8 ). A series of phos­
phate standards is run prior to test samples and is used to construct a standard curve. This is an 
adaptation of the procedure of Lowry and Lopez, (1946) by Marzban and Hinton 1970).
6.6.3.S Total, Cytosolic and Microsomal Protein Content
The estimation of protein content of a sample is based on that of Lowry et al (1951). It was 
adapted for use on an autoanalyser by Schuel et al (1968) and Hinton et al (1972). (See diagram 
9). An appropriate dilution of a particular liver fraction is firstly digested with NaOH and then 
mixed with "Lowry buffer" containing sodium hydroxide, and sodium hydrogen carbonate. A 
1% copper sulphate solution and a 2 % sodium potassium tartrate solution are mixed 1:1:10  with 
water, while a 1:2 solution of Folin Ciocalteu’s reagent is also mixed in. A set of protein stand­
ards ranging between 0.01 to 2mg/ml BSA is used to construct a standard curve.
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DiagranA&toanalyser Manifold for Estimation of
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Air
ESTIMATION OF PROTEIN USING AN AUTO ANALYSER  
Diagram 9
Flow Rate 
0.6m/min
NaOH Low Sensitivity______
[0.66N]
[1. ON] High Sensit_iyltry _ _ 
SAMPLE Low Sensitivity
1 . 6
T 7 T
0.23
_High _Sen_sitiyij:y l._2__________
Bubble suppressor----------------------------
AIR
LOWRY BUFFER-
COPPER TARTRATE-
FOLIN REAGENT-
WASH
I- - - - - - - - - -
REPUMP
»
I
1------
- 2 . 0
1 . 6 -
1 . 6
1 . 6
" 0 . 6
• 1 . 2
SC'VvAA-W'A/-
1 . 6 ^  WASH CUP
WASTE
COLORIMETER
720nm
ONE COIL IN
OIL BATH
at 37°C.
SC
SC
DC
D(
Sample rate 1 MIN } SET ON SAMPLER
Wash
}
36 S e c s .  }
DC = Double Coil 
SC = Single Coil
54
6.6.3.4 Total Glutathione
Both the reduced form (GSH) and the oxidised form (GSSG) of glutathione are present in the 
cytosolic fraction of liver homogenate. The method developed by Brehe and B irch,(1963) is 
based on the enzymatic redox cycling of GSH, coupled to the reduction of Ellmans reagent 
containing 5,5’dithio-bis(2-nitrobenzoic acid) (DTNB) and is specific for total free glutathione. 
The rate of cycling and hence the reduction of DTNB is linearly related to the glutathione 
concentration. The formation of TNB, the reduced form of DTNB is followed spectrophotomet- 
rically at 412nm.
NADPH
NADP
GSSG 2TNB
2GSH DTNB
1ml of Ellmans reagent i.e.l50m M  sodium phosphate buffer, 15mM (EDTA), 0.3mM DTNB 
and 0.04% w/v Bovine Serum Albumin,(BSA) pH7.2 1ml of 50mM Im idazole-HCl buffer 
containing ImM  EDTA and 0.02% w/v BSA, pH 7.2 and 30ul of 2mM NADPH and lOul of 
lOU/ml glutathione reductase. The reaction is initiated by the addition of 1ml of either a GSH 
standard or a sample, diluted 1/50 with ice cold O.OIM HCl. These are mixed in the cuvette and 
the change in absorbance is followed 25°c. A standard curve of GSH ranging from 0 to 25 uM 
is prepared using O.OIM HCl as the diluent.
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Microsomal Enzymes
6.6.3.5 Glutathione S-Transferase
The cytosolic glutathione s-transferase group of enzymes catalyse the conjugation of many 
xenobiotics possessing an electrophilic centre with reduced glutathione, l-chloro-2 ,4-dinitro­
benzene is the prefered model substrate as it is active with all the major transferases. The reac­
tion is performed at the pH at which the nonenzymatic reaction is minimal. ImM glutathione and 
ImM l-chloro-2,4-dinitrobenzene in O.IM potassium phosphate buffer, pH 6.5 are placed in a 
spectrophotometer cuvette at 25^c. 5ul of liver cytosol is added and the increase in absorbance at 
340nm is measured. (Boyland et al 1969)
6.6.3.6 Total cytochrome P450
The total cytochrome P 4 5 Q (CYP450) content of an hepatic microsomal fraction can be meas­
ured by virtue of the fact that the reduced carbon monoxide adduct gives a difference spectrum 
with a peak at 450nm.( Omura and Sato, 1964). A 1/10 dilution of a microsomal fraction with 
6 6 mM Tris-HCl buffer, pH 7.4 is reduced by sodium dithionite crystals. This is scanned be­
tween 500 and 400nm to obtain a corrected baseline. Carbon monoxide is bubbled through the 
sample cuvette, this binds to the reduced cytochrome and on rescanning of the sample, gives a 
peak at 450nm. The height of this peak is the difference between A490-450nm and can be used 
in the following equation to calculate the concentration of P 4 5 0  present: A=ECL A=peak 
height, E=Molar Extn co-efficient=91mM cm '^, L=path length =lcm  and C= unknown conc.
6.63.1 Ethoxyresorufin O-deethylase
The 0-deethylation of ethoxyresorufin to resorufin is catalysed exclusively by the P450 I family 
of the mixed function oxidases and particularly the A1 isoenzyme.(Guengerich et al (1982), 
Phillipson et al (1984) and Burke et al 1974, 1977 & 1983.) 20ul of 50uM ethoxyresorufin is 
incubated at 37°C in the presence of lOul of microsomal fraction (20mg/ml), O.IM Tris HCl 
buffer, pH 7.4, and 20ul of 20mM NADPH to initiate the reaction. The formation of the pink 
resorufin product can be followed with time by the increase in fluorescence. (Excitation 
550nm/Emission 582nm)
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6.6.3.8 Pentoxyresorufin 0-depentylase
The O-depentylation of pentoxyresorufin to resorufin is a diagnostic assay for the phenobarbital- 
inducible forms of cytochrome P 4 5 0  ie. the CYP2B familly. (Lubet et al 1985). 5ul of ImM 
pentoxyresorufin is incubated in the presence of lOul of microsomal fraction (20mg/ml), O.IM 
Tris HCl buffer, pH 7.4 and 20ul of 20mM NADPH. The product formed at 37°C is monitored 
by the increase in fluorescence with time.(Exctinction 550nm/ Emission 582nm)
6.6.3.9 Ethylmorphine N-demethylase
Ethylmorphine is a substrate of the microsomal CYP3A subfamily. lOmM Ethylmorphine is 
incubated at 37°C with 50mM phosphate buffer, pH 7.25, 150mM MgCl2 , 1% NaHCog and a 
20mg/ml microsomal suspension. The reaction is initiated by the addition of lOmM NADPH and 
terminated after 10 mins at 37®c by the addition of ice cold 12.5% TCA. The ethylmorphine 
undergoes N-demethylation resulting in the formation of formaldehyde the concentration of 
which can be measured by incubating the supernatant from the above incubate with Nash re­
agent at 58°C for lOmins. (Nash et al 1953). (Nash reagent is made up of ammonium acetate, 
acetyl acetone and glacial acetic acid. The stoichiometry between formaldehyde formation and 
ethylmorphine N-demethylation is assumed to be 1:1. (Lu et al 1972).
6.6.3.10 Benzphetamine N-Demethylase
Benzphetamine is a substrate for the major phénobarbital inducible P450 (CYP2B sub family) 
and may also be associated with the CYP2C subfamily ( Lemoine et al 1988). 15mM Benzphet- 
amine-HCl is incubated with 50mM phosphate buffer, pH 7.25, 150mM MgCl2 , 1% NaHCOg 
and 25uls of a 20mg/ml microsomal suspension. The reaction is initiated in the tests only bythe 
addition of 40mM NADPH and terminated after lOmins at 37^c by the addition of ice cold 15% 
TCA. Blanks and a series of formaldehyde standards are also set up. The rate of formation of 
formaldehyde is monitored by incubating the supernatant from the tests and blanks with Nash 
reagent at 58^c for 10 mins. ( Nash reagent : 180ml 16.67% ammonium acetate, 0.4ml acetyl 
acetone, pH6  with glacial acetic acid.) The values for test-blank absorbance at 412nm are read 
from the standard curve. Activity = nmoles/min/mg of microsomal protein.
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6.6.3.11 Epoxide Hydrolase
7-^H-styrene oxide is converted by microsomal epoxide hydrolase to the product 7-^H-styrene 
glycol. Unreacted styrene oxide is extracted into petroleum ether and discarded. The styrene 
glycol formed is extracted into ethyl-acetate and the amount of radioactivity present in an aliquot 
of the extract is determined. (Oesch et al 1971). 50ul of a microsomal suspension (20mg/ml), 
230ul of water and 0.1ml of 0.5M Tris-HCl buffer, pH 9.0 are incubated at 37°C. The reaction is 
initiated by the addition of 20ul of radiolabelled styrene oxide, (activity = 1.31uCi/mg) then 
incubated at 37°C for a further 5 mins. The reaction is terminated by addition of 9ml of petrole­
um ether and tumble mixing for 10 mins. The aqueous phase is removed by rapid freezing at -80 
°C, after which the upper organic layer is poured off.The aqueous phase is thawed, then a fur­
ther 9ml of petroleum ether is added and the procedure repeated. 2ml of ethyl acetate is added to 
the aqueous phase followed by a tumble mix for lOmins. 0.5ml of the ethyl acetate layer is 
added to 4.5ml of scintillant and counted on a scintillation counter. A set of heat denatured 
microsomes is used as blanks.
Calculation:
Epoxide hydrolase activity (nmol/min/mg protein)
= (dpm of sample - dpm of blank) x 4
mg protein/incubate x 5 x specific activity of styrene oxide(dpm/nmol)
where the specific activity of styrene oxide solution 
= dpm/2 0 ul
800(nmol of styrene oxide/2 0 ul)
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Thyroid and Clotting Time
6.6.3.12 Thyroxine (Time Points 6 and 7).
Thyroxine (T4) is measured in serum using the commercially avaiable AMERLEX-M T4 RIA 
KIT from the Kodak company. This radioimmunoassay depends on the competition between 
thyroxine in the serum and ^^^I-thyroxine for a limited number of binding sites on a T4 specific 
antibody. The proportion of the ^^^I-thyroxine bound to the antibody is inversely related to the 
concentration of the thyroxine in the serum. Separation of the antibody-bound fraction is effect­
ed by centrifugation of the Amerlex-M suspension , followed by décantation of the supernatant.
1By measuring the proportion of ^^'^I-thyroxine bound in the presence of reference standard sera 
containing various known amounts of T4, the concentration of T4 present in unknown samples 
can be interpolated.
6.6.3.13 Thrombotest
The determination of the clotting time of rat blood using the commercially available "Thrombot­
est" kit is based on the method of Hjort et al 1961. Essentially the method is as follows:
1ml of whole blood is added to citrated test tubes and gently mixed. lOul of this is then added to 
a test tube containing the "Thrombotest " solution which is incubated at 37°C and a stop watch 
is started. After 20 seconds the tube is tilted at 5 second intervals and observed for clotting. The 
end point is taken to be when the mixture is seen to gel and not flow down the tube.
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Cytochrome P 45 0  Isoform Identification
6.6.3.14 Gel Electrophoresis
A mixture of heat denatured proteins can be separated from each other by subjecting them to 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis.( SDS PAGE). (Laemmli,1970). 
Proteins complexed with SDS have the same charge to mass ratio and essentially the same free 
mobilities. Under the right conditions it is possible to separate proteins such that the distance 
travelled by the various components is logarithmically related to their molecular weights. The 
gels are run with a deliberate discontinuity in pH, gel concentration and voltage gradient. A 10% 
running gel is prepared by mixing 10ml of 1.5M Tris-HCl buffer, pH 8.8 containing 0.4% w/v 
SDS. 13.3ml of a 30% w/v acrylamide gel containing 0.8% w/v N,N-methylene bisacrylamide 
(gel stock) is added and 16.6ml of distilled water. Polymerisation is initiated by the addition of 
20ul N, N, N^, N^- tetramethylethylenediamine (TEMED) and 240ul of ammonium persulphate. 
A 3% stacking gel is prepared by mixing 2.5ml of a buffer containing 0.5M Tris-HCl pH 6.8  and
0.4% w/v SDS, 1ml gel stock and 6.5ml water. 20ul of TEMED and 60ul of ammonium persul­
phate initiate polymerisation. The samples are diluted 1:1 with buffer containing 15.6mM Tris- 
HCl, pH 6 .8 , 2.3% w/v SDS, 15% v/v glycerol, 5% v/v 2-mercaptoethanol and 0.001% w/v 
bromophenol blue. After boiling, the samples are loaded into wells in the stacking gel with posi­
tive control samples, molecular weight markers and a sample buffer blank. A current of 20mA is 
applied until the front marked by the tracking dye reaches the top of the running gel. The current 
is increased to 40mA voltage 60v, until the bromophenol blue is 0.5 cm from the gel end. The 
gel is removed and either stained over night in 5:2:13 propan-2-ol/acetic acid/water mix contain­
ing 0.05% Coomassie blue or subjected to electrophoretic transfer to nitrocellulose sheets for 
immunoblot analysis.
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6.6.3.15 Western Blot Analysis
This technique involves the electrophoretic transfer of proteins from polyacrylamide gels to 
nitrocellulose sheets which are then subjected to immunological staining. (Towbin et al 1979). 
Following electrophoresis (as above), the gel is soaked in buffer containing 9.09g Tris-HCl, 
43.2g glycine dissolved in 600ml of methanol made upto 31 with water, pH 8.3. (Transfer 
buffer). Transfer is carried out using a Biorad sandwich system, as described by Towbin et 
al.l979, with a current of 80mA, voltage 60v applied for 3 hours. The nitrocellulose sheet is 
washed in "wash buffer" containing 2.2ml Triton X-100, 1% phosphate buffered saline and 1% 
bovine serum albumin in IL  of water.The BSA is present to saturate all non-specific binding 
sites. The first step in staining involves binding with an appropriately diluted antibody to one of 
the cytochrome P45 0  isoenzymes.This is poured over the nitrocellulose sheet and left for 1 hour 
at 4^c. Several saline washes with the "wash buffer" follow the removal of the antibody. The 
second step in immunoblotting involves the reaction with antibodies which have been raised 
against the immunoglobulins of the species used to raise the first antibody. These second anti­
bodies have been linked to horseradish peroxidase enzyme which upon addition of a suitable 
substrate, produce a coloured band corresponding to the isoenzyme of interest. Further saline 
washes remove any unbound antibody from the nitrocellulose sheet. Bands which appear can 
only be qualitively described as more or less intense than positive control samples run at the 
same time as unknowns.
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CHAPTER 7 
RESULTS
The results presented in the following three sections are biochemical and histological findings 
from the study outlined in Materials and Methods, to investigate the hepatic effects of BHT 
administration over two generations in the rat. An identical study had been conducted up to 
16 months post weaning but was terminated early after the animals suffered from heat stress, 
due to a mechanical failure with the temperature regulating system. Only major differences 
between the two studies will be commented on and the reader is referred to section four of 
the results to view the data.
SECTION 1. The effects of BHT administration on the Fo Generation.
Groups of seven male and fifty female rats were fed BHT in the diet at nominal doses of 25, 
100 and 500mg/kg b.wt./day prior to and throughout the mating period. The doses for this 
study and the aborted study were chosen from the results of a dose ranging study, where the 
doses for both sexes were; 500 (low), 750 (mid) or 1000 (high) mg BHT /kg body 
weight/day.
7.1 GROSS OBSERVATIONS 
Males.
1. Food Consumption.
The addition of BHT to the diets did not result in any difference in food consumption 
between controls and dosed groups. (Fig. la). All groups showed a fall in consumption at two 
distinct times, i.e. "pilot mating" and "mating proper".
2. Body Weights.
There was no difference in body weight gain between controls and BHT treated animals (Fig. 
lb).A non-treatment related lower body weight was noted in the high dose group animals.
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3. BHT Consumption.
Figure Ic shows the amount of BHT consumed in the diet by the males over a 28 day period. 
The nominal intake was achieved in the low and mid dose groups, however the actual mean 
intake of the high dose group animals was calculated to be 453.6mg/kg b.wt instead of the 
nominal 500mg/kg b.wt.
FIGURE la. FOOD CONSUMPTION of Fo MALES
30
20 60-20 0 40-40
Control
D ays after BHT Administration
Mean food consumption of males, days prior to and post BHT administration. Values 
presented are means (n=7). Food consumption was measured three times per week.
FIGURE lb . WEIGHT GAIN of Fo MALES
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Body weights were measured on a weekly basis, prior to and post BHT administration.Results 
are mean values. (n=7).
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FIGURE le . BHT CONSUMPTION of Fo MALES
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The results presented show the concentration of BHT in the diet analysed at two weekly 
intervals.
4. Mating Success.
BHT did not appear to have any deleterious effects on mating success, as there was no 
statistically significant difference between control and treated animals (Fig. Id).
FIGURE Id. MATING SUCCESS of Fo MALES
rniST nign
Control
Low
M id
H i g h
con low
Mating success was calculated as the number of females out of 8 made pregnant per male per 
dose group of males, each dose group having 7 males. Values are means (n=56) expressed 
as percentage.
5. STATISTICAL ANALYSIS.
All statistical analysis of data was calculated using a Student’s T-test, where 
* = p< 0.05, ** = p< 0.01 and *** = p<0.001.
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Females : Up to 20th Day o f  Gestation.
l.Food Consumption.
There was no difference in food consumption between controls and BHT treated females (Fig. 
2a). A drop occurred in all groups during the mating period.
FIGURE 2a. FOOD CONSUMPTION OF Fo FEMALES
20
20 3010 40 50-30 -20 -10 0
Control 
 (---
Low
High
Davs after BHT Administration
Results are presented as the mean food consumption per dose group, (n=50 animals/dose 
group) measured three times per week both pre and post BHT administration and up to 
weaning.
2. Body Weights.
All dosed females gained weight at a similar weight as the control females, from receipt to 
confirmation of pregnancy (Fig. 2b).
FIGURE 2b. W EIGHT GAIN FOR Fo FEMALES
250
200
- 2 . Week of BHT Administration
Results presented are mean body weights/week/group. (n=50 animals/group).
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3. BHT Consumption.
During the course of BHT administration all dose groups received the following average 
amounts : Low: nominal 25mg/kg , actual 23.6mg/kg, Mid : nominal lOOmg/kg, actual 
96.1mg/kg and High : nominal 500mg/kg , actual 463.6mg/kg b.wt/day (Fig 2c).
FIGURE 2c. BHT CONSUM PTION of Fo FEMALES
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SOOmg
Day o( BHT Adm inistralion
The results presented are the mean actual amount of BHT consumed per dose group as 
measured every 2 weeks in the diet up to 70 days post administration.
4. M ating Success.
An index of mating success/fertility for the females is presented with the data for the FI 
generation (see section 2). However, all females remained in good health throughout the 
period of BHT administration and all groups produced similar numbers of litters. The reader 
should note that the numbers of litters produced in this study were almost half of the numbers 
produced in the earlier aborted study. This will be discussed later.
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1.2 GROSS OBSERVATIONS AND HISTOLOGY OF DAMS AT AUTOPSY.
Those dams sacrificed at the 20th day of gestation did not show any abnormalities on opening, 
with the exception of 1 low dosed and 1 high dosed animal which showed a deformed leg and a 
darker liver respectively. There was no statistical difference in terminal body weight between 
control dams and treated dams with and without litters. (Table 5a). There was an increase in the 
liv e r  w e ig h t in the d osed  fem ales, the g re a te s t in c re a se  seen in the dam s rece iv in g  
500mg/kg/day. The high dosed females showed an increase in the liver:body weight ratio (with 
and without litter) over controls but this increase was not found to be statistically significant. No 
biochemical analysis of the livers from these dams was carried out. Table 5b shows that only the 
high dosed female livers had mild centrilobular cell hypertrophy with eosinophilia, no effects 
seen at 25 or lOOmg/kg b.wt. when compared with controls. High mitotic activity was seen in 
both the controls and 25mg/kg b.wt./day group livers com pared to the mid and high dosed 
animals.
TABLE 5a  Liver and body w eights for dams sacrificed  on the 20th day o f  gestation  (Tim e Point 1)
B H T D ose Body W eight^  
(g)
Body W eight ^ 
(g)
Liver W eight 
o f dam s (g)
L iverrBody W eight 
(inci litter) (%)
Livert.Net B ody W eig  
(%)
Control 341.72±1.16 287.79±4.57 12.91±0.46 3.78=0.14 4.49=0.12
Low 353.88±13.44 303.84±16.10 14.14±0.80 3.99±0.11 4.65=0.07
Mid 3<4.18±16.71 296.74±12.36 14.01±0.51 3.99+0.22 4.75=0224
High 346.90±11.25 292.<9±S.23 16.0310.42 4.64±0.18 5.49=0.18
Results arc presented as mean ±SEM . Each group consisted o f  5 animals.
 ^ Body weight o f  dam with litter.
^ Body weight o f dam without litter.
TABLE 5 b Histopathological changes seen in livers o f  dam s (Time Point 1)
Dose G roup NAD CH M ean m itotic 
figures per section 
(median lobe)
Mean mitotic 
figures per section 
(left lobe)
Control (5) 5 0 5.6 5.4
Low (5) 5 0 7.4 8.8
Mid (5) 5 0 0.0 022
High (5) 0 5 0.8 0.4
Figures represent numbers o f animals cxhibidng NAD or lesion indicated. 
N.AD No Abnormalities Dctcctfd  
CH Centrilobular Cell Hypertrophy with eosinophilia 
( ) Number o f dams examined.
7.3 GROSS OBSERVATIONS, HISTOLOGY AND BIOCHEMISTRY OF DAMS 
AUTOPSIED AT THE END OF LACTATION /  WEANING.
Those females that became pregnant and were not removed at time point 1, i.e. at 20th day of 
gestation, were allowed to give birth and feed a maximum of 8 pups upto weaning and then 
removed from the study. In a previous study where an identical dosing regimen was followed to 
the above ( prior to early termination of the study), those females receiving 500mg/kg b.wt/day 
BHT were sacrificed at the end of weaning as were a control group of dams. Aged matched 
females that had not become pregnant (nulliparous), and fed either control diet or diet with BHT 
500mg/kg b.wt, were also examined histologically and biochemically.
7.3.1 Gross Observations 
LFood.
There was no difference in food consumption between control dams and dams receiving a 
nominal 500mg/kg b.wt. BHT.(Figure 3). The steady increase seen throughout gestation ex­
panded markedly during lactation reaching a peak in untreated dams of over four times the levels 
found in age-matched non-pregnant females.(Data not shown). In the treated groups this increase 
was less marked.(Figure 3).
2 . Body Weights.
The body weight gain of treated dams throughout pregnancy and lactation was similar to control 
animals.(Figure 4). Figure 5 shows that the terminal body weights of animals receiving BHT at 
500mg/kg b.wt. was greater than controls regardless of having under gone lactation or not. 
Those animals that had been pregnant showed greater body weights than the nulliparous fe­
males. Removal of animals from the BHT diets and feeding them with control diet for 14 days 
did not alter the pattern of body weights in dams that had undergone lactation when compared to 
controls.
3. BHT consumption.
No attempt was made to alter the BHT intake of the diets during pregnancy and lactation, to
avoid unnecessary disturbance to the dams and pups. Thus the BHT content in the diet was
based on the food consumption and body weights prior to confirmation of pregnancy.
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FIGURE 3. Food Consumption of Dams During Pregnancy and Lactation.
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Results presented are mean food consumption measured three times per week (n=25 
dams/dose group) It is presented as amount consumed in terms of day of conception which 
was not easily determined from one dam to the next hence the difference in days between 
controls and test
FIGURE 4. Body Weight Gain of Dams Throughout Pregnancy.
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150 15020- 2 0  -1 5  -1 0  - 5 -1 5 -10 20- 5 150 5 10
Day of gestation Day of gesta tion
The mean body weight and body weight gain were measured weekly up to the 20th day of 
gestation (n=25). This was presented in terms of day of gestation.
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7.3.2.Histopathology
Histological examination of the livers of those dams receiving either control diets or diets con­
taining BHT at 500mg/kg b.wt./day, showed enlarged hepatocytes in the centrilobular zone in 
the treated animals. The cells showed a basophilic rim with the central part of the cell being 
filled with a "ground glass" appearance.
Electron microscope exam ination of the livers from the dams killed at the end of lactation 
showed proliferation of the smooth endoplasmic reticulum, loss of glycogen, hypertrophy and 
dilation of the bile canaliculae. There was also dilation of sinusoids and the presence of mem­
brane bound vesicles. See photographs 1 and 2. (Results from the dose ranging study indicate 
that these changes are more pronounced in the 750 and lOOOmg/kg b.wt groups-data not shown.)
FIGURE 5. TERM INAL BODY W EIGHTS of NULLIPAROUS FEMALES and DAMS.
350
300
250
200
Control
- SOOmg
0
ISO
100
Non Preg. Laoating Reversed
Each bar represents the mean terminal body weight for 4 animals. Non pregnant animals 
(nulliparous) had been unsuccessfully mated animals receiving either control diet or 
500mg/kg. b.wt/day BHT diet prior to and post mating. Lactating animals had produced pups 
and were killed directly after weaning of pups. Reversed animals were control and BHT 
treated dams that had weaned pups and were killed 14 days post removal of pups. The 
previously BHT fed animals had received control diet during this 14 day period. Mean values 
+/- SEM and statistical analysis are presented in table 6 .
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PHOTOGRAPH 1. Control Liver From Lactating Dam.
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The electron micrograph shows a liver horn a control dam at the end of lactation. 
KEY: M=Mitochondria, N=Nucleus. SER=Smooth Endoplasmic Reticulum 
RER=Rough Endoplasmic Reticulum. - = lum.
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BHT dosed dams had been fed diets containing a nominal 500mg/kg b.wtVday prior to and 
throughout pregnancy and lactation.
KEY
N : Nucleus 
M : Mitochondria 
V : Vacuole
SER : Smooth endoplasmic reticulum 
RER : Rough endoplasmic reticulum 
BC : Bile canaliculi
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Figure 6 shows that the terminal liver weights of all dosed animals was greater than their 
corresponding controls. The greatest increase was seen in those animals that had under gone 
lactation and was two fold greater in the BHT treated dams than in the BHT nulliparous/non 
pregnant females.
FIGURE 6 . MEAN TERM INAL LIVER W EIGHTS
:
N on Preg.
Control
500 mg
Lactating R eversed
Figure 6 shows the mean terminal liver weights of 4 dams per group. Non 
pregnant/nulliparous females had been unsuccessfully mated and were either control diet fed 
or BHT diet fed at 500mg/kg b.wt. Lactating dams were either control fed or BHT fed dams 
killed at the end of lactation. Reversed dams were either maintained on control diet for 14 
days post end of lactation or had been previously fed 500mg/kg b.wt. BHT pre and post 
pregnancy and then fed control diet for 14 days post end of lactation. Mean values +/- SEM 
and statistical analysis of results are presented in table 6 .
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7.4 BIOCHEM ICAL ANALYSIS OF THE FEM ALES’ LIVERS.
7.4.1. Enzymes Used as Indicators of Hepatotoxicity.
Figure 7a and table 6 show ,a statistically significant decrease in glucose 6 -phosphatase 
(G6Pase) activity in those females that had received 500mg/kg b.wt/day BHT and had under 
gone lactation compared to control dams. A non statistically significant decrease in G6Pase 
activity was also seen in BHT treated nulliparous animals (Non Pregnants) when compared 
to their controls. Lactation in combination with BHT treatment produced the greatest decrease 
in this activity. Fourteen days after the removal of BHT from the diets of previously treated 
dams resulted in levels of activity that resembled that found in non pregnant control diet fed 
animals. The control dams of this pair exhibited an increase in activity which was slightly 
higher than those in the reversed animals.
FIGURE 7a. GLUCOSE 6 -PHOSPHATASE ACTIVITY
0 .0 3 5
0 .0 3
0 .0 2 5
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Non Preg. Lactating R eversed
The results are the mean activities from age-matched non-pregnant/unsuccessfully mated 
controls or BHT fed animals and control dams or BHT fed dams at the end of lactation.(n=4). 
"Reversed" dams were either maintained on control diet or had previously been fed BHT then 
control diet for 14 days post end of lactation. Mean values +/- sem and statistical analysis are 
presented in table 6 .
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Total hepatic glutathione levels were significantly reduced in BHT lactating dams to 1/3 of 
the activities found in the control dams. This activity was even lower than the levels found 
in the nulliparous controls and the nulliparous BHT treated animals. Removal of BHT from 
the diet resulted in increased enzyme activity in the previously treated animals. This increased 
activity was two fold higher than non pregnant/non dose animals. The control dams examined 
14 days post end of lactation also showed increased activities similar to those of the reversed 
animals.
FIGURE 7b. TOTAL HEPATIC GLUTATHIONE ACTIVITY
0.12
0 .08
0 .06
0.04
0.02
Control
SOOmg
Non P 'sg . Lactating R eversed
Results are the mean of 4 samples from control and BHT treated non-pregnant animals which 
were age-matched with controls and BHT treated dams. Reversed dams were given control 
diet for 14 days post end of lactation but had previously been exposed to 500mg/kg b.wt. 
BHT prior to and throughout pregnancy and lactation. All mean values +/- sems are presented 
in table 6 .
75
■I 1 1 .
S, 2, SLn
I
3 s &
S’ p o
CTQ K.
Cu CL 3 §
0 1- t
1 g* R-mo s s- 1
= a. n
CL 3 » ë
S. E S'S- H CL
I IR- (TQ
I
w i
P*
I I
g p
H- 63
I !
° I 
l i ^E-w II
■ (re
li
I
I
" CP 5‘
I I  
1 1 ' ^ ^
r
w  s '
lA tf
§r
CL. O ,
Î5. * <8
il
3
I
I
1
0
1
ar
I
§
1
II
S,
t
II
H-
s  r  ?
CL p ere p (reQ . CL CL
CL CL
S
VO
i iK ) WN(-n
P
o \ i cro8o OS
P P o pto v<
II
VO I C5 P so
o g I OSo to
(re
Po I (O' (reos to
I go I
0
1
o8 (TQ
§
Os
Os
Oè oLo o o (re00 VO
II
Os if3
o
b
o
b g go (re
w s  %pp
p p
o
(re
I  §
3  1+
to
8 os
o o p
w Ol
(re
I
ii
0 |
°2
U
ii
i "u
II
I?z  
c 
es
I I
il
II
5
il
"5
Iz
>z
H
R
76
>i
7.4.2. Enzymes Used as a Measure of Microsomal Enzyme Induction.
There was a statistically significant three fold induction of Glutathione S-Transferase activity 
(GST) over control values in the BHT treated/lactating dams (Fig. 8a and table 6 ). Similarly, 
the nulliparous BHT treated animals also exhibited a statistically significant induction in 
activity which was two fold greater than control values. Removal of BHT from the diet 
(reversed treatment group) resulted in GST levels similar to those of the BHT treated non­
pregnant animals. All three treated groups showed higher GST activity than their 
corresponding controls. In control animals the "state" of lactation has only a minimal effect 
on this activity, whilst 14 days post the end of lactation the levels of this enzyme are 
increased to levels greater than those seen in the non-pregnant control animals.
FIGURE 8a. GLUTATHIONE S-TRANSFERASE ACTIVITY
Control
Non Preg. Lactating R eversed
Glutathione S-transferase activity was measured in age matched non-pregnant and lactating 
females fed either control diet or a nominal 500mg/kg b.wt/day, prior to and post mating. 
Values presented are means (n=4). Means, +/- SEM and statistical analysis are presented in 
table 6 .
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Figure 8b shows that total cytochrome P450 (CYP450) levels were significantly raised over 
control levels in all BHT treated animals. This induction was of a similar magnitude in both 
the non-pregnant/BHT treated animals and in the lactating/BHT treated dams, although the 
lactating animals had lower activities than the non-pregnants. Removal of the compound 
resulted in a drop in activity in the previously treated animals to levels below its control 
group. Control dams of this group showed the highest basal activity levels of any control 
group.
FIGURE 8 b. TOTAL CYTOCHROM E P450 LEVELS
VI' '
-,
Control
SOOmg
Non Preg. Lactating R eversed
The results presented are the mean values of total CYP450 activity in BHT treated and 
control females and dams at the end of lactation and also control and reversed dams 14 days 
after the end of lactation (n=4 ).
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Specific isoenzymes of CYP450 were measured to confirm that BHT is a CYP2B class of 
inducer and also to evaluate what effects lactation and BHT have on these parameters in the 
maternal liver. Ethoxyresorufin o-deethylase (EROD) activity is classically induced by 3 
methylcholanthrene and polycyclic aromatic hydrocarbons and inducers of this type are 
termed CYPIA inducers. Figure 8c and table 6 show that EROD activity is slightly lowered 
in the BHT treated non pregnant females compared to their controls but this drop was not 
signiticant. This drop was also seen in those animals that had under gone lactation and had 
been exposed to BHT. When comparing the non-pregnants with the lactating animals it is 
clear that lactation has an inhibitory effect on this activity irrespect of treatment with BHT 
or control diet.
FIGURE 8c. ETHOXYRESORUFIN O-DEETHYLASE ACTIVITY
voncrol
SOOmg
N on Preg. Lactating R eversed
The results presented are the mean EROD activities in non-pregnant and lactating animals fed 
BHT in the diet at 500mg/kg b.wt./day prior to and post mating (n=4) and age-matched 
controls. Reversed animals had previously been exposed to oOOmg/kg b.wp'day BHT 
throughout pregnancy and lactation and fed control diet for 14 days after the end of the 
lactational period. Mean values -/- SEM and statistical analysis are presented on table 6 .
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Figure 8d shows that Pentoxyresomfin o-depentylase (PROD) activity was greatly and 
significantly increased in BHT treated animals. Those animals that had undergone lactation 
in addition to BHT treatment exhibited the greatest induction, two fold greater than BHT 
treatment alone produced. Measurement of PROD activity was made in the reversed dams and 
in the corresponding controls, 14 days post end of lactation. The mean values are presented 
on table 6 and show that feeding control diet for 14 days to animals previously exposed to 
500mg/kg b.wt BHT, results in PROD activities similar to those of the control diet fed 
animals. This enzyme level is in a similar range of activities found in all control fed animals 
but is double that seen in the non pregnant controls, indicating that BHT treatment and 
lactation have a synergistic effect on PROD induction. As with other control levels of PROD 
activity, this value is too small to be displayed on figure 8d and so was not included.
FIGURE 8 d. PENTOXYRESORUFIN-O-DEPENTYLASE ACTIVITY
250
ntroi
SOOmg
Non Preg. L acan n g
The results presented are the mean PROD activities in the non-pregnant and lactating control 
and BHT treated animals. Control samples had very low levels of this activity (n=4). Mean 
values +/- SEM and statistical analysis are presented in table 6 .
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CONCLUSIONS
BHT has no effect on body weight gain or food consumption of either the Fo males or 
females when fed the compound in the diet at doses up to 500mg/kg b.wt./day. It does not 
appear to be teratogenic at this dose or lower nor does it have any major effect on the germ 
cells (using mating success and numbers of viable foetuses as a rough index).
When fed continuously through out pregnancy and lactation at 500mg/kg b.wt./day, BHT 
causes an increase in the liver weight to values greater than pregnancy/lactation alone. This 
hepatomegaly can be attributed to; 1. a physiological hypertrophy to the demands of lactation 
and 2 . to the induction of the drug metabolising enzymes of the liver, especially those of the 
mixed function oxidases associated with the smooth endoplasmic reticulum. This is confirmed 
by electron microscope examination of the livers, showing clear hypertrophy of the S.E.R. and 
also biochemically, where frank hepatotoxic signs indicate the liver is under considerable 
stress when challenged with both pregnancy and the metabolism of BHT. BHT (as reported 
in previous studies) does fall into the class of compounds that induce the CYP2B subfamily 
of the microsomal cytochrome P450 system. In the lactating dam exposed to BHT for periods 
up to 8 weeks at 500mg/kg b.wt., the induction of the PROD isoenzyme appears to be 
enhanced two fold over non-pregnant levels and 100 fold over control diet fed lactating dams. 
This strongly suggests that the hormonal status of the dam acts synergistically with BHT to 
increase the levels of PROD and as total P450 levels can not account for such an increase it 
could be suggested that this PROD induction is at the expense of other isoenzymes, eg 
EROD. 14 days after the removal of BHT from the diet and after the end of lactation, the 
liver of the reversed animal appears to be remodelling with respects to basal enzyme levels. 
There are clear differences in the enzymes used as indicators of hepatotoxicity, whilst the 
enzymes used as indicators of microsomal induction clearly show a return to non treated 
control levels.
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SECTION 2
The effects of BKT administration on the FI Generation .
(From Conception to Birth and upto I Month Post Weaning).
7.5 GROSS OBSERVATIONS
7.5.1 Effects on Fertility/Foetuses
On the 20th day or gestation 5 dams per group were killec and the number of viable foetuses 
and resorption sites was examined, i able / shows that there was a slight reduction in the number 
of foetuses in those dams receiving BHT in the diet but this was not found to be statisticallv 
different from control values. The table also shows that there was no difference in the number of 
resorption sites although those animals receiving a nominal 1CX)mgkg b.wt./day of BHT had a 
lower mean number of foetuses and a lower number of resorption sites than any other group. 
There was no difference in the number of pups born /litter (Table 8a) but there was a trend 
towards an increase in the number of pups/litter found dead or dying before reduction of litter 
size on ± e  6 th day after birth with increasing dose.(Tables 8b and 8c). Table 8d shows there was 
no statistical difference in the maleifemale ratio of pups between controls and dosed groups.
TABLE 7 Number of foetuses and resorption sites in dams autopsied on the 20th day of 
gestation
No foetuses/dams Resorption sites/dam Number of dams
hiion SEM Mean 5EM
Control 13.0 0.9 0.4 022 5
Low 118 0.6 OB 0.18 " 5 .
Mid 1.0 0.0 0.00 5
High 1 ^  * 0.8 0.4 022 5
TABLE 8a Number of Pups'Litter
Num ber .Number Pups per litter
of pups of litters Mean
Control 228 20 11.4 0.7
Low 251 24 10.5 0.7
Mid 265 24 11.0 0.8
High 207 20 10.4 0.7
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Tables 8b, 8c and 8d.
Number of Pups/Litter found dead or dying before reduction of litter size on 
TABLE 8 b titb day after birth
Number of litters Pups deaths/litter 
Mean SEM
Control
Low
Mid
High
20 0.55 
24 0.50 
24 0.88 
20 0.75
0.33
0.18
0.39
0.28
TABLE 8 c Number of pups in affected litter found dead or dying 
litter size on 6th day after birth
before reduction of
Pup deaths/affected litter Number of As % 
Mean SEM  litters
affected
Control 2.75 0.18 4/20 20
Low 1.71 0.29 7/24 29
Mid 3.00 0.98 7/24 29
High 1.88 0.48 8/20 40
TABLE 8 c1 Number of male and female pups/litter
Number Pups/ditter Total number
of litters Mean SEM of pups^
Males
Control 2 0 . 5.4 0.45 108
Low 23® 4.9 0.47 114
Mid 24 4.9 0.40 115
High 20 4.6 0.48 100
Females
Control 2 0 . 5.5 0.45 110
Low 2 3 b 5.5 0.62 127
Mid 24 5.9 0.55 138
High 20 5.1 0.55 100
Excludes those pups which had died prior to sexing. Thus the total num ber will diffei 
from Table 8br
One litter had only two pups both of which died before their sex could be ascertained-
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7.5.2. Effects on Growth of Pups From Birth to One Month Post Weaning.
Table 9a shows that there was a slight reduction in litter size and therefore in total litter 
weight in the pups bom to dams treated with 500mg/kg b.wt/day BHT, but there was no 
difference in the mean pup weight at birth (Table 9b). At 6 days post partum, the number of 
pups to be suckled per dam was either increased or decreased to 8 , maximising the number 
of males. Cross fostering was within the same dose group. Table 9c shows that the mean pup 
weight at this time was significantly reduced in those pups from high dosed dams.
TABLE 9a Weight of entire litters at birth
Number of litters Mean Utter 
Weight (g) SEM
Control 20 77.66 4.88
Low 23^ 74.92 5.14
Mid 24 73.72 3.52
High 20 64.55* 3.57
TABLE, 9b Weight of individual pups at birth
Number of litters Mean Body
Weight (g)
Control 20 7.00 0.29
Low 23^ 7.32 0.50
Mid 24 6.97^ 0.26
High 20 6.31 0.09
TABLE 9c Weight of individual pups at time of matching of iitter sizes
birth)
Number of litters Pup weight (g)
Mean SEM
Control 20 132 0.54
Low 23^ 13.9 0.55
Mid 24 13.1 0.39
High 20 11.6* 0.49
Tables 9a,b and c are mean values +/- sem of the litter weights and the individual pup 
weights of the FI generation animal, exposed in utero to BHT at nominal concentrations of 
25, 100 and 500mg/kg b.wt/day. (n= ll for con, low, mid and n=10 for high).
* Statistically significant from control (P<0.05).
^ One litter (P63) had only two pups and was therefore not included in the calculation.
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Table 10 and figure 9 show that this weight deficit was maintained in the pups suckled by high 
dose group dams upto 21 days after birth (weaning / time point 2). The pups in all groups were 
healthy through out this period, despite the failure to gain weight at a comparable rate by the 
pups in the "high" dose group. These pups appeared to develop at a slower rate than controls 
bom on the same day, this being most obvious in terms of coat development. Figure 10a shows 
that at 21 days post weaning the animals receiving 250mg BHT/kg b.wt /day remained lighter 
than controls and also lighter than the two lower doses. The animals receiving lOOmg BHT/kg 
b.wt/day also show a reduction in weight gain compared to controls but not as great as the high
dose group animals.
Weight of all individual pups at weaning (21 days post-partum)
Number of pups Weanling
Mean
weight (g) 
SEM
Control 218 52J5 1.34
Low 241 53.47 1.14
Mid 253 52.71. 1.14
High 20 0 41.43 1.46
* Statistically significant from control (P<0.05).
Fig._. 9 Growth of pups to weaning.
Development of pups until time of weaning. Litters were weighed, at weekly intervals. Here the 
average weight/ pup for each litter at each time has been plotted against the days from birth. The 
single points at day 0 and day 21, on the other hand, correspond to the mean body weights at 
birth and at weaning.
a. Control
b. Low Dose (nominally 25mg/kg/day BHT)
c. Mid Dose (nominally lOOmg/kg/day BHT)
d. Top Dose (nominally 500mg/kg/day BHT)
Control Low D ose Mid Dose 1 op Dose
îcl
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FIGURE 10a. Mean Body Weights of the FI Generation Animal.
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Figure 10a displays the mean body weights of the F I generation male animal after weaning 
onto diets containing 25mg, lOOmg and 250mg/kg b.wt. BHT or control diet fed animals 
(n=48 con, n=49 low and mid and n=59 higlji Mean values +/- sem and statistical analysis 
can be found on table 11. It should be noted that this figure incorporates aU of the animals 
of the study and not solely those for time point 2 .
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7.5.3. Effects on Food Consumption and BHT Intake.
At weaning the high dose was reduced to 250mg/kg b.wt/day, as outlined in materials and 
methods. All pups took readily to the powdered diet regardless of the presence of BHT. 
Figure 10b shows there was no difference in food consumption between controls and dosed 
pups at 21 days post weaning, all pups consuming an average of 2 5 mg/animal/d ay. BHT 
consumption remained close to target intake values (Figure 10c).
FlG.lOb
120 140 16080 10020 40 600
Contrd
D ays From W eaning/BHT Administration
The results are the mean food consumption figures per dose group monitored three times per 
week. Day 0 is the day that the pups were removed from their mothers and given diets 
containing the appropriate amount of BHT. All animals for all time points have been included 
in the calculations.
FiG.ioc BHT Consumption 
F1 Males
300
250
200
150
100
269 373 493 52219535211
283 403 508255 5551052814
100mg
after BHT Admin/ W eaning
Figure 10c illustrates the BHT content of the diets as measured fortnightly. This incorporates 
the entire study up to termination so that the reader can see the fluctuations from the nominal 
amounts with time.
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7.6 GROSS OBSERVATIONS AT AUTOPSY.
At the 20th day of gestation (time point 1) and at 21 days post partum (weaning/time point
2), there was no difference in the terminal body weight, liver weight or liver; body weight
ratio between controls and dosed animals. 4 weeks post weaning (time point 3), there was
a dosed related decrease in body weight and Hver weight, with an increased Hver: body
weight ratio in the high dose group animals (Figures 11a, 11b, 11c and Table 11). 
FIGURE 11a MEAN BODY WEIGHTS
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FIGURE 11b MEAN LIVER WEIGHTS
HIGH
2 3
FIGURE 11c % ITVERiBODY WEIGHT RATIO
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Figures 11a, 11b and 11c represent the mean terminal body weights, Hver weights and Hver: 
body weight ratio of aU the animals examined at time points 1 , 2 and 3 expressed in terms 
of % of control values. Means, + /-  sem and statistical analysis are presented in table 11. 
(Time point 1, n = 5 , time point 2, n= 20 and 3, n= 5). AU treated animals had been exposed 
in utero to BHT at doses of 25mg, lOOmg and 500mg/kg b.wt, with the 500mg group being 
reduced to 250mg at weaning.
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TABLE 11. MEAN BODY, LIVER and LIVERiBOD Y W EIG H T RATIOS,
Time Point 1 (20thi day of 
gestation)
2  (21 days post b .rfti 
weaning)
3 (4 weeks post 
weaning)
BHT Dose 
(mg/kg/day)
Body Weight (g)
0 4.09 ± 0.51 [25f
1
53.89 ±  8.86  [20f 321.40 ± 9.56 [5]
25 3.86 ±  0.48 [25p 
(95)
48.92 ±  7.38 [20f 
(91)
275.58 ± 1 1 .5 6  [5] 
(86)*
100 4.56 ± 0.58 [25]" 
(112)
53.90 ±  8.98 [20]^ 
(100)
261.30 ±  19.38 [5] 
(81)*
2504 4.38 ± 0.56 [25]“ 
(107)
42.04 ±  7.68 [20]^ 
(78)*
247.96 ±  6.34 [5] 
(77)**
Liver Weight (g)
0 0.34 ± 0.07 [25]“ 2.43 ±  0.56 [20]" 15.90 ± 0.46 [5]
25 0.34 ±  0.07 [25]“ 
(100)
2.27 ±  0.52 [20]" 
(93)
13.30 ±  0.41 [5] 
(84)**
100 0.41 ±  0.08 [25]“ 
(123)
2.48 ±  0.08 [20]" 
(102)
14.68 ±  1.86 [5] 
(92)
2504 0.38 ±  0.08 [25]“ 
(116)
2.08 ±  0.08 [20]" 
(86)*
13.74 ± 0.44 [5] 
(86)**
Liver Weight as % of Body Weight (%)
0 8.12 ±  1.59 [25]“ 4.44 ± 1 . 0 1  [20]" 4.95 ±  0.04 [5]
25 9.18 ±  1.84 [25]“ 
(113)
4.16 ±  0.96 [20]" 
(94)
4.85 ± 0.21 [5] 
(98)
100 9.29 ± 1.89 [25]“ 
(114)
4.56 ±  1.05 [20]" 
(103)
5.56 ±  0.40 [5] 
(112)
2504 8.63 ±  1.79 [25]“ 
(106)
4.94 ±  1.13 [20]" 
(111 )
5.54 ±  0.11 [5] 
(1 1 2 )* * *
Table 11 shows the mean terminal body and liver weights and the mean liver: body weight ratios (as 
percentage).
Statistical analysis was carried out using Student’s T test where, * =  significantly different from control 
P < 0.05, ** P <  0.01, *»* P< 0.001.
( )  % of control
♦  Pups from dams fed 500mg/kg b.wt/day BHT prior to conception and through out weaning, 
a: Group consists of 5 foetuses of 5 dams per group, 
b: Group consists of 4 pups of 5 dams per group.
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MACROSCOPIC FINDINGS.
No macroscopic changes were found in any of the major organs at either the 20th day of 
gestation, weaning (time point 2) or at 4 weeks post weaning (time point 3).
7.6.1. Histopathology.
Examination of sections of liver taken at autopsy from the 20th day of gestation foetuses, 
exposed to BHT in utero, did not show any difference from the livers of control foetuses 
(see electron microscope photograph 3, page 91).
Similarly, liver sections from pups at weaning (time point 2) and 4 weeks post weaning (time 
point 3) did not show any significant differences from their respective control livers when 
examined at both the light and electron microscope level. However, centrilobular enlargement 
and proliferation of the smooth endoplasmic reticulum were observed in time point 3 animals 
weaned onto diets containing BHT at a nominal 250mg/kg body weight/day. This finding was 
less noticeable in the two lower dose groups at this time point and even less obvious in 
sections taken at weaning (time point 2).
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PHOTOGRAPH 3. LIVER OF FOETUS AT 20th DAY OF GESTATION.
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At th is  stage of development cords of l iv e r  c e l l s  ( hepatocytes) 
can be seen to be forming amongst the haemophetic c e l l s ,  namely; 
lymphocytes, macrophages and red blood c e l I s . p  -  rep resen ts  lum.
Key: H=Hepatocytes, RBC=Red blood c e l ls ,  M=Macrophages, L=Lyrnphocytes
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7.7 CHANGES IN BIOCHEM ICAL PARAMETERS W ITHIN GROUPS and 
DEVELOPMENT ALLY.
7.7.1.Enzymes Used as Indicators of Hepatotoxicity.
Figures 12a and 12b show that there is a dose related increase in the absolute and relative 
activity of Glucose 6-phosphatase (G6Pase), at time point 1. At time point 2 this increase is 
still present but it is not significantly different from controls. Time point 3 shows only the 
250mg BHT /kg b.wt. group has still elevated activity whilst the two lower groups are non 
significantly lower than controls. Developmentally, this enzyme’s activity appears to have 
reached a peak at weaning (time point 2 ), which is maintained in the control animal 4  weeks 
post weaning (time point 3). The reader should note that a different profile in G6Pase activity 
was found in the earlier study, the results of which are presented in section 4 .
12a GLUCOSE 6-PHOSPHATASE 
Absolute
CON
MID
HIGH
Relative
200
150
100
CON
LOW
MID
HIGH
Figures 12a and 12b represent the mean values for G6Pase activity as measured in animals 
at 20th day of gestation,(dme point 1) n=5, weaning, n=20, (time point 2) and 4 weeks post 
weaning,n=5, (time point 3). All animals were exposed to BHT in utero at 25mg (low), 
lOOmg (mid) and 500mg (high) per kg b.wt. The 500mg dose was reduced to 250mg. Means, 
+/- sem and statistical analysis are presented in table 12.
92
Total glutathione levels (GSH) are decreased in all animals exposed to the highest dose of 
BHT at all three time points (Figures 13a and 13b). These decreases are not statistically 
significant but may be biologically important. Low and mid doses of BHT produce a non 
significant trend towards increases in this activity. Developmentally, GSH levels show a drop 
at time point 2 with an increase at time point 3 (Figure 13b and table 12).
13a TOTAL GLUTATHIONE 
Absolute
CON 
LOW 
MID
r  I
HIGH
Time Point
13 b R ela tive
CON
LOW
MID
HIGH
Time Point
Figures 13a and 13b show the mean absolute and relative GSH activity in male rats exposed 
to BHT in utero at doses of 25mg (low), lOOmg (mid) and 500mg/kg b.w t/day (high), until 
4 weeks post weaning. The 500mg dose was reduced to 250mg at time point 2. Mean values 
+/- sem and statistical analysis of data is presented in table 12. Time point 1 n=5, time point 
2 n=20 and time point 3 n=5.
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TABLE 12. PARAMETER USED AS INDICATOIL) OF HEPATOTOXICITY.
TIME POINT 1 (20th day of 2  (21 days post 
gestation) ] weaning)
3 (4 weeks post 
weaning)
BHT Dose 
(mg/kg/day)
GLUCOSE 6-PHOSPHATASE : nmoles/min/mg homogenate protein
0 5.97 ±  1.34 [5]" 30.97 ±  6.03 [5]*’ 30.51 ±  0.80 [5]
25 7.27 ±  2.29 [5Y 
(122)
29.99 ±  4.22 [5 f  
(97)
28.93 ±  3.30 [5] 
(95)
100 10.99 ± 2.95 [5]* 
(184)
35.61 ±  3.05 [5]" 
(115)
27.37 ±  2.10 [5] 
(90)
2504 11.13 ±  4.43 [5]» 
(186)
33.97 ±  3.83 [5Ÿ 
(110)
35.91 ±  6.78 [5] 
(118)
TOTAL GLUTATHIONE : /tmoles/mg cytosolic protein
0 0.116 ±  0.013 [5]“ 0.079 ±  0.010 [5]'’ 0.094 ±  0.008 [5]
25 0.138 ±  0.015 [5]‘ 
(120)
0.082 ±  0.006 [5]b 
(100 )
0.107 ±  0.005 [5] 
(114)
100 0.132 ±  0.015 [5]» 
(114)
0.099 ±  0.022 [5]*’ 
(124)
0.101 ±  0.006 [5] 
(108)
2504 0.109 ±  0.012 [5]‘ 
(95)
0.068 ±  0.006 [5]*’ 
(85)
0.086 ±  0.110 [5] 
(92)
Table 12 shows the mean absolute and relative activities of Glucose 6-phosphatase and Total glutathione 
as measured in the subcellular fractions of liver samples taken from male FI generation males exposed 
inutero and upto 4 weeks post weaning to 25, 100 or 500mg/kg/day BHT.
[ ] Number of animals per group.
( ) % of control.
4 Pups from dams fed 500mg/kg b.wt/day BHT prior to mating and through out lactation, 
a : [5]a refers to the number of dams from which 4/5 foetal livers were pooled for biochemical assays, 
b : [5]b refers to the number of dams from which 3/4 pup livers were pooled for biochemical assays. 
Results presented as mean ±  sem, statistical analysis was carried out using Student’s T test, 
where * = significantly different from controls P ^ 0.05, *• P ^ 0.01, ♦** P < 0.001.
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7.7.2 Enzymes Used as a Measure of Microsomal Enzyme Induction.
There was no significant difference in Glutathione S-Transferase (GST) activity between the 
control animals and those animals exposed to BHT as measured at time point 1 (Figure 14a). 
At weaning (time point 2), there was a significant increase in activity in those animals 
receiving the high dose of BHT (500mg/kg in utero and 250mg/kg at weaning). 4 weeks post 
weaning there was a dose related increase in GSTransferase activity, these increases being 
significant in the mid and high dose groups (Figure 14a). The constitutive levels of this 
enzyme appear to increase with age (Figure 14b and table 13).
14a GLUTATHIONE S-TRANSFERASE
Relative
200
150
100
Absolute
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M
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Figures 14a and 14b are the mean GST activities measured in male rats exposed to BHT in 
utero at doses of 25mg, (low), lOOmg, (mid) and 500mg/kg b.wt.(high). The 500mg dose was 
reduced to 250mg at weaning. Mean values V- sem and statistical analysis are presented in 
table 13.
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Figure 15a shows that total hepatic cytochrome P450 activity was not measurable in the livers 
of the 20th day of gestation foetuses. The same result had been found in the earlier aborted 
study which suggested that the method used to obtain the microsomal fraction was 
inappropriate when dealing with the foetal liver and so was altered. However, there did not 
appear to be any improvement in the detection of total P450. This is a critical time in the 
development of CYP450 and therefore requires further detailed discussion. The reader is 
referred to the discussion section. At weaning this enzyme shows a dose related increase in 
activity, this being significant in both the mid and high dose groups. At 4 weeks post weaning 
this activity is still raised in the high dose group but decreased in both the low and mid 
groups compared to controls. Total CYP450 appears to increase with development (Figure
TOTAL CYTOCHROME P45015b).
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Figures 15a and 15b show the mean total CYP450 values expressed as % of controls and in 
absolute terms. The results are from male animals exposed in utero to 25mg (low), lOOmg
(mid) and 500mg (high) BHT /kg b.wt./day. Means +/- sem and statistical analysis are 
presented on table 13.
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Ethoxyresorufin o-deethylase activity (EROD), a diagnostic measurement of the 1A subfamily 
of CYP450, was not measurable in the foetal livers. As noted with total CYP450
activity, it was felt that this was probably a developmental event rather than inappropriate 
analysis (Figure 16a). There was a dose dependant induction of EROD activity at time points 
2 and 3 which was similar in magnitude when expressed as % of controls. The constitutive 
levels of this enzyme appear to fall with age (Figure 16b).
16a ETHOXYRESORUFIN O-DEETHYLASE
Relative
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16b ETHOXYRESORUFIN O-DEETHYLASE
Absolute
The results presented are the mean EROD activity determined in liver microsomes from male 
rats exposed to BHT in utero at doses of 25mg, lOOmg and 500mg/kg b.wt./day. The 
treatment continued until 4 weeks post weaning with the high dose group lowered to 250mg 
at weaning. Means +/- sem and statistical analysis of results are presented in table 13.
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Figure 17a shows that Peutox.yresorufin-o-depentylase (PROD) activity could not be detected 
at time point 1. Again the reader is referred to the discussion section. At time points 2 and 
3 PROD activity was significantly increased in a dose dependant manner, greatest induction 
bemg found in the high dose group animals exposed to 500mg/kg b.wt. in utero and weaned 
onto diets containing 250mg/kg b.wt BHT. This induction reached 3000% of control values. 
This activity does not increase significantly with age (Figure 17b).
17a PENTOXYRESORUFIN O-DEPENTYLASE
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Figures 17a and 17b represent the mean activities of PROD as determined in liver microsomal 
fractions from male rats exposed in utero and up to 4 weeks post weaning with BHT at 
nominal concentrations of 25mg, lOOmg and 500mg or 250mg (at weaning). Mean values +/- 
sem and statistical analysis of data are presented on table 13.
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Epoxide hydrolase activity was detected in some of the foetal livers. However, there was great 
variation between these samples and it is felt that at this time point the activities can not be 
considered representative of the true activity (see table 13). There was significant dose related 
induction of this activity at time points 2 and 3 (Figure 18a ) and the activity appears to 
increase with age (Figure 18b and table 13).
EPOXIDE HYDROLASE 
Relative
400
300
200
100
EPOXIDE HYDROLASE 
Absolute
Time Point
Mean Epoxide Hydrolase activity was measured in the microsomal fraction of the liver’s from 
BHT male rats. The animals had been exposed in utero to 25mg, lOOmg and 500mg/kg 
b.wt./day and were weaned onto diets containing the same BHT content with the exception 
of the high dose group which were fed 250mg/kg at weaning. Mean values +/- sem and 
statistical analysis of the data is presented in table 13.
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T A J J D E I J .  JhJNZYlMES UN V U i^V iL U  UN A H ^ U m U T l U  IVULl AJ5UJLIMVI.
TIME POINT
............... r
1 20th Day of Gestation I 2 Weaning 3 4 weeks post weaning
BHT Dose  
(mg/kg/day)
Glutathione S-Tansferase: ^moles/min/mg cytosolic protein
0 0.183 ±  0.015 [5 f 0.378 ±  0.028 [5p 0.915 ±  0.054 [5]
25 0.174 ±  0.013 [5 f  
(95)
0.361 ±  0.042[5]*’ 
(95)
1.027 +  0.067 [5] 
(112)
100 0.181 ±  0 .0 1 4 [5 f  
(99)
0 .417 ±  0.051 [5]” 
(110)
1.199 ±  0.028 [5] 
(131) **
250 ♦ 0.168 ±  0.013 [5 f  
(92)
0 .729 ±  0 .072[5]” 
(193) **
1.507 ±  0.133 [5] 
(161) **
Epoxide Hydrolase : nmoles/min/mg microsomal protein
0 + 0 .1 0 6 ±  0.093 [5r 4 .6 3 4 +  0.356 [5p 6.549 ±  0.607[5]
25 + 0.023 ±  0.023 [5]* 
(22)
6.508 ±  0.605 [ 5 f  
(140) *
7.112 ±  1.461 [5] 
(109)
100 + 0 .4 1 6 ±  0 .3 0 0 [5 f  
(393)
8 .0 8 6 +  0.960 [5]'’ 
(175) **
10 .349+  0.706 [5] 
(158) **
2 5 0 $ + 0 .0 9 7 ±  0 .6 1 9 [5 f  
(92)
11.538 ±  1.188 [5p  
(249) ***
14.045 ±  1.715 [5] 
(214) **
Total Cytochrome P450 : nmoles/mg/microsomal protein
0 No detectable activity 0.61 ±  0 .02  [5]= 0 .77 ±  0 .04  [5]
25 No detectable activity 0 .67 ±  0 .05 [5]*> 
(110)
0.73 ±  0 .04  [5] 
(94)
100 No detectable activity 0 .8 4 +  0 .07  [5]" 
(138) **
0.66 ±  0.07  [5] 
(86)
2 5 0 $ No detectable activity 0 .80 ±  0 .04  [5]" 
(145) **
0.83 ±  0 .04  [5] 
(108)
Ethoxyresorufin O-deethylase : pmoles/min/mg microsomal protein
0 No detectable activity | 1 7 .9 5 +  1.74 [5]*’ 1 1 .1 4 +  1.81
25 No detectable activity 26.28 +  0 .97 [5]*’ 
1 (146) **
16.18 ±  1.96 [5] 
(145)
100 No detectable activity 27.01 +  2 .90  [5]*’
(150) *
1 7 .3 2 +  1.96 [5] 
(1 5 Q *
2 5 0 $ No detectable activity 3 3 .0 2 +  1.44[5]'’ 
1 (184) ***
19.33 ±  2 .26  [5] 
(174) *
Pentoxyresorufin O-deethylase : pmoles/min/mg microsomal protein
0 No detectable activity 4 .5 2 +  1.08 [5]" 6.46 +  2.83 [5]
25 No detectable activity 10.50 ±  2.71 [5]  ^
(232)
16.36 ±  5 .84 [5] 
(253)
100 No detectable activity 44.61 ±  14.88 [5]*’ 
(9870 *
95.24 ±  25 .97  [5] 
(1474) *♦
2 5 0 $ No detectable activity 90.36 ±  15.13 [5]" 
(1999) ***
193.83 ±  60.35[5] 
(3000) *
Table 13 shows the mean activities of enzymes involved in xenobiotic metabolism in livers from foetal
and young adult male rats exposed to BHT in utero at doses tç to  SOOmg/lcg body weight/day and weaned onto diets containing u{*o 250mg/kg body 
weight/day.
Results are presented as the mean ± sem, statistical analysis was carried out using Student’s T test 
where •  denotes significandy differed from control, P â  0.05, *• 0.01, ""*• P ^  0.001 
[ ] Number of samples assayed. ()  % of control.
a : [5] refers to number of from which 4/5 foetal liver samples were pooled for biochemical assays, 
b  : [5] refers to number of dams from which 3/4 pim litters were pooled for biochemical assays.
* Time po i#  1 and 2 dams fed SOOmg/lcg b.wt/day BHT in diet.
+  Activity only found in 2 coKrols, 1 low, 2 mid and 2 high dose group samples.
Ethylmorphine N-demethylase is an enzyme activity associated with the CYP3A subfamily, 
the hepatic levels of which have been shown to be strictly regulated by the pituitary through 
growth hormone. Low levels of growth hormone have been associated with increased 
expression of the CYP3A protein in rat liver and hence increased ethylmorphine n- 
demethylase activity (Lemoine et al 1988). It was decided that this activity should be 
examined at critical times in the FI generations development after the failure of the high dose 
group animals to gain weight at the same rates as controls was noted. Thus it was not 
included in the initial protocol of enzymes to examine. Figure 19a (and table 14) shows that 
Ethylmorphine N-demethylase activity was detectable in the foetal livers examined at time 
point 1, and that this was reduced non significantly in those animals exposed to 500mg/kg 
b.wt. BHT in utero. Only the control samples and high dose group samples were examined. 
At time point 2, (weaning/21 days post birth), there was a statistically significant induction 
of this activity in those animals weaned onto 250mg/kg b.wt. BHT, indicating low levels of 
growth hormone. Time point 3 showed that this activity was significantly decreased in the 
BHT exposed animals compared to controls, which would suggest that these animals have 
higher growth hormone levels than the controls of the same age. This could be seen as an 
attempt by these animals to "catch up" the control animals with respects to body weight. 
Figure 19b indicates that this activity tends to increase with age in both the treated and the 
non-treated animals, with the exception of time point 2 controls.
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FIGURE 19a. ^^EAN  RELATIVE ETHYLMORPHINE N-DEMETHYLASE ACTIVITY.
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FIGURE 19b MEAN ABSOLUTE ETHYLMORPHEVE N-DEMETHYLASE ACHVTTY
Control
Figures 19a and 19b are the mean Ethylmorphine N-demethylase activities in liver 
microsomal fractions from animals exposed in utero and up to 4 weeks post weaning to BHT 
at concentrations of 500mg/kg B .w t (time point 1) and weaned onto 250mg/kg b.w t (time 
point 2 and 3).and their controls. Means +/- sem and statistical analysis are presented on table 
14. It should be noted that only controls and high dose group animals were examined.
TABLE 14. ETHYLMORPHINE N-DEMETHLASE ACTIVITY
TIME POINT I 2 3
20th Day of gestation 3 weeks post birth 4 weeks post weaning
BHT Dose 
(mg/kg/day)
Ethylmorphine N-demethylase ; nmoles/min/mg microsomal protein
0 1.09 ± 0.35 [5] 0.20 ± 0.16 [5] 6.36 ± 0.66 [5]
250$ 0.36 ± 0.25 [5] 
(33)
0.97 ± 0.25 [5] 
(375):^
4.52 ± 0.35 [5] 
(71)*
Table 14 shows the mean ethylmorphine n-demethylase activity in liver samples taken from 
control and highest dose BHT treated animals up to 4 weeks post weaning. Values are presented 
as the mean activity r  sem, where n.=5.
( ) % of control activity. Statistical analysis was conducted using Student’s T test, where
* = significantly different from control P< 0.05, ** P < 0.01. P< 0.001.
♦ Time points 1 and 2 dams fed 500mg/kg b.wt/day BHT, pups weaned onto 250mg/kg BHT diets.
7.7.3. Gel Electrophoresis of Microsomal Proteins.
Photograph A shows the electrophoretic separation of the microsomal proteins from both 
control and high dose BHT group animals only. Lane 1 shows a range of molecular weight 
markers/standards; 66KDa : Bovine Albumin, 45KDa : Egg Albumin, 36KDa : Glyceraldeliyde-3- phosphate 
dehydrogenase, 29KDa ; Carbonic Anhydrase, 24KDa : Trypsinogen, 20.1KDa : Trypsin Inhibitor, 14.2KDa : a- 
Lactaibumin. Lane 2 shows the liver microsomal proteins from animals pretreated with 3
consecutive i.p. injections of phenobarbitone (PB), (80mg/kg body weight) i.e. the positive 
control sample. Four distinctly darker staining bands are present in this lane; band 1, 
apparent molecular weight (Mwt.) 56.9KDa, band 2, Mwt.54.9KDa, band 3, Mwt. 52.5KDa 
and band 4, Mwt. 46.8KDa (as determined by their relative mobility index (Rf). In 
comparison with the positive control sample, lane 3 (foetal livers from control dams) and 
lane 4 (foetal livers from 500mg/kg body weight dams), only exhibit two of these darker 
staining bands in the same area. These bands have been labelled o; and 13 to distinguish them 
from the bands in the positive PB sample, a  and B have apparent Mwts. of approximately 
57KDa and 55KDa respectively, band B appearing to be darker in lane 4 i.e foetal livers 
from dams fed 500mg/kg body weight/day BHT. Lanes 5 and 6 are liver microsomal proteins 
from pups at the end of weaning, from dams fed either control diets or BHT at 500mg/kg 
body weight/day. Both lanes show 4 distinct bands at similar positions to those of the PB 
treated animals. These bands have been labelled a , B, y & a and have apparent Mwts. of 
58.2KDa, 55KDa, 52KDa and 47KDa, respectively. These values were identical for both 
control and treated samples, the only difference being darker staining in BHT treated 
samples. Lanes 7 & 8 are control and 250mg/kg body weight BHT treated samples from 
animals one month post weaning. The darkest staining bands are seen in lane 8 , which has 
a fifth band (labelled e, Mwt 49KDa) not present in the control sample. Lanes 9 & 10 show 
a similar induction profile of bands to those seen in both the positive control (lane 2 ) and also 
BHT treated animals up to 1 month post weaning (lane 8). Again an increase in staining 
intensity is evident in lane 10 (BHT treated up to 6 months post weaning). The bands labelled 
y and a appear to be highly induced in the livers from the BHT treated animals.
103
PHOTOGRAPH A. SDSPAGE of M ICROSOM AL PROTEINS,
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Lane 1: Molecular weight markers (66KDa -14KDa) 40juls/lane.
Lane 2: Phenobarbitone (PB) induced microsomes (80mg/kg body weight/day) 25/>ds/lane. 
Lane 3: Time point 1 (Control) 20th Day of Gestation Foetal Liver. 25/xls/lane.
Lane 4: Time point 1 (BHT treated) 20th Day of Gestation Foetal Liver from dams fed 
500mg/kg body weight/day BHT. 25/4ls/lane.
Lane 5: Time point 2 (Control) Pups at end of weaning. 25/xls/lane.
Lane 6 : Time point 2 (BHT treated) Pups weaned by dams fed 500mg/kg body weight/day 
BHT. 25/xls/lane.
Lane 7: Time point 3 (Control) Four weeks post weaning. 25/xls/lane.
Lane 8 : Time point 3 (BHT treated) Animals receiving 250mg/kg body weight BHT in diet 
for four weeks post weaning. 25/xls/lane.
Lane 9: Time point 4 (Control) Six months post weaning. 25/xls/lane.
Lane 10: Time point 5 (BHT treated) Animals receiving 250mg/kg body weight/day BHT 
for six months post weaning. 25/xls/lane.
All microsomal samples were diluted in sample buffer such that 1ml contained Im g of 
microsomal protein.
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7.7.4. Immunological Identification of Induced Cytochrome P450 Isoenzymes.
The proteins from SDS-Page for controls and high dose group BHT treated animals (all three 
time points) were subjected to the transfer procedure onto nitrocellulose sheets, as detailed 
in the materials and methods section 6.6.3.15 Western Blot Analysis. Three identical gels 
were run in duplicate so that one could be stained whilst the other transferred prior to blotting 
with one of three antibodies raised against three cytochrome P450 isoenzymes. The antibodies 
were raised in rabbits against CY PlA l, CYP2B1 and CYP2E1 which corresponded to the 3 
major isoforms of three subfamilies of CYP450, classically induced by 3 Methylcholanthrene 
(3MC), Phénobarbital (PB) and Ethanol. Unfortunately, due to a fault in the power pack used 
to carry out the transfer, no proteins were transferred and at the end of a lengthy procedure 
no bands were detected. Several repeats of this technique confirmed that the problem was not 
with the antibodies etc but with the power pack. As this was a method that had been 
successful carried out several times before using this same equipment, it took a long time to 
find this fault and unfortunately there was not enough time to re-blot the gels using other 
equipment.
However, previous blots using control and high dose group BHT samples from time point 3 
only, did show that the antibody raised against CYP2B1 bound to two bands in both the 
controls and test samples. There was a greater degree of staining with the BHT test sample 
than in the control, indicating more of that particular isoenzyme in the treated animal i.e. an 
induction. The positive control sample was hepatic microsomal protein from a phenobarbitone 
treated animal which produced three bands on the nitrocellulose sheet with this antibody, 
suggesting a difference between PB induced P450s and BHT induced P450s. ( Blot not 
shown). Thus immunological identification of the isoenzymes induced by BHT was achieved.
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7.8 Serum Biochemistry
Table 15 presents data on the blood clotting ability of animals treated with BHT at 500mg/kg 
b.wt. in utero and subsequently at 250mg/kg b.w t untü 4 weeks post weaning. This was 
carried out as earlier reports suggested that BHT may have an effect on clotting time. These 
results came from the first, aborted study and were so conclusive that measurement of this 
parameter was not repeated in this the second two generation study. The results do not show 
any differences from control values in any of the treated groups at doses up to 250mg/kg 
b.wt. after exposure in utero at doses of 500mg/kg b.wt. No measurements were made in the 
20 th day of gestation animal.
Table 15. Thrombotest- A Measure of Clotting Ability.
Time
Point
Dose
mg/kgfday
2
(F I pups)
3
(Ifl)
0 65.08±2.84 81.50+1.71
25 6L50±2.91 80.96±2.19
100 62.50+2.64 79.73±1.91j
250 61.60+1.63 78.33+1.29
n 5 15
Significantly different P < 0.05.
The results presented are the mean clotting time (secs) +/- sem determined in the serum of 
male rats exposed to BHT in utero and up to 4 weeks post weaning at doses of 500mg/kg and 
250mg/kg at weaning (time point 2 onwards). 
n= number of samples per group. 
a= Dams fed 500mg/kg b.wt BHT.
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CONCLUSIONS
BHT administration in utero and up to 4 weeks post weaning at doses up to 500mg/kg 
b.wt./day to the Fo generation, had no effect on the number of viable foetuses, the number 
of resorption sites, the number of pups born per litter or on the ratio of malesifemales. There 
was no difference in the mean body weight of individual pups at birth. There was a trend 
towards an increase in the number of pups/litter found dead or dying with increasing dose up 
to 6 days after birth and prior to reduction of litter number to eight pups/htter/dam. Pups born 
to high dosed dams failed to gain weight at a comparable rate to all other groups and 
maintained this weight deficit up to examination at 4 weeks post weaning. There was no 
difference in food consumption between control diet fed FI generation animals and BHT diet 
fed FI generation animals. BHT fed animals showed increased liver:body weight ratios at all 
three time points. No macroscopic changes were seen in treated groups at time points 2 or 
3 compared with control animals, nor were there any histopathological changes in the livers 
at any time point or dose level.
BHT administration did alter the activities of several biochemical parameters. Enzymes 
involved in phase I and phase II metabolism were generally increased with treatment and also 
with age, whilst specific isoforms of the cytochrome P450 dependant mixed function oxidases 
were induced at all three time points. As the induction profiles of the various CYP450s forms 
an important part of this thesis, the results will be discussed in greater detail in the discussion 
section. No effect on blood clotting ability was noted.
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SECTION 3.
The effects of BHT administration on the FI Generation during adult life.
(From 6 months post weaning until 22 months post weaning)
7.9 GROSS OBSERVATIONS
7.9.1 Effects on Health.
The continued administration of BHT in the diet at doses of 25, 100 and 250mg/kg b.wt./day, 
had no deleterious effects on the health of the animals up to the termination of the study. All 
animals remained healthy and active during this period, with the exception of a few animals, 
randomly spread through out the dose groups, that were removed from the study on humane 
grounds.
7.9.2 Effects on Growth.
Figures 20a to 20c show that from time point 4 onwards (6 months post weaning), the 
animals receiving the mid dose of BHT (lOOmg/kg b.wt.) and the high dose of BHT 
(250mg/kg b.wt.) were consistently lighter than either the control or low dose group (25mg/kg 
b.wt.) animals. This weight deficit was apparent from time point 2 and was maintained until 
termination of the study. All animals gained similar amounts of weight on a weekly basis, but 
the high dose group animals never attained the same mass as animals in other dose groups 
born on the same day.
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M EAN BODY W EIGHTS O F THE F I  GENERATION M ALE.
Figures 20a, b and c.
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Figures 20a to c represent the mean body weights of the F I generation males fed BHT at 
nominal doses of 25mg (low), lOOmg (mid) and 250mg (high)/kg body weight/ day following 
exposure in utero and up to 22 months post weaning. Body weights of control animals are 
also presented. Body weights were monitored on a weekly basis and are presented as body 
weight days from weaning. It should be noted that the high dose group was reduced from 
500mg/kg body weight/day given to the FO generation to 250mg/kg body weight/day. Mean 
values ±  sem, number of animals and statistical analysis are presented on table 16.
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7.9.3 Effects on Food Consumption and BHT Intake.
There was no significant difference in the food consumption of the BHT dosed animals when 
compared to controls (Figures 21a, 21b and 21c). BHT intake remained close to the target 
intakes (see Section 2, page 87, Fig. 10c).
MEAN FOOD CONSUMPTION OF F I GENERATION MALES.
Figures 21a, 21b and 21c.
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Figures 21a, b and c represent the mean food consumption (g/ animal /day) of the FI 
generation males fed BHT at 25mg (low), lOOmg (mid) and 250mg (high)/kg b.wt./day from 
6 months post weaning (time point 4) to 22 months post weaning (time point 7). 
Corresponding control values are also presented. Food consumption was measured three times 
per week.
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7.10 GROSS OBSERVATIONS AT AUTOPSY.
The condition of the animals prior to each time point autopsy was good. Figure 22a shows 
that the terminal body weights of the 250mg high dose group animals were significantly 
reduced compared to controls at both time points 5 and 6 . At time point 6 the mean terminal 
body weights of the mid dose group (lOOmg) were also significantly lower than controls. 
Figure 22b shows that there was no difference in terminal liver weights between controls and 
dosed groups at any time point, with the exception of the mid dose group animals at time 
point 5 (11 months post weaning). However, the high dose group animals had significantly 
raised liver:body weight ratios at time points 4, 5 and 6 (Figure 22c and table 16). At time 
point 5 all BHT fed animals had significantly increased liver:body weight ratios.
Figure 22a. MEAN TERM INAL BODY W EIGHTS AS % OF CONTROLS.
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Figures 22a and 22b are the mean terminal body weights and mean liver weights of the FI 
generation male rats fed BHT at concentrations of 25mg (low), lOOmg (mid) and 250mg 
(high)/kg b.wt./day. The results are from 6 months up to 22 months post weaning. Absolute 
mean values +/- sem, n and statistical analysis are presented on table 16.
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Figure 22c. MEAN LIVER:BODY WEIGHT RATIOS AS % OF CONTROLS.
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Figure 22c represents the mean liver:body weight ratios of the FI generation animal 
expressed as a percentage (%) of controls. Animals had been exposed to BHT in utero and 
then weaned onto diets which delivered 25, 100 or 250mg/kg body weight/day BHT. Sample 
times were 6, 11, 16 and 22 months post weaning (Time points 4,5,6 and 7 respectively). 
Absolute mean values ±  sem, number of animals and statistical analysis are presented in 
table 16.
TABLE 16. MEAN BODY, LIVER and LIVERiBODY WEIGHT RATIOS.
Time Point 4  (6 months post 
weaning)
5 (11 months post 
weaning)
6  (16 months post 
weaning)
7 (22 months post 
weaning)
BHT Dose 
(mg/kg/day)
Body Weight (g)
0 583.76 ± 22J1 i5] 682.16 ± 2538 [10] 736. 08 ± 25.51 [10] 682.60 ± 24.21 [10]
25 622.54 ± 41.41 [5] 
(107)
672.31 ± 13.63 [8] 
(99)
697.18 ± 28.72 [9] 
(95)
700.32.91 ± 32.91 [13] 
(103)
100 576.48 ± 35.47 [5] 
(99)
646.06 ± 24.12 [8] 
(95)
660.56 ± 18.49 [9] 
(90) **
652.92 ± 2535 [11] 
(96)
250* 547.63 ± 18.76 [4] 
(94)
554.04 ± 1739 [10] 
(81) ***
599.66 ± 1531 [13] 
(81) «** ' ^
648.64 ± 14.36 [19] 
(95)
Liver Weight (g)
0 19.44 ±1.25 [5] 2233 ± 0.84 [10] 25.97 ± 1.05 [10] 2634 ± 1.03 [10]
25 21.14 ± 1.75 [5] 
(109)
24.31 ± 0.81 [8] 
(109)
26.14 ± 1.94 [9] 
(101)
26.29 ± 0.87 [13] 
(99)
100 20.66 ± 1.05 [5] 
(106)
25.55 ± 1.02 [8] 
(114) *
25.43 ± 1.02 [9] 
(98)
30.02 ± 136 [11] 
(113)
250* 21J4 ± 0.50 [4] 
(11)1
21.67 ± 1.01 [10] 
(97)
25.27 ± 0.92 [13] 
(97)
27.06 ± 1.10 [19] 
(102)
Liver Weight as % of Body Weight (%) —
0 332 ± 0.11 [51 3.28 ± 0.08 [10] 335 ± 0.16 [10] 3.90 ± 0.13 [10]
25 339 ± 0.11 [51 
(102)
3.62 ± 0.10 [8] 
(110) *
3.78 ± 032 [9] 
(107)
3.80 ± 0.16 [13] 
(97)
100 3.61 ± 0.15 [51 
(109)
3.97 ± 0.15 [8] 
(121) ***
3.89 ± 0.11 [9] 
(109)
4.74 ± 0.44 [11] 
(121)
250* 3.94 ± 0.07 [4] 
(119) **
3.90 ± 0.11 [10] 
(119) ***
4.27 ± 0.11 [10] 
(120) *■*
4.16 ± 0.12 [19] 
(106)
Table 16 shows ihe mean terminal body and liver weights and the mean livertbody weight ratios (as percentage). 
Statistical analysis was carried out using Student’s T test where. * = significantly different from control 
P g 0.05, • •  PS 0.01. PS 0.001.
( )  % of control
♦ Pups from dams fed 500mg/kg b.wt/day BHT prior to conception and through out weaning
1 1 2
M ACROSCOPIC FINDINGS.
Macroscopic examination of the major organs was carried out at each time point autopsy. 
The following is a summary of the major findings.
TIME POINT 4 : 6 months post weaning.
2/5 mid dose group animals and 1/5 high dose group animals were observed to have darker 
livers.
TIME POINT 5 : 1 1  months post weaning.
5/8 mid and 5/10 high dose group animals had darker livers compared to controls.
3/8 mid and 4/10 high dose group animals had decreased body fat.
2/8 mid and 2/10 high dose group animals had darker and enlarged thyroids.
TIME POINT 6 : 16 months post weaning.
6/13 high dose group animals had darker livers compared to controls.
4/13 high dose group animals had darker/enlarged thyroids than controls.
TIME POINT 7 : 22 months post wening (Termination).
Table 17 is a complete list of the macroscopic changes observed in the animals at the
termination of the study. It has been included to make the reader aware of the range of
organs examined and the various terms used to describe them. It also shows the number of 
masses found in aU of the groups which would be too long winded to identify individually. 
A description of these masses is given in the footnote list on the next page.
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TABLE 17 Macroscopic Changes Seen in Rats at Autopsy.
Time Point 7 (22 months post-weaning - Termination)
BHT dose 
(mg/kg/day)
0
(1 0 )
25
(13)
100
(11)
250
(19)
Liven Mottled 1 1 4 4
Friable 1 1 2 ^ 3
Darker 0 1 2
Smaller 0 0 0 D
Other 0 0 0 1^
Kidney: Left
Blistered 0 0 0  . 1
Mottled 1 3 3 3
Hydronephrotic 0 1 1 2
Old age nephrotic 4 1 3 1
Loss of structure 1 1 . . 3 2
Olive coloured 0 2 1 1
Enlarged 0 0 2 1
Other 1^ 0 1^ 1^
Kidney: Right
Blistered 1 0 1 1
Mottled 1 3 3 3
Hydronephrotic 0 1 1 2
Old age nephrotic 4 1 3 1
Loss of structure 1 1 3 2
Olive coloured 0 2 1 1
Enlarged 0 0 2 2
Other 0 0 1^ 0
Thyroid: Enlarged 1 1 0 0
Dark 0 2 0 0
Small 0 0 1 0
Adrenals: Enlarged 0 2 0 0
Haemorrhagic 0 1 0 0
Spleen: Darker 1 0 0 . 0
Enlarged 0 1 1 1
Small 0 0 0 2
Lymph nodes 0 0 0 1
Lungs: Mottled 2 2 2 5
Body fat: Reduced 1 2 2 1
Increased 2 1 0 0
Masses: 5-' 8^ 3h 5^
Othen 2 Î im
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FOOTNOTES FOR TABLE 17.
Footnotes:
a Left kidney has pale cortex
b Possibly due to post mortem changes
c Haemormagic medulla
d Small yellow foci of necrotic tissue
e Fluid filled
f Masses found on 4 separate animals:
(i) Possible papilloma left shoulder
(ii) Mass on tail. Possible papilloma on shoulder
(iii) Small soft lump.
(iv) Small soft lump
g Masses found on 7 separate animals:
(i) Mass left hand side
(ii) Large mass under right foreleg. Non penetrative, vascular and dark red i; 
appearance
(iii) White soft vascular lump. Large lump lower abdomen
(iv) Soft white lump left hand side of back.
(v) Small white dense mass.
(vi) Possible papilloma right-hcmd side.
(vii) White crumbly mass, possibly papilloma, 
h Masses on 3 separate animals.
(i) Wart on hind fooL
(ii) ■ Small mass left shoulder.
(iii) Crumbly mass
i Masses on 4 separate animals
(i) Hard, non-vascular oval mass right hind quarters
(ii) Mass on back
(iii) Dense white non-vascular mass
(iv) Subcutaneous vascular mass attached to body. Size 3.5cm x 2.5cm. Small, denst 
white, non vascular mass.
j  (i) Enlarged caecum
(ii) Abrasion left hand side
k Wasted back legs
1 Exposed area abdomen
m Yellow lungs
( ) Number of rats per group.
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7.10.1. Histology.
Time point 4 : Examination of liver sections from animals treated with BHT in utero and up 
to 6 months post weaning showed that all sections had centrilobular enlargement of the 
hepatocytes, which were eosinophilic in appearance. One animal out of five in the mid dose 
group and one out of five in the high dose group showed focal büe duct proliferation. (Data 
not presented). Kidneys, adrenals and thyroids of treated animals showed no difference from 
controls.
Time point 5 : Table 18 summaries both the liver histopathology and histochemistry of 
sections taken from animals 11 months post weaning. As in time point 4, there was a dose 
related centrilobular enlargement of hepatocytes, the appearance of which suggested 
hypertrophy of the smooth endoplasmic reticulum. Inflammatory cell infiltrate was present 
in both controls and high dose treated animals at the same frequency, as was büe duct 
hyperplasia. Thus it was not possible to show a clear correlation between BHT administration 
and büe duct hyperplasia or inflammatory ceU infiltrate. Sections were also examined 
morphologicaUy and histochemicaUy to identify and quantitate any foci of ceüular alteration 
(AHF) which may have been present at this time point.
One low dose group animal, 1 mid and 2 high dose group animals were each found to have 
a single focus made up of clear ceUs. No clear ceU foci were found in the control animals 
but 1 had " a nodule of eosinophilic ceUs surrounded by an incomplete ring of minimaUy 
compressed adjacent hepatic tissues". The pathologist reported that "the nodule and the AHF 
appeared to be naturaUy occurring phenomena", whüst clear ceU AHF have been shown to 
be the predominant, spontaneously occurring type of foci in one strain of male rat (Harada 
1989).
1 1 6
Histochemical identification of AHF in this study was based upon the expression of two 
enzyme markers; Glucose 6 -phosphatase (G6Pase) and gamma Glutamyltranspeptidase (gGT). 
Cells within altered hepatic foci generally have a decreased expression of G6Pase activity, 
whilst an increase in gGT is normally observed.
One control animal was found to have a single small focus with decreased G6Pase activity 
whilst all BHT treated animals showed the normal mid and periportal distribution of staining 
for G6Pase. No gGT activity was noted in the liver sections from any of the control animals 
examined in contrast to the dose related increase in periportal activity seen in the BHT 
treated animals. Two out of ten animals in the 250mg/kg body weight/day BHT dose group 
were found to have AHF with increased expression of gGT activity.
Histopathological examination of the kidneys and adrenals of BHT treated animals did not 
reveal any differences from controls (data not shown). Hyperactive thyroids were diagnosed 
in 6/8  mid and 10/10 high dose group animals. Hyperactivity was diagnosed if some 
or all of the following were present : reduced foUicular size, absence of colloid, hyperaemia 
or increase in size of the follicular cells. The photographs on page 119 show sections of 
thyroid glands from both a control and a BHT treated animal examined by electron 
microscopy. The BHT treated animal clearly shows signs of thyroid hyperactivity 
(photograph 5), e.g. reduced foUicular size and coUoid depletion.
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TABLE 18. Histopathological Changes in the Liver of Rats 11 Months Post Weaning.
TIME POINT 5.
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PHOTOGRAPH 4. CONTROL THYROID.
T
Photomicrograph of thyroid from a male rat fed unadulterated 
diet for 11 months post weaning (Time point 5).
Stain: Haematoxylin and Eosin. Formalin fixed.
Magnification XIO.
PHOTOGRAPH 5. BHT TREATED THYROID.
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body weight/day for 11 months post weaning (Time point 5).
Note the increase in the ratio of follicular cells (PC): colloid 
(C) suggesting an increase in thyroid activity.
Stain. Haematoxylin and Eosin. Formal in fixed.
Magnification XIO.
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Time point 6 : The liver histopathology and histochemistry findings are presented in table 
19 (page 121). Centrilobular enlargement was noted in 12/13 high dose group animals 
(250mg/kg/day BHT) and in 3/9 low dose group animals (25mg/kg/day BHT). Inflammatory 
cell infiltrates found at the same frequency through out aU groups including controls. Bile 
duct hyperplasia was noted in aU of the animals, no clear correlation with BHT 
administration could be made. The only nodule reported was found in one of the control 
group animals. Morphologically, most of the AHF were diagnosed as clear cell type, similar 
numbers occurring in the controls and the BHT treated animals. One eosinophilic AHF was 
diagnosed in each of the three dose groups. HistochemicaUy, the control group sections all 
appeared normal when examined for either glucose-6 -phosphatase (G6Pase) (photograph 6) 
or gamma glutamyl transpeptidase (gGT) (photograph 7) activities. There was an increase 
in periportal gGT activity in 8/9 and 13/13 samples in the 100 and 250mg/kg body 
weight/dat BHT groups, respectively (photograph 8). This is a simUar pattern as seen in 
sections taken at time point 5 (1 1  months post weaning) but now more pronounced in the 
high dose group animals. There were no gGT foci identified in any section examined in any 
of the dose groups.
Histopathological examination of the kidneys and adrenals did not show any treatment related 
effects, those changes that were noted were age related. The thyroid continued to show signs 
of hyperactivity in both the lOOmg/kg body weight/day (mid) and 250mg/kg body weight/day 
(high) dose groups, all animals in the high dose group now exhibiting some degree of 
hyperactivity.
1 2 0
TABLE 19. Histopathological Changes in the Liver of Rats 16 Months Post Weaning.
TIME POINT 6.
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PHOTOGRAPH 6. DISTRIBUTION OF GLUCOSE 6 PHOSPHATASE.
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This shows the normal d i s t r ib u t io n  of glucose 6 phosphatase in 
the l iv e r  of r a t s .  No e f fec t  was seen in the majori ty  of animals 
t rea ted  with BHT when compared to con tro ls .  At 16 months post 
weaning one small AHF def ic ien t  in GBPase a c t i v i t y  was noted in 
a r a t  fed 250mg/kg body weight/day BHT. At termination of the 
experiment 3 animals t rea ted  with the same dose showed small areas 
of moderately reduced a c t iv i t y .
Stain:  Glucose 6 phosphatase. Frozen cryosta t  sect ion .  
Magnification XIO.
HCriDGRAPH 7 .  NORMAL GANf4A GT ACTIVITY. 
I
Photomicrograph of normal distribution of gamma glutamyl 
transpeptidase (gGT) activity in rat liver.
Stain: gGT. Frozen cryostat section.
Magnification XIO.
PHOTOGRAPH 8. gGT ALTERED HEPATIC FOCUS
#
Photomicrograph showing an altered hepatic focus (AHF) of gaimia
glutamyl transpeptidase (gGT) in a rat treated with 25Qrag/kg 
body weight/day BHT for 22 months post weaning.
Stain: gGT. Frozen cryostat section.
Magnification XIO.
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Table 20 summarises the histopathology and histochemistry results obtained from liver 
sections from animals treated with BHT in utero and up to 22 months post weaning i.e. time 
point 7. There was a clear dose related centrilobular enlargement in the livers of these 
animals, 18/19 high dose group animals (250mg/kg body weight/day BHT) showing this 
change. Examination of the results of time points 5 and 6  show that this change had 
progressively worsened with age in the high dose group animals more so than in any of the 
other BHT treated groups. Control animals did not show this change at any of the three time 
points examined, therefore, it is reasonable to conclude that BHT treatment was the cause 
of this change. Inflammatory ceU infiltrate was noted in both the control animals and the 
BHT treated ones. Although there is no clear distinction between BHT treatment and the 
numbers of animals found to have inflammatory ceU infiltrate, it appears that mid and high 
dose group animals have a lower percentage of animals with this finding compared to 
controls. BUe duct hyperplasia was found throughout aU groups at this time (see photograph 
9, page 127). There did not appear to be any statisticaUy significant difference between 
controls and treated animals, nor was thereany increase in this change with age. By 22 
months, cystic degeneration was evident in various animals in aU four groups but there was 
no significant difference due to BHT treatment. Four nodules of eosinophiUc ceUs were 
identified in the high dose group animals with one in each of the control, low and mid dose 
groups (see photograph 11, page 128). In the previous time point, 16 months post weaning, 
only one nodule was identified and that was found to be in the control group. This would 
suggest that age was an important factor.
Histopathologically, all groups were found to have at least 50% or more of the animals with 
clear cell altered hepatic foci (AHF), this number being greatly increased from time point 
6 . An example of a clear ceU AHF can be seen in photograph 10, page 127. The 
identification of eosinophilic foci appears to be age related and dose related, with an 
increased number of animals found to have these in the high dose group. Three out of 19 
animals (16%) were found to have basophiUc AHF which were not found in any other time
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point or dose group. The significance of this finding will be discussed in greater detail later. 
Histochemical characterisation of the AHF revealed that 3/19 high dose group animals had 
a decreased expression of glucose-6 -phosphatase activity, whilst none were found in any of 
the other groups. There appeared to be a dose related increase in the number of animals with 
an increased periportal expression of gamma glutamyl transpeptidase activity, 7/11 mid dose 
group and 17/19 high dose group animals. Only 1/10 controls was found to have increased 
activity.
Histological examination of the kidneys of these animals did not show any treatment related 
effects, most observations, for example, chronic progressive nephropathy, being randomly 
scattered throughout aU groups. Similarly, examination of the adrenal glands did not show any 
treatment related damage, in fact a lower percentage of treated animals than controls showed 
any abnormalities. Hyperactivity of the thyroid gland was again found in only the mid and 
high dose group animals, almost 1 0 0 % in both cases (data not shown).
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TABLE 20. Histopathological Changes in the Liver of Rats 22 Months Post Weaning.
TIME POINT 7.
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PHOTOGRAPH 9. BILE DUCT HYPERPLASIA.
>v. *
- (
Photomicrograph of sect ion of l iv e r  from male ra t  t rea ted  with 
250mg/kg body weight/day BHT for 16 months post weaning.
Bile duct hyperplasia  is  evident in th is  sect ion.
Stain: Haematoxylin and Eosin. Formalin fixed.
Magnification XIO.
PHOTOGRAPH 10. CLEAR CELL ALTERED HEPATIC FOCUS.
Photomicrograph of l iv e r  sect ion taken from a male r a t  t rea ted  
with lOOmg/kg body weight/day BUT for 16 months post weaning showing 
a c lea r  ce l l  (glycogen) AHF. This was not treatment re la te d .
Stain:  Haematoxylin and Eosin. Formalin fixed.
Magnification XIO.
VX7
PHOTOGRAPH 11. NODULE OF EOSINOPHILIC CELLS
The photomicrograph shows a sect ion of r a t  l i v e r  following 
treatment with 250mg/kg body weight/day BHT for 22 months 
post weaning. There is  a nodule of eos inophi l ic  c e l l s .
Note the compression of adjacent trabeculae and hepatocytes 
Stain:  Haematoxylin and Eosin. Formalin fixed t i s sue .  
Magnification XIO.
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7.11 CHANGES IN BIOCHEM ICAL PARAMETERS IN THE AGING ANIMAL.
7.11.1. Enzymes Used as Indicators of Hepatotoxicity.
Figures 23a and 23b show that at time point 4, 6 months post weaning, there is no statistically 
significant difference in the activity of glucose 6-phosphatase between controls and treated 
animals. It should be noted that the levels found at this time point are approximately half of 
those found at time point 3, 4 weeks post weaning (Table 21). This is not a treatment related 
change as control values are also halved, but could be an age related decrease or methodology 
problem ( the reader is referred forward (section 4) to the data obtained in the earlier aborted 
study where the results do not show this drop in the control values at time point 4). At time 
points 5, 6 and 7 the mean GoPase activity of both the low and high dose group animals is 
consistently reduced by approximately 15-20% of corresponding control values. Over the 
same three time points the mid dose group shows approximately a 30% decrease in activity 
at both time points 5 and 7 but values similar to controls at time point 6 . Table 21 has mean 
activities +/- sem for all 4 time points and shows that developmentally this enzyme activity 
increases in the control animal, reaching a peak at 4 weeks post weaning, declining to 
approximately half of this activity at 6 months post weaning then gradually increasing to this 
peak value by 22 months post weaning. From 6 months post weaning onwards (time point 4) 
the BHT fed animals show a trend towards a decrease in this activity, suggesting the 
possibility of a "disturbance" in the e.r. where this enzyme is located in the membrane.
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FIGURES 23a and 23b.
MEAN ABSOLUTE AND RELATIVE GLUCOSE 6 -PHOSPHATASE ACTIVITIES
(Time points 4 to 7 inclusive).
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Figures 23a and 23b represent the mean glucose 6-phosphatase activities in liver homogenates 
from male rats exposed to BHT in utero and up to 6 months (time point 4), 11 months (time 
point 5), 16 months (time point 6) and 22 months (time point 7) post weaning onto diets 
containing BHT at nominal concentrations of 25mg (low), lOOmg (mid) and 250mg (high)/kg 
b.wt/day. Mean values +/- sem, n (number of animals) and statistical analysis are presented 
on table 21. 130
Total glutathione activity (GSH) is non significantly decreased in all BHT treated animals at 
time point 4 compared to controls (Figures 24a and 24b). This is an important detoxification 
protein for the liver and was examined to see what effects BHT administration had on the 
levels and how these changed with long term exposure. At time point 5 both the low 
(25mg/kg) and the mid (lOOmg/kg) groups have values similar to controls but the high dose 
group (250mg/kg) is significantly lower than controls. By time points 6 and 7 (16 and 22 
months post weaning) all dose groups have GSH activities similar to their control groups 
(Figures 24a, 24b and table 21). Developmentally, total glutathione activity appears to be very 
high in the 20 th day of gestation fetuses, falls at weaning from this fetal value, then gradually 
increases with age reaching a peak at 6 months post weaning (time point 4). Both the 11 and 
16 months post weaning control animals show decreases in GSH activity but at termination, 
22  months post weaning, this enzyme activity increases to values similar to those seen in the 
20th day of gestation fetuses. Only the high dose group animals up to time point 5 (11 
months post weaning) show a consistently lower GSH activity which would suggest that the 
liver’s detoxification pathway was very active and that the liver could not maintain the levels 
of glutathione of animals of a similar age.
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FIGURES 24a and 24b.
MEAN ABSOLUTE AND RELATIVE TOTAL GLUTATHIONE ACTIVITIES.
(Time Points 4 to 7 inclusive).
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Figures 24a and 24b represent the mean absolute and relative total glutathione activities found 
in the cytosolic fraction of livers from BHT fed animals at 6 , 11, 16 and 22 months post 
weaning (time points 4, 5, 6 & 7 respectively). The mean values +/- sem, n (number of 
animals/group) and statistical analysis are presented on table 21 along with the values from 
time points 1 to 3.
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TABLE 21. PARAMETER USED AS INDICATOR OF HEPATOTOXICITY.
TIME POINT 4 5 6 7
6 months post 
weaning
11 months post weaning 16 months post weaning 22 months post weaning
BHT Dose 
(mg/kg/day)
GLUCOSE 6-PHOSPHATASE : nmoles/min/’mg homogenate protein
0 14.95 ±  2.82 [5] 17.39 ± 3.17 [10] 19.70 ± 1.60 [10] 33.38 ± 5.95 [10]
25 16.78 ± 1.59 [5] 
(112)
14.11 ± 3.17 [8] 
(81)
17.35 ± 1.42 [9] 
(SB)
28.50 ± 2.73 [13] 
(85)
100 17.24 ± 0.94 [5] 
(102)
12.44 ± 2.79 [8] 
(72)
19.10 ± 0.74 [9] 
(97)
25.39 ±2.80 [11]
c% )*
250* 15.27 ±  1.72 [4] 
(102)
14.90 ± 2.91 [10] 
(86)
16.76 ± 0.99 [13] 
(85)
27.72 ± 232 [19] 
(83)
TOTAL GLUTATHIONE : pmoles/mg cvtosolic protein
0 0.142 ± 0.024 [5] 0.128 ± 0.008 [10] 0.086 ± 0.005 [10] 0.117 ± 0.011 [10]
25 0.116 ± 0.029 [5] 
(82)
0.132 ± 0.005 [8] 
(103)
0.083 ± 0.002 [9] 
(96)
0.114 ± 0.009 [13] 
(98)
100 0.128 ± 0.017 [5] 
(90)
0.124 ±  0.006 [8] 
(97)
0.087 ±  0.009 [9] 
(101)
0.110 ±  0.009 [11] 
(94)
250* 0.117 ±  0.026 [4] 
(82)
0.102 ±  0.006 [10] 
(79) **
0.086 ±  0.007 [13] 
(100)
0.119 ±  0.009 [19] 
(102)
Table 21 shows the mean absolute and relative activities of Glucose 6-phosphatase and Total glutathione as measured in
the subcellular fractions of liver samples taken from male FI generation offspring weaned onto diets containing either 25.100 or
250mg/kg b.wt/day BHT.
[ ] Number of animals per group.
( ) % o f  control
♦ Pups from dams fed 500mg/kg b.wt/day BHT prior to mating and through out lactation.
Residts presented as mean ±  sem. statistical analysis carried out using Student's T test, where * = significantly different from controls 
P ^ 0.05, * " P 3  0.01. P S 0.001.
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7.11.2 Enzymes Used as a Measure of Microsomal Enzyme Induction.
1. GLUTATHIONE S-TRANSFERASE
There was a clear dose related increase in the relative activity of Glutathione S-transrerase(s) 
(GST) at time points 4, 5, 6 and 7 (Figure 25a and table 22). The substrate used is active with 
aU the major isoenzymes and was measured to see what effect if any BHT had on the levels 
of this important detoxifying activity/, which catalyses the conjugation of glutathione with both 
exogenous and endogenous electrophiles. This increase was found to be statistically significant 
only for those animals dosed with 100 or 250mg,/kg b.wt. BHT (Table 22). At time point 7 
those animals receiving 25mg/kg b.wt BHT showed no difference in activity over control 
values.
These cytosolic enzymes appear to increase with age until 6 months post weaning when 
activity falls to half of that found in the animals 4 weeks post weaning. Apart from a 
slight fall at 16 months post weaning, the activity of GST appears to increase with age.
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FIGURES 25a AND 25b
MEAN RELATIVE and ABSOLUTE GLUTATHIONE S-TRANSFERASE ACTIVITIES
(Time points 4 to 7 inclusive).
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Figures 25a and 25b are the mean glutathione s-transferase activities, both absolute and 
relative to controls, measured in the cytosolic fraction of livers obtained from male rats 
exposed to BHT in utero and up to 22 months post weaning. Animals were weaned onto diets 
containing 25, 100 or 250mg BHT/kg b.wt. Mean values +/- sem, n and statistical analysis 
are presented on table 2 2 .
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Figure 26a shows that total hepatic Cytochrome P450 (CYP450) activity showed no difference 
to control values in any of the dose groups at time point 4 (6 months post weaning). At time 
point 5 (11  months post weanjng), the activities measured in the mid and high dose groups 
were increased, significantly in the high dose group only (Table 22). At time points 6 and 7 
only the high dose group animals had significantly raised CYP450 activity, the low dose 
group showing a non significant fall at both time points. In absolute terms, figure 26b shows 
that the constitutive levels of this activity are fairly constant with age/time, mean values 
approximately 0.7 nmoles/mg microsomal tissue in the control animal. Total CYP450 remains 
induced in the aging treated animals receiving BHT at lOOmg/kg b.wt /day and above. 
FIGU RE 26a MEAN TOTAL CYTOCHROM E P450 ACTIVITY.
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Figures 26a and 26b present the mean total cytochrome P450 activities expressed as % of 
control values and absolute values. Activities were assayed in the microsomal fraction of the 
livers of male rats fed BHT in the diet at 25mg (low), lOOmg (mid) and 250mg (high)/kg 
b.wt. at 6 , 11, 16 and 22 months post weaning (time points 4, 5,6 and 7). Mean values +/- 
sem, n and statistical analysis are presented on table 2 2 ).
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Ethoxyresorufin o-deethylase (EROD) activity showed a non significant induction with all 
doses of BHT at ail time points, with the exception of the low dose group animals examined 
at time point 4 (Figure 27a and table 22). Only time points 5 and 6 showed clear cut evidence 
of a dose related induction. Figure 27b indicates that this activity decreases with age in the 
control animal, plateauxing at 11 months post weaning (time point 5). Inducabfiity of EROD 
activity in the treated groups is still possible up to 22 months post weaning.
FIGURE 27a ETHOXYRESORUFIN O-DEETHYLASE ACTIVITY
(Relative to control values)
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Figures 27a and 27b are the mean EROD activities measured in the microsomal fraction of 
livers of rats fed BHT in the diet at nominal concentrations of 25mg (low), lOOmg (mid) and 
250mg (high) up to 22 months post weaning. Mean values +/- sem, n and statistical analysis 
are presented in table 2 2 . 137
Figure 28a (and table 22) shows that at all 4 time points there was significant induction of 
Pentoxyresorufin o-depentylase activity (PROD) in those animals receiving BHT at 
concentrations of lOOmg/kg b.wt. and above. The greatest induction relative to controls was 
seen at time point 7 (22 months post weaning) in the 250mg/kg b.wt dose group (high) (figure 
28a). Low doses of BHT (25mg,/kg b.wt) also showed induction of PROD over all 4 time 
points, but these were neither significant nor of the same magnimde as those in the other dose 
groups. Developmentally, PROD was not detectable in the fetal liver but increased with age 
until 11 months post weaning, lowest activity being detected in the 22 months post weaning 
control animal. The greatest absolute activity was found in the high dose group animals at 11 
months post weaning but the greatest percentage increase was found in the 250mg/kg dose 
group at 22  months post weaning.
FIGURE 28a PENTOXYRESORUFIN O-DEPENTYLASE ACTIVITY
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Figures 28a and 28b are the mean relative and absolute PROD activities measured in the 
microsomal fraction of livers from male rats fed BHT in the diet at 25mg (low), lOOmg(mid) 
and 250mg (high) up to 22 months post weaning. Mean values +/- sem, n and statistical 
’analysis are presented in table 22 .
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Epoxide hydrolase activities are presented in figures 29a (relative) and 29b (absolute) and also 
on table 22. All dose groups at all 4 time points showed a clear dose related induction of this 
activity over control values, maximum induction being measured at time 7 in the 250mg/kg 
b.wt. high dose group. Figure 29b shows that there is a trend towards increased activity in the 
control animal, peaking at 11 months post weaning, with a fall at time point 6 .
FIGURE 29a EPOXIDE HYDROLASE ACTIVITY
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FIGURE 29b EPOXIDE HYDROLASE ACTIVITY
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Figures 29a and 29b are the mean relative and absolute Epoxide hydrolase activities measured 
in the microsomal fraction of the liver of BHT fed male rats. Animals had been exposed to 
BHT in utero and then weaned onto diets containing 25mg (low), lOOmg(mid) and 250mg 
(high) BHT up to 22 months post weaning. Mean values +/- sem, n and statistical analysis 
are presented on table 2 2 . 139
Figures 30a and 30b show that the activity of Ethylmorphine N-Demethylase (END) is 
reduced at 6 months and 22 months post weaning in those animals receiving 250mg/kg 
b.wt/day BHT when compared to control values. Both control groups at time points 4 and 
7 have similar levels of activities which would indicate that peak constitutive levels had been 
reached and that the aging animal maintains this basal level.
FIGURE 30a ETHYLM ORPHINE N-DEMETHYLASE ACTIVITY
(Relative to control values)
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FIGURE 30b ETHYLMORPHINE N-DEMETHYLASE ACTIVITY
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Figures 30a and 30b represent the mean END activity in the liver microsomal fraction from 
male rats fed unadulterated diet (control) or BHT at a dose of 250mg/kg b.wt/day (high) up
to 22 months post weaning. These high dose group animals had been exposed to BHT in
utero at 500mg/kg b.wt. fed to the dam. Mean +/- sem, n and statistical analysis are presented 
on table 22.
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TABLE 22 ENZYMES INVOLVED IN XENOBIOTIC METABOLISM.
TIME POINT 4 5 6 7
6 months post 
weaning
11 months post 
weaning
16 months post 
weaning
22 months post 
weaning
BHT Dose 
(mg/kg/day)
GLUTATHIONE S-TRANSFERASE: jimoles/min/mg cytosolic protein
0 0.434 ± 0.016 [51 1.275 ± 0.115 [10] 1.081 ± 0.047 [10] 1.527 ± 0.124 [10]
25 0.480 ± 0.027 [5] 1.520 ± 0.159 [8] 
(119)
1.218 i  0.058 [9] 
(113)
L535 ± 0.096 [13] 
(100)
100 0.597 ± 0.030 [5] 
(137) ***
1.735 ± 0.185 [8] 
(H O *
1.471 ± 0.041 [9] 
(136) ***
1.994 ± 0.118 [11] 1 
(131) ** i
250a 0.692 ± 0.033 [4] 
(159) ***
1.995 ± 0.183 [10] 
(157)
2.059 ± 0.099 [13] 
(190) ***
2.432 ± 0.164 [19] 
(159) ***
EPOXIDE HYDROLASE ; nmoies/min/mg microsomal protein
0 5.450 -  0.419 [5] 11.288 ± 2.604 [10] 7.39 ± 0.339 [10] 10.757 ± 2.405 [10] j
25 13.268 ± 1.566 [5] 
(118)
13.130 ± 1.580 [8] 
(134)
13.065 ± 2.341 [9] 13.594 ± 2.740 [13] 
(126)
100 10.994 ± 1.488 [5] 
(202)*
15-510 ± 3.483 [8] 
(137)
12.830 ± 0.768 [9] 
(173) ***
15.734 ± 1.761 [11] 
(146)
250a 13.957 -  1.949 [4] 
(256) -
26.967 ± 4.242 [10] 
(239) **
17.029 ± 1.490 [13] 
(230) ***
27.884 ± 6.533 [19] 
(259) *
[] Number of animals per group ( ) % of Control 
* Significantly different from control ? < 0.05 , * * P <  0.01, *** P ^ 0.001 
Results are presented as mean ± sem.
a Time point 1 and 2 - dams were fed 500mg BHT /kg b.wt/day
Only 4 animals in group treated with 250mg BHT /kg b.wt/day as one animal died post pump insertion.
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TABLE 22. ENZYMES INVOLVED IN XENOBIOTIC METABOLISM (Continued).
TIME POINT 4 5 6 7
6 months post 
weaning
11 months post 
weaning
16 months post 
weaning
22 months post 
weaning
BHT Dose 
(mg/kg/day)
TOTAL CYTOCHROME P450: nmoles/ mg microsomal protein
0 0.76 ±0.03 [5] 0.78 ±0.08 [10] 0.66 ± 0.05 [10] 0.71 ±0 .07  [10]
25 0.76 ±0.05 [5] 
(100)
0.76 ±0.05 [8] 
OW)
0.59 ±0.08 [9] 
ÜG)
039 ±0.05 [13] 
C%)
100 0.73 ±0.03 [5] 
0%)
0.89 ±0.06 [8] 
(114)
0.64 ±0.05 [9] 
(97)
0.74 ±0 .12  [11] 
(102)
250a 0.76 ±0.12 [4] 
(100)
0.99 ±0.04 [10] 
(127) *
0.88 ±0 .04  [13] 
(134) *
1.14 ±0 .30  [19] 
(159)
ETHOXYRES CRU FIN 0-DEETHYLASE : pmoles/ min/ mg microsomal protein
0 14.69 ±2.57 [5] 936 ±1.49 [10] 7.99 ±0.43 [10] 9.01 ±1 .75  [10]
25 13.03 ±2.01 [5] 
(89)
10.32 ±1.20 [8] 
(108)
833 ±1.11 [9] 
(107)
11.73 ± 2 .9 4  [13] 
(130)
100 20.70 ±2.45 [5] 11.20 ± 1.83 [8] 9.03 ± 033 [9]
(141) (117) (113) (123)
11.07 ± 2 .04  [11]
250a 15.47 ±0.79 [4] 
(105)
11.80 ±0.98 [10] 9.92 ±0.89 [13] 13.02 ± 4 3 2  [19] 
(124) (124) (145)
PENTOXYRESORUFIN-O-DEPENTYLASE : pmoles/ min /mg microsomal protein
0 12.75 ±1.51 [5] 20.95 ±3.63 [10] 9.37 ±0.99 [10] 3.34 ± 0 .55  [10]
25 19.74 ± 5 J1 [5] 32.90 ±6.14 [8]
(155) (157) (64:
5.99 ± 0 3 6  [64] 4.67 ± 1.12 [13] 
** (140)
100 312.46 ± 57.08 [5] 
(2451) ***
165.05 ± 55.77 [8] 81.13 ± 19.91 [9] 50.55 ± 10.08 [11] 
(788) ** (866) *** (1512) ***
250a 391.28 ± 36.72 [4] 
(3069) ***
589.64 ± 36.08 [10] ■ 
(2815) ***
264 ± 34.91 [13] 253.08 ±93.23[19] 
(2819) *** (7567) **
ETHYLMORPHINE N-DEMETHYLASE : nmoles/ min/ mg microsomal protein
0 4.167 ± 0.131 [4] Not Assayed Not Assayed 4.324 ± 1.238 [5]
250 , 3363 ± 0.404 [4] 
(81)
Not Assayed Mot Assayed 3.280 ± 0.508 [5] 
CO
[ ] Number of animals per group. ( ) % of Control.
* Significantly different from control, P^ 0.05, ** P< 0.01, *** P^ 0.001 
Results are presented as mean ± sem.
a : Time point 1 and 2 -dams were fed 500mg BHT /kg b.wt/day.
Only 4 animals in group treated with 250mg BHT /kg b.wt./day as one animal died post pump insertion.
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7.11.3 Gel Electrophoresis of the Microsomal Proteins.
Photograph B shows the electrophoretic separation of the microsomal proteins from both 
control and high dose BHT treated animals from 6 months post weaning (time point 4 ) to 
22 months post weaning (time point 7). Lane 1 shows a range of molecular weight markers 
from 66kda to 24kda, lane 2 positive control microsomes from animals treated with 3 
consecutive i.p. injections of phenobarbitone (80mg/kg b.wt). 4 distinct dark staining bands 
are present in the positive control lane. Band 1 has an apparent molecular weight of 
54.95KDa which is very close to the reported molecular weight of the major phenobarbitone 
induced isoenzymes i.e. 55KDa and may correspond to CYP2B1/OT2B2 isoforms. Band 2 
has a molecular weight of 51.3KDa which may be the male specinc CYP2C isoform which 
has been reported to have a m.wt. of 51KDa and a 16a hydroxylase activity towards 
testosterone. Bands 3 and 4 have m.wts. of 46.8KDa and 45.7KDa respectively which 
indicates that they are possibly also P450s.
Lanes 3 and 4 are proteins from control animals and high dose BHT fed animals (250mg/kg
b.wt.) 6 months post weaning, time point 4 respectively. The darkest staining bands are in the
molecular weight range of the P450s, the 4 darkest labelled a, b, y and o. The bands have
apparent molecular weights of 57KDa, 50KDa, 49KDa and 47KDa respectively for both
controls (lane 3) and BHT fed (lane 4). The photograph shows that the a, b and o bands are
darker in the BHT animals than in the controls suggesting increased protein concentration and
therefore induction. The male specific P450 (CYP2C) may be band b, although its molecular
weight as determined by its electrophoretic mobility is 50KDa and not 51KDA. One
difference to note between the positive control lane (2) and lanes 3 and 4 is the lack of a
band corresponding to the major PB inducible P450 isoenzyme, the a band in both these lanes
having a molecular weight of 57KDa. Either BHT does not induce the same isoenzymes of
P450 as Phenobarbitone or there is an inconsistency m the running of the gel. Two minor
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forms induced by PB have been reported to have molecular weights of 56KDa (P450 PB-6) 
and 57.7KDa (P450 PB-2b).
Lanes 5 and 6 are control microsomes and BHT microsomes from animals at time point 5, 
11 months post weaning. Again, the 4 major bands have m.wts. as those in lanes 3 and 4 and 
again BHT treatment causes an apparent increase in the levels of these proteins as evidenced 
by darker staining. There does not appear to be any difference in staining intensity between 
BHT animals 6 months post weaning and BHT animals 11 months post weaning.
Lanes 7 and 8 again show greater induction of putative P450 enzymes in lane 8 ( 250mg 
BHT) compared to control lane 7. Both lanes appear to be less stained at this time point (6, 
16 months post weaning) than previous time points which could suggest either a drop in 
protein levels with age or poorly staining samples.
Lanes 9 and 10 are animals 22 months post weaning both controls and BHT fed respectively. 
As in earlier time points BHT treatment appears to cause an induction of proteins which have 
molecular weights in the P450 range when compared to PB positive control samples. These 
lanes may show a decreased staining compared to earlier time points.
These findings are confirmation of the P450 enzyme induction found in the fluorometric 
assays of EROD and PROD and also in the induction profiles of the various other microsomal 
enzyme activities examined. Specific isoenzyme identmcation can be achieved by employing 
antibodies raised to the various P450s of interest.
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PHOTOGRAPH B. SDSPAGE of MICROSOMAL PROTEINS.
B 1 2 3  4 5 6  7 8 9  10.
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Lane 1 : Molecular weight markers (66KDa -24KDa) 40/>ils/lane.
Lane 2: Phenobarbitone (PB) induced microsomes (80mg/kg body weight/day) 25/.ils/lane. 
Lane 3: Time point 4 (Control) 6 months post weaning. 25jLcls/lane,
Lane 4: Time point 4 (250mg/kg b.wt BHT) 6 months post weaning. 25//ls/lane.
Lane 5; Time point 5 (Control) 11 months post weaning. 25jLtls/lane.
Lane 6: Time point 5 (250mg/kg b.wt BHT) 11 months post weaning. 25/tls/lane.
Lane 7: Time point 6 (Control) 16 months post weaning, 25jnls/lane.
Lane 8: Time point 6 (250mg/kg b.wt BHT) 16 weeks post weaning. 25/xls/lane.
Lane 9: Time point 7 (Control) 22 months post weaning. 25jt>tls/lane.
Lane 10: Time point 7 (250mg/kg b.wt BHT) 22 months post weaning. 25/ds/lane.
AU microsomal samples were dUuted in sample buffer such that 1ml contained Img of 
microsomal protein.
145
7.11.4. Immunological Identification of Induced Cytochrome P450 Isoenzymes.
It was intended to further identify which isoforms from which family were preferentially 
induced by BHT feeding and to monitor how this induction profile altered with time in the 
aging animal. However, as detailed in section 7.7.4 all gels were blotted at the same time 
using the same equipment and therefore no data is available with regards to specific 
isoenzyme induction. This technique could have resolved the question of whether or not BHT 
induces the same P450s as Phenobarbitone or a different spectrum of proteins. It would also 
have made clearer the induction of C Y PlA l as found with the increase in EROD activity if 
the CY PlA l antibody had been used in the blot. It is thought that this induction is minimal 
and reflects substrate overlao between the different isoforms and not a C Y PlA l inducer.
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7.11.5 Cell Proliferation as Measured by BromoDeoxiuridine Incorporation.
The effect of BHT on liver cell proliferation was monitored in animals at time points 4, 5 and 
6. Due to the unscheduled deaths of some of the animals post pump insertion, it was felt that 
time point 7 animals would not be examined as loss would have greatly altered the numbers 
to be examined for altered hepatic foci at the end of the study. A minimum of 1000 S-phase 
cells per section were examined for each dose group per time poinn 
No effect was seen at any dose level throughout the duration of the study when compared to 
control values (Data not shown).
7.11.6 Serum Biochemistry
1. Thrombotest
The Thrombotest was not carried out at any time point in this study since the results from the 
earlier aborted study clearly showed that BHT had no effect on clotting ability at these doses.
2. Total Thyroxine
Total thyroxine levels (TTJ were measured in the serum form animals at time points 6 and
7, 16 and 22 months post weaning respectively. A dose related increase in thyroid
hyperactivity was seen histologically with doses of lOOmg BHT/kg b.wt and above. Table
indicates that there was no difference in the concentration of total thyroxine in any of the
dose groups compared to controls, nor was there any significant change with time.
T A B ^  23 THYROXINE MEASUREMENT_____________
Total senim thyroxine levels (mean)
BUT dose 16 monûis 22 months
(mg/kg/day) (ng/l) (ng/l)
Ô 43.15+323 38.16i2.72
25 36.94±4.16 36.62±2.97
100 39.44±3.40 36.11 ±4.63
250 43.75±5.92 43.66±2.03
Table 23 represents the mean total T4 concentration in the serum of male rats fed BHT upto 
16 and 22 months post weaning. Numbers (n)= 10 con, 9 low, 9 mid & 13 high : 16 months 
post weaning and 10 con, 13 low, 11 mid and 19 high 22 months post weaning.
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CONCLUSIONS
The continued feeding of BHT to the adult male rat, previously exposed in utero and up to 
22 months post weaning had no effect on health or food consumption when examined at 
various time points. Animals receiving 250mg BHT /kg b.wt./day remained lighter than all 
other groups despite gaining similar amounts of weight on a weekly basis. These high dose 
group animals had increased liver to body weight ratios at autopsy, and showed liver 
hyperplasia. No morphological changes to any of the major organs, at any of the 4 time points 
could be attributed to BHT treatment. BHT produced a dose related proliferation of the 
smooth endoplasmic reticulum and hyperactivity of the thyroid gland both of which 
progressed in severity with age. The highest dose of BHT did appear to cause an increase in 
the number of basophilic altered hepatic foci at time point 7 (22 months post weaning), this 
was not noted at any other time point, and also an increase in the periportal activity of gamma 
glutamyltranspeptidase, a histochemical marker used to further identity A.H.F. There was also 
an increase in the number of nodules identified which were only present at this level in the 
250mg/kg BHT dose group at time point 7.
Biochemically, BHT did not produce evidence of significant hepatotoxicity at any time point 
but did induce various microsomal enzymes, especially those involved in the metabolism and 
excretion of xenobiotics. This induction pattern did not alter appreciably with age, with the 
exception of Ethoxyresorufin o-deethylase activity which showed a decrease with time. BHT 
reduced the activity of Ethylmorphine N-demethylase in the mature and aging rat, an activity 
which may indirectly reflect inverse growth hormone levels. This could indicate that 
compared to the control animals BHT treated animals still have high levels of growth 
hormone in maturity. BHT did not result in cell proliferation at any dose group nor at any 
time point.
148
SECTION 4.
7.12 A SUMMARY OF THE FINDINGS OF THE EARLIER/FIRST BHT STUDY.
As noted in the opening paragraph of the materials and methods section, an identical study 
to the one reported was prematurely terminated due to heat stress which occurred between
I
16 and 22 months post weaning. The following is a short summary of the results obtained 
in that earlier study and the readers attention wül be drawn to any major differences both. 
The study which has been reported in this thesis will be termed Study A and the terminated 
study, Study B.
The most striking difference occurred in the early stages where the number of litters 
produced in Study A was approximately 50% of those in Study B (See table 24). This finding 
was believed to be a biological aberration and not due to either BHT or the conditions m 
which the FO generation were kept.
TABLE 24 A COMPARISON of LITTE R  NUMBERS in STUDY A and STUDY B. 
STUDY A
Num ber of Pups/L itter
M ean SEM No of litters
Control 10.2 0.7 20
Low 10.7 0.7 23
Mid 11.0 0.8 24
High 10.5 0.7 19
STUDY B
N um ber of Pups/L itter
M ean SEM No of litters
Control 11.29 0.8 45
Low 10.97 1.1 41
Mid 11.16 0.8 39
High 9.86 1.2 35
These litters had been exposed in utero to BHT at doses of 25mg (low), lOOmg (mid) and 
500mg (high) which were fed to both Fo males and females prior to and throughout mating.
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Tables 25 and 26 show the mean weight of the entire number of litters per group at birth and 
the mean body weight of each pup at the time of litter reduction, respectively. These have 
been included to show that similar weight ranges were achieved in both studies per dose 
group, the high dose group appearing to have a decreased mean body weight per litter. This 
may be accounted for by the fact that fewer pups were bom per litter in this dose group 
compared to others and therefore had a lower mean body weight. However, table 26 shows 
that at the time of reduction (6 days post birth), the mean body weight of the high dose group 
pups was lower than all other groups.
TABLE 25 A COMPARISON OF MEAN ENTIRE LITTER  W EIGHTS AT BERTH, 
STUDY A
Control
Low
Mid
High
M ean Body 
W eight (g)
74.42
71.52
73.78
64.50
SEM
3.90
4.97
3.59
3.65
Number of litters
19 
22 
24
20 _L
STUDY B
M ean Body 
W eight (g)
SEM N um ber of litte rs
Control 71.31 6.95 45
Low 73.67 2.75 41
Mid 71.15 1.95 39
High 65.77 2.67 35
These litters were bom to dams that had been fed BHT at dose of 25mg (low), lOOmg (mid) 
and 500mg (high) prior to and through out mating with similarly dosed males.
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TABLE 26 A COMPARISON of MEAN INDIVIDUAL PUP W EIGHT 6 DAYS
_____________POST PARTUM
STUDY A
Mean Body 
W eight (g)
SEM Number of litters*
Control 13.2 0.54 20
Low 13.9 0.55 23
Mid 13.1 0.39 23
High 11.6 0.49 20
STUDY B
M ean Body 
W eight (g)
SEM Num ber of litters
Control 12.26 0.47 38
Low 13.02 0.39 35
Mid 12.88 0.52 38
High 12.04 0.40 34
Table 27 clearly shows that in both studies the mean body weights of the high dose group 
animals was lower than all other groups at weaning. This suggests that this is not a chance 
finding and may be related to BHT treatment of the dams.
TABLE 27 A COMPARISON of MEAN INDIVIDUAL BODY W EIGHTS at W EANING 
STUDY A
M ean Body 
W eight (g)
SEM Num ber of litters*
Control 52.55 1.34 20
Low 53.47 1.14 23
Mid 52.71 1.14 21
High 41.43 1.46 20
STUDY B
Mean Body 
W eight (g)
SEM Num ber of litters*
Control 53.67 1.47 32
Low 54.84 1.57 31
Mid 54.48 1.53 29
High 44.36 1.71 31 ,
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Table 28 shows the mean body weights, liver weights and liver to body weight ratios of the 
animals through out study B, the aborted study. This has been included to allow the reader 
to compare how the animals gained weight in both studies and to confirm that the lower body 
weights of the high dose group animals was found in both studies.
TABLE 28 BODY and LIVER W EIGHTS of the F I GENERATION AT AUTOPSY
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Biochemical analysis altered in study A from study B (the aborted study) by the substitution 
of Benzphetamine N-demethylase with Pentoxyresorutin o-depentylase (o-dealkylase), the 
latter being shown to be a much more sensitive and specific marker for induction of the 
mixed function oxidase activity carried out by the CYP2B sub family (table 29).
The reader’s attention is drawn to the fact that in both studies, total cytochrome P450 activity 
could not be measured in the 20th day of gestation fetal liver, despite changing the 
microsomal preparation conditions in study A. Both the pH and the concentration of Trizma 
base were altered as was the homogenisation procedure. A second point to note is the 
difference in glucose 6-phosphatase activities obtained at time points 1, 2 and 3 in both 
studies (table 30). Study A has higher activities at time point 1 which can be attributed to the 
more accurate dating of fetuses in study A compared to study B. G6Pase activity is known 
to develop and be highly expressed at birth, i.e. 21 days of gestation. It was felt, 
retrospectively, that the fetuses in study B were on average 19th day of gestation which could 
account for the low activity. Time point 3 results can not be so easily explained. The control 
animals of study A had approximately 50% of the activity of the animals in the aborted study 
at the same time point. This result may be a technical error in the assay, however the trend 
in both studies is the same.
Due to the early termination of the study, no reliable information with regards to the detection 
of altered hepatic foci and numbers could be gathered.
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TABLE 29 ENZYMES INVOLVED in XENOBIOTIC METABOLISM - STUDY B
Time Point
BHT dose 
(mg/kg/day)
1^
(20th day 
gestation)
2^
(at weaning)
3
(4 weeks 
post weaning)
4
(6 months 
post weaning)
6
(16 months 
post weaning)
Total Cytochrome P450: nmole/ms microsomal orotein
0 ND 0.657=0.056 0.881=0.086 0.567±0.029 0.937=0.'041(10)
25 ND 0.724=0.048 0.742±0.032 0.563±0.018 0.829=0.035(11)
100 ND 0.724m0.053 0.740=0.037 0.589=0.018 0.998=0.125(9)
250^ ND 0.812=0.039 0.866=0.061 0.701=0.025* 0.919=0.072(10)
n 5 7 10
Benznhetamine N-deme±vlase: nmohmin/ms microsomal orotein
0 ND 4.583=0.570 13.640±1.441 10.207=0.695 Not Assaved
25 ND 5.343±0.469 10.800+0.828 9.615±0=09 Not Assaved
100 ND 9.272=0.950* 10.610±1.037 10.021±0.493 Not Assaved
250^ ND 11.439±1.694* 14.150=1.410 11.413+0.534 Not Assayed
n 5 7 10
Ethoxvresorufin 0-deethvlase: nmole/min/ms microsomal orotein
0 ND 12.430=22239 8.905=12236 2.447=02295 7.610±1.010(10)
25 ND 15.306±2.143 13.043=1.102* 3.327±0.309 8.460±1.140(11)
100 ND 29.911=7 J57* 12.311±0.951* 3.424+0.237* 7.880=3.990(9)
250^ ND 24.132=2.235* 13.127=1.647* 32223±0.312 7.140='3.710(10)
n 5 7 10
Glutathione S-transferase: nmoles/min/mz cvtosolic nrotein
0 0.187±0.025 0.947=0.102 1.730±0.105 1229±0.059 1.040=3.070(10)
25 0.226=0.023 0.999=0.067 1.887±0.096 1.329=0.049 1.180=0.070(11)
100 0.195±0.009 1.066=0.064 2.481+0.137* - 1.446±0.092 1.380=32:00(9)
250^ 0.212=0.010 2.034=0.291* 2.740±0.129* 1.792+0.076* 1.180=3.034(10)
n 5 5 7 10
* Signiiîcandy different from control (P<0.05).
Results are presented as meaniSEM . T he n u m b e r  (n) per dose ^oup for time points 1-4 is 
given at the base of each table. T he number (n) per oose group in time point 6 is given in 
parenthesis.
^ = Pups from dams treated with 500mg,d<g,/day BHT.
ND = Activity of enzyme too low to be detected.
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TABLE 29 Continued.
Time Point
BHT dose 
(mglkglday)
(20th day 
gestation)
2^
(at weaning)
3
(4 weeks 
post weaning)
(6 months 
post weaning)
(16 months 
post weaning)
Eooxide Hvdrolase activity: nmol/min/mg microsomal protein
0
25
100
250^
1.645±0.470 3.476+0.835 7.468+1.218
1.372±0.237 4.738±0.908 8.931±0.924
1.252±0.257 5.669+1.049 11.069+0.995*
1.321+0.178 12.813+2.051* 14.604+1.697*
8.149±1.385
11.027±1.760
14.020=2.703
18.263±3.056*
10
12.470db0.950(10)
15.890±0.860(11)*
23.640±2.360(9)*
24.480+1.160(10)*
Pentoxvresorufin-O-dealkviase: pmol/min/mg
0
25
100
250^
6.73±0.140(10)
67.58155.510(11) 
95.63±25.360(9)* 
389.60±53.640(10)*
* Signincandy different from control (P<0.05).
Results are presented as mean ±SEM. The number (n) per dose ^oup for time points ^  1-4 is 
given at the" base of each table. The number (n) per dose group in time point 6 is given in 
parenthesis.
 ^ = Pups from dams treated with 500mg/kg/day BHT.
cp = Pentoxyresorufin 0-deaIkyIase was assayed at Time Point 6 only.
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TABLE 30 ENZYMES USED as INDICATORS of HEPATOTOXICITY - STLDY B
Time Point
BHT dose 
(mg/kg/day)
1^
(20 th day 
gestation)
2^
(at weaning)
3
(4 weeks 
post weaning)
4
(6 months 
post weaning)
6
(16 months 
post weaning)
Glucose 6-ohosnhatase: nmoles/min/'mz homozenate orotein
0 2.425=0.746 47.74014.200 60.19015.950 56.72013.390 23.10514.430(10)
25 2.59010.357 46.73013.690 61.30016.670 54.41013.370 2029012.340(11)
100 1.41810.083 - 39.10013.850 45.29013.410* 45.36013.270* 18.78012.400(9)
250^ 2.04210.133 36.90013.440 43.63012.650* 43.55013.620* 16.86011.780(10)
Total glutathione: umoies/mz cvtosolic orotein
0 0.06410.005 0.15210.012 0.13010.008 0.12310.007 0.10010.C07(10)
25 0.06510.008 0.12810.017 0.11110.008 0.12110.015 0.10510.005(11)
100 0.07410.005 0.16510.020 0.11410.013 0.12710.012 0.08510.':07(9)
250^ 0.07210.008 0.13110.012 0.09610.007* 0.07810.008* 0.07010.006(10)*
n 5 5 10 10
* Signincantiy different from control (P<0.05).
Results are presented as mean ±SEM. The number (n) per dose group tor time points 1-4 is 
given at the base of the table. The number (n) per dose group in time point 6 is given m 
parenthesis.
a _= Pups from dams treated with cCOmgdcg/day BHT.
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TABLES 31a and 31b show the Thyroxine levels in animals at time points 5 and 6 and 
Thrombotest results measured in aU time points in study B. The reader should note that no 
biochemical examinations were conducted at time point 5 in the aborted study nor any at 
termination. These results have been included to show that there were no differences between 
studies in Thyroxine levels and also why the Thrombotest was not conducted in study A.
TABLES 31A AND 31B SERUM BIOCHEMISTRY.
TABLE 31A THYROXINE (TT4) LEVELS
Time Point
Dose
mglkglday
5
(ng/l)
6
(ng/l)
0 60.41±6.58 (15) 54.1812.61 (10)
25 54.69±3.75 (15) 49.2712.45 (11)
100 65.05±7.72 (14) 47.7213.68 ( 8)
250 6L32±3.90 (15) 58.9213.91 (10)
T.ABLE 31B THROMBOTEST
Time 1 2 3 4 6
Point (FO dams) (FI pups) (FI) (FI) (FI)
BHT dose
mglkglday
0 46.30011.470, 65.08012.840 81.50011.710 78.45011.540 64.75011.600(10)
25 51.75011.250 61.50012.910 80.96012.190 76.17011.640 67.73012.900(11)
100 5020012260 62.50012.640 79.73011.910 78.76011.440 68.83012.300(9)
250 —NT---- 61.60011.630 78.33011290 75.30011280 67.65012.900(10)
500 48.7511.13 — — NX— — NT— — NT— — NT—
n 5 5 15 15
— _ — - -------------- 1
Significantiy different P < 0.05.
n = No of samples per dose group. The number of samples assayed for Time Point 6 is given in 
( )
NT = Not tested as dose not employed in relevant part of study.
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CHAPTERS
î
DISCUSSION OF RESULTS
The aim of this study was to investigate why treatment of rats with high doses of BHT in a 
study carried out by Olsen et al (1986) should have resulted in an increase in liver tumours 
whüe single generation studies have given consistently negative results. In this study the 
hepatic changes in the F I generation were examined systematically at times prior to birth and 
then up to 22 months post weaning, in animals fed 25, 100 or 250mg/kg body weight/day 
BHT post weaning.
The results of this two generation feeding study have shown that the FI generation male rat, 
exposed in utero to 500mg and up to 22 months post weaning to 250mg/kg body weight/day 
BHT, had an increase in the number of eosmophihc altered hepatic foci and a statistically 
significant increase in basophilic altered hepatic foci at termination (time point 7). These 
animals were found to also have an increase in the number of nodules at 22 months post 
weaning compared to age-matched control animals. These nodules were not considered to be 
hyperplastic in the strictest sense as they were small in size and had an incomplete and id- 
defined ring of compression of the adjacent dver cords. Centrilobular enlargement of 
hepatocytes was a consistent finding in many of the high dose treated rats from 6 months to 
22 months post weaning. The hepatocytes showed clear indications of hypertrophy of the 
smooth endoplasmic reticulum, a finding confirmed by the sustained induction of some of the 
various isoenzymes of the cytochrome P450 dependant mixed function oxidases and other 
enzyme systems involved in xenobiotic metabolism. Electron microscope examination of 
livers from BHT treated animals taken at time point 3 (4 weeks post weanmg) in the 
first/earder study also confirmed this hypertrophy (Robens Institute, 1993).
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Pups bom to, and nursed by dams fed 500mg/kg body weight/day BHT, had consistently 
lower body weights than any other BHT dose group or age-matched controls, a phenomenon 
that persisted up to the termination of this study. The only other organ to exhibit changes 
with BHT treatment was the thyroid gland. A müd degree of hyperactivity, evidenced by 
depletion of colloid and alterations in follicular cells, was noted in both the lOOmg and 
250mg dose groups, this being most pronounced at 22 months post weaning in the highest 
dose group. No thyroid changes were seen at 25mg/kg body weight/day BHT.
Dams fed diets containing 500mg/kg body weight/day BHT prior to and throughout 
pregnancy and lactation exhibited hepatomegaly that was greater than that induced by 
pregnancy alone. They also showed induction of enzymes involved in xenobiotic metabolism 
and signs of hepatotoxicity as indicated by reduced glutathione levels and glucose-6- 
phosphatase activities.
These findings wül now be discussed in relation to how they compare with the results of 
Olsen et al (1986), with the results of single generation studies and also with respect to the 
mechanism of action of BHT in hepatocarcinogenesis.
Liver histopathology
The histopathological changes observed in this study were consistent with that of Olsen et 
al (1986). No tumours were seen in the present study which was terminated at 91 weeks. 
This is consistent with Olsen’s study where tumours were only seen in animals more than 115 
weeks old. However, preneoplastic changes were seen in the current study; basophilic altered 
hepatic foci (AHF) and nodules were found at 22 months post weaning only (time point 7) 
in the 250mg/kg body weight/day BHT group. These were found to be statisticaUy significant 
and probably due to BHT. Olsen reported that "basophüic adenomas were seen occasionaUy, 
but eosinophilic adenomas predominated. "
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As discussed in the introductory chapter, the presence and characterisation of AHF is 
generally believed to be a good marker as to the possibility of future tumour production. 
Their morphology, histochemical staining properties, number, phenotype, time of appearance 
and most importantly the volume of the liver occupied by the total number of AHF are all 
factors taken into consideration when evaluating the carcinogenic potential of a substance. 
However, not aU AHF wül progress to malignant tumours (Peraino et al, 1984) whüe some 
believe that their presence is an unrelated paraUel event to tumorigenesis. The eosinophilic 
AHF identified at 16 and 22 months post weaning, in rats fed diets of lOOmg/kg body weight 
BHT and above, were not found to be statisticaUy significant and, in any case, such foci do 
not appear to be directly connected to the development of cancer (GangoUi et al, 1987).
In this study AHF were demonstrated both by standard haematoxyhn and eosin staining and 
immunohistochemical staining. The three glucose 6-phosphatase (G6Pase) deficient foci found 
at the highest dose at 22 months post weaning (time point 7) were thought likely to be due 
to BHT treatment. Their low incidence, smaU size and lateness of appearance are in strong 
contrast to the G6Pase deficient AHF induced by genotoxic agents (Pitot, 1990). There was 
considerable staining of aü portal tracts for gamma glutamyl transpeptidase (gGT) in aü 
samples which made identification of gGT positive foci difficult. It is not clear whether the 
two gGT positive AHF found in the high dose group animals at time point 5 and the single 
focus found at each of the three dose levels at time point 7 are Hkely to be due to treatment. 
The ceUs of the basophüic AHF, which were only found in the 250mg dose group at 22 
months post weaning, were described by the pathologist as "simüar in size to the normal 
hepatocytes" (Robens Institute, 1993). These were not believed to have the same significance 
as the smaU basophüic AHF seen in mice, which are generaUy thought to be precursors to 
tumour development (GangoUi et al 1987). The six nodules that were only present in the aged
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animal fed 250mg/kg body weight/day BHT, were described as being "small with an 
incomplete and ül-defined ring of compression of adjacent Hver cords." They were, 
therefore, not thought to be hyperplastic nodules and subsequently regarded as an "area 
change", a variant of AHF. (Greaves, 1990). AHF or area changes of this type may 
represent a parallel but unrelated event to tumour development, rather than an early stage of 
the neoplastic process but their appearance could act as a marker for tumour development. 
Thus, the histology data suggests that tumours, as found by Olsen, would not have been 
found if the study had been extended to 104 weeks. It is not known whether continuing BHT 
feeding upto three years would have resulted in an increase in the incidence of tumours. In 
Olsen’s study more treated animals survived to 144 weeks of age than control animals, ( 44% 
males, 39% females : 250mg /kg body weight/day BHT compared to 16% males and 17% 
females : controls) and Hver tumours were only reported in rats more than 115 weeks old. 
This would suggest that BHT had a beneficial effect in the animals and that their longevity 
could be a major factor in tumour incidence.
Pitot (Pitot, 1977) has presented a review on the relationship between ageing and 
carcinogenesis and has shown that neoplasia increases with survival time. It would appear 
that, since BHT has been shown to be non-genotoxic in many studies (Bomhard et al 1992) 
and also not to be carcinogenic in many one generation feeding studies (Deichmann et al 
1955, NCI 1979, Hirose et al 1981, WiUiams et al, 1990 ) then the tumours in Olsen’s study 
must have arisen by a non-genotoxic mechanism in the second generation animal. BHT may 
then be considered to be a promoter of hepatocarcinogenesis in these studies, m the second 
generation animal exposed to high doses over a chronic period. Indeed BHT’s role in the 
enhancement of the development of AHF has been demonstrated by Maeura, (Maeura et al 
1984).
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Gross Observations On The FI Generation.
Results from both this study and the earlier study (Robens Institute 1993), showed that aU 
dose groups produced pups with similar birth weights, but at the time of reduction of the 
litter number to eight pups per dam, six days post partum, those pups suckled by dams 
receiving a nominal 500mg/kg body weight/day BHT had a significantly reduced body weight 
compared to controls and the other dose groups. Although BHT did not cause teratogenic 
effects or effects on fertility, it was found that there was a dose related trend towards an 
increase in the number of pups/Utter found dead or dying before reduction at day six but the 
actual number of deaths m affected litters was not found to be influenced by BHT treatment. 
In a dose ranging study (Robens Institute, 1990) it was found that an decrease in weight gain 
occurred in pups from dams treated with 500mg or more BHT when the litter size was below 
eight. This would strongly suggest that the pups from the high dose group dams were either 
not receiving enough mük or the milk was of a poorer nutritional quality (this wül be 
discussed in greater detaü later). This faüure to attain the same body mass as control pups 
bom at the same time was the most evident physiological observation to persist throughout 
the duration of the study. This fiuiding was also observed in Olsen’s experiment (1986). 
Meyer and Hansen (1980) showed that m their study the reduced body weight observed at 
weanmg was associated with a delay m development, but that there was no permanent 
impairment. This observation would be consistent with a müd impairment of nutrition during 
weaning. No effects on body weight gain were found in a one generation rat feeding study 
with 0.1% BHT in the diet for 16 weeks (Gaunt et al, 1965). These results would suggest 
that some event occuring during the period between birth and weaning, plays a critical role 
in the developmental effects seen in the pups fed by high dose BHT treated dams. The only 
difference noted between this study and the earher study was that the mid dose group animals
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in this study also exhibited a reduced body weight gain which was not seen in the earlier 
study. Whether this developmental effect is due solely to BHT from the milk is still unclear. 
Snell et al, (1977) also showed a retardation in body weight gain occurred in postnatal rats 
exposed in utero to methylmercury, the effect persisting beyond weaning as found in this 
study. Similarly, Spyker (1975) observed a retardation of body growth during postnatal 
development in mice also exposed to methylmercury at low doses in utero. These studies wül 
be discussed later with regard to their proposed mechanism behind this growth retardation 
and that apparently caused by BHT.
In this study, aU BHT treated animals receiving doses of lOOmg/kg body weight/day and 
above, had increased hver:body weight ratios which were evident from 21 days post-partum 
untü 22 months post weaning. This is a consistent finding in BHT studies (Gübert et al, 1965 
and 1969, Gaunt et al, 1965). This increased ratio is probably more reflective of the lower 
body weights rather than an increase in absolute hver weights, which tended to be simüar 
to control values at the appropriate age of development. In the earher study (Robens Institute, 
1993), a shght increase in absolute hver weight was noted in the high dose group animals 
compared to controls, although this was only statisticahy significant at time point 7. 
However, when expressed in terms of body weight, the 250mg/kg body weight/day BHT 
treated group had larger hvers than their mass would have suggested. This would indicate 
that despite the negative effects on body weight, the hver was being stimulated to enlarge; 
a work hypertrophy most probably in response to the presence of BHT. This is confirmed 
by the induction of hepatic total CYP450 activity and specific isoenzymes. (This wü be 
discussed later).
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Many workers have shown liver enlargement in rats treated with BHT (see Gilbert et al 
1965) and have shown it to be a well defined response by the liver to a variety of exogenous 
compounds resulting in an increase in liver weight and an increase in the activity of 
"processing enzymes". Hence in conclusion, the only gross or histopathological differences 
observed between the rats treated with BHT over two generations or in a single generation 
study is the reduced weight gain in weaning observed in the former group.
Effects of BHT Dose on Developmental Changes in Liver Biofhpmistry.
The effect that BHT had on the development of the liver in terms of biochemical function 
was determined by the examination of various key enzymes. (This was not determined in 
Olsen’s study). These were divided into indicators of hepatotoxicity; Glucose 6-phosphatase 
(G6Pase) and total Glutathione (GSH) and enzymes used as markers of microsomal enzyme 
induction e.g. the cytochrome P450 dependant mixed function oxidase system ( m.f.o). 
Effects of Age and  BHT Dose on G6Pase Activity.
G6Pase is an enzyme whose activity is known to be highly expressed around the time of 
birth, (Snell, 1981) and is vitally important in carbohydrate metabolism. The results differed 
between the two studies. In the second study this activity could be measured in foetal livers 
assayed on the estimated 20th day of gestation. There appeared to be a dose related increase 
in activity which would indicate that BHT may be reaching the foetus and inducing this 
enzyme. BHT has been reported to cross the placental barrier and been shown to be secreted 
in rat mük (Me Martin et al 1979). In the earüer BHT study (Robens Institute, 1993) a 
different pattern of enzyme activity was noted. No dose related effects could be identified and 
the mean absolute activities were low. This may reflect the fact that these livers were from 
a mixture of (estimated) 19th and 20th day of gestation foetuses, some of which may not 
have fuUy expressed activity. In the repeat study reported here, more accurate dating of the
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foetuses was achieved and hence higher absolute activities. If  a chemical produced a toxic 
effect in the liver by disrupting the endoplasmic reticulum, with which G6Pase is associated, 
then a decrease in G6Pase activity could result either as a direct result of damage or because 
of the need to retain glucose in the hver (Feuer et al 1965). Histological examination of liver 
sections taken at the estimated 20th day of gestation did not show any difference between 
control or BHT exposed foetuses. There was no difference in glycogen levels or appearance 
and hence no damage to the developing hepatocytes. As mentioned earlier, Snell et al (1977) 
and Spyker (1975) both showed retardation in body weight gain in postnatal rats and mice 
exposed in utero to methylmercury. Methylmercury was found to produce a prolonged 
decrease in G6Pase activity and a decrease in hepatic glycogen levels in the F I offspring, 
which resulted in the animals becoming and remaining hypoglycaemic. This neonatal 
hypoglycaemia is a natural transient event brought about at birth when the maternal supply 
of free glucose is abruptly stopped. In normal circumstances this is corrected in the neonate 
both by the breakdown of hver glycogen stores and hepatic gluconeogenesis, events largely 
under the control of the pancreatic hormones, glucagon and insuhn whose blood 
concentrations change in a reciprocal fashion at birth.
In this study with BHT, the hver of the weanhng animal sthl showed an increase in G6Pase 
in the highest two dose groups, although these were not statisticahy significant. By four 
weeks post weaning only the high dose group (250mg/kg body weight/day BHT) continued 
to show increases over control values, both low and mid dose groups showing a drop in 
activity. These decreases were not statisticahy significant, nor were they thought to represent 
signs of hepatotoxicity as they were within control values. From time point 5(11 months post 
weaning) to time point 7 (22 months post weaning) ah dose groups showed a decrease in 
G6Pase activity by approximately 20%, this only being statisticahy significant in the mid
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dose group at time point 7. From the evidence so far, BHT does not appear to have 
decreased the levels of G6Pase or hepatic glycogen to those that would render either the 
foetus or weanling rat hypoglycaemic.
Thus BHT does not appear to bring about a retardation in the developmental growth of the 
neonate as methylmercury does by decreasing the hepatic levels of G6Pase. Thus some other 
factor must be responsible for this effect in this study.
Effects of Age and BHT Dose on Total Glutathione Levels
Total glutathione (GSH) is a measure of both reduced and oxidised glutathione in the hver. 
It is the major free thiol in the cytoplasm and its principal role is to combine with activated 
metabohtes decreasing covalent protein binding and protecting the hver from the possibhity 
of serious injury. Thus, any depletion of the glutathione pool would pose serious problems 
to the hver’s detoxification system. The results from this study showed the high dose group 
animals had consistently lower GSH levels than controls from time point 1 (estimated 20th 
day of gestation) to time point 5 (11 months post weaning) in both experiments, the decrease 
in activity only being statisticahy significant at time point 5 in the second experiment and 
time points 2-5 in the first experiment. These results would suggest that BHT was being 
actively metabohsed by the hver, but the presence of high doses of BHT has overwhelmed 
the hver’s detoxification system and greatly reduced the levels of GSH. The results would 
also indicate the presence of active intermediates of BHT in the hver and that the hvers of 
high dose group animals at 11 months post weaning were under considerable stress, 
especiahy when considered m conjunction with the lower G6Pase activities seen at the same 
time point. Both low and mid dose groups had similar GSH levels to controls over the same 
time points, with the exception of time point 4 where ah BHT fed animals showed a 10-18 % 
fah in activity compared to controls. From 16 months post weaning unth 22 months post
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weaning, the levels of GSH in the high dose group animals did not show any difference from 
control values. These results would indicate that up to 11 months post weaning, the 
metabolism of BHT resulted in decreases in total glutathione levels, leaving the liver open 
to the possibility of attack from electrophilic species. A similar observation on GSH levels 
was reported by Nakagawa et al (1986) in a one generation study, and other workers have 
suggested that overwhelming the normal detoxification pathways of BHT could result in 
reactive intermediaries, such as a quinone methide, substantially reducing the GSH pool 
(Takahashi et al, 1983). In this study the Hver appears to have restored its GSH pool by 16 
months post weaning, being able to cope easily with the removal of BHT.
Although BHT treatment did not produce severe toxicity to the Hver as it developed from the 
foetus to 22 months post weaning, it did cause depletion in the GSH levels in addition to 
altering the levels of G6Pase. There was no evidence in either the 20th day of gestation 
foetuses or weanHngs, that BHT per se adversely affected carbohydrate metaboHsm, thus the 
retarded weight gain seen 21 days post partum must have been as a result of events outside 
the uterus i.e. post birth.
Effects of Age and BHT Dose on Glutathione S-Transferase Activity.
Glutathione-S-transferases (GSTs) are famüies of cytosoHc and microsomal proteins with 
different substrate specificities and inducabüity profiles. They are responsible for the 
conjugation of glutathione with reactive/activated metaboHtes, making them more water 
soluble and hence facHitating in their elimination (Habig et al, 1974). MetaboHsm studies 
conducted in the rat have shown that glutathione conjugation via the GSTs is an important 
mode of BHT excretion (Golder et al 1962, Daniel et al 1965, Tye et al 1965). The results 
of this study, which employed a substrate of aU the major forms of rat Hver microsomal 
GSTs i.e. l-chloro-2,4 ,dinitrobenzene (CDNB), showed that GST activity towards this
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substrate was induced in a dose dependant manner at all time points, with the exception of 
time point 1 where the activity was the same in treated animals as in controls. Thus it would 
appear that GSTs are detectable in the 20th day of gestation liver but that BHT does not 
appear to induce the major forms of this family of proteins in the foetus. The induction of 
G6Pase activity found at time point 1 would indicate that BHT (and/or its metabolites) may 
be reaching the foetal liver, so it can be assumed that the GST results obtained at this time 
point are a true reflection of the non inducabUity of foetal GSTs by BHT. Time points 2-7 
showed clear dose dependant induction of GST, greatest absolute activity being found in the 
250mg/kg body weight/day (high) dose group animals at time point 7 (termination). These 
findings are consistent with the results of the earlier/first study and also with the results of 
other workers who have shown that phenol and its metabolites, covalently bind to and 
activate the microsomal glutathione s-transferase(s) which use CDNB as a substrate. Since 
BHT is a phenolic antioxidant then it is not unexpected to obtain results that show it to 
induce microsomal GSTs (Morgenstem et al 1987).
The Importance of the Hepatic Microsomal Cytochrome P450 Isoenzymes,
As discussed in chapter 2 of this thesis, much work has been conducted into the induction 
properties of BHT with respect to the cytochrome P450 (CYP450) dependant mixed function 
oxidases (MFO) (Gilbert et al 1965 and 1969, Crampton et al 1977 and Powell et al 1986). 
Although the importance of this detoxification process has already been discussed, it is worth 
while emphasising that if a chemical induces particular isoenzymes of the CYP450 families 
i.e C Y PlA l, it could result in the activation of carcinogens to their proximate or ultimate 
carcinogenic form. Powell et al (1986) have shown that changes in hepatic activating and 
detoxifying enzyme profiles are implicated m both the mechanism of periportal hepatocyte 
damage and in the change of site of damage according to dose and duration of BHT
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treatment. In the uninduced liver, most of the Cytochrome P450 isoenzymes are present at 
their highest concentrations in the centrilobular hepatocytes (Powell et al 1984) thus 
metaboHsm would take place at this site. However, alterations in the isoenzyme profile via 
induction or inhibition of various cytochrome P450s, could lead to periportal hepatocyte 
damage (PoweU et al, 1991).
This is an example of how alterations in the CYP450 isoenzyme profile can lead to the 
production of toxic metaboHtes at inappropriate sites, resulting in ceU damage.
No previous study has examined the induction profile of the CYP450s with BHT over the 
majority of an animals life span. In the two generation BHT feeding study carried out by 
Olsen (1986) no CYP450 measurements appear to have been conducted.
It could be postulated that if  BHT does alter the phase I and phase n  detoxification pathways, 
then the metaboHc fate of both BHT and endogenous substances may be changed. Instead of 
eliminating metabohtes, they may remain in the Hver for longer periods than normal and also 
at higher concentrations than normal, increasing the possibiHty of damage. Also, a shift in 
the isoenzyme profile of the cytochrome P450s may result in the production of inappropriate 
metabohtes which could, in a compromised system with decreased glutathione levels, produce 
hepatotoxic effects, which could themselves be precursors to tumour formation (Grasso and 
Hinton, 1991). Thus the induction profiles of two of the major isoenzymes of the CYP450 
famüies, i.e. C Y PlA l and CYP2B1/2B2 were monitored to see how the levels change with 
age and with BHT feeding. The C Y PlA l isoform, which is a member of the CYPl famüy 
is classicaUy induced by 3 MethylCholanthrene (3MC) and has been shown to be the isoform 
responsible for the metaboHc activation of carcinogens (e.g. aromatic amines, poly cyclic 
aromatic hydrocarbons) to their ultimate carcinogenic form (loannides and Parke, 1987). The 
CYP2B1/2B2 isoforms are members of the CYP2 famüy inducible by Phenobarbitone (PB).
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These two isoforms possess distinctly different substrate binding sites (Phillipson et al, 1984) 
and exhibit marked differences in substrate specificity (Burke and Mayer, 1983), so that they 
often play contrasting roles in the metaboHsm of drugs and chemical carcinogens to their 
reactive intermediates (loannides and Parke, 1987 and 1989). The isoform(s) induced by 
BHT WÜ1 be discussed subsequently, but it is first nesseccary to outline the developmental 
expression of the CYP450s before BHT’s effect on this system is presented.
Developmental Expression of Various P450 Isoenzymes.
Lum et al, (1985) have examined the foetal and neonatal development of both of these 
isoenzymes up to 14 weeks of age, in the F I generation offspring bom to control or 3MC 
treated Fo generation rat dams. Ethoxyresorufin-o-deethylation (EROD) was used as a 
marker enzyme for C Y PlA l activity, whilst the N-demethylation of Benzphetamine was used 
to monitor CYP2B1/2B2 activity. The authors found EROD activity was highest in the 1-2 
week old animals and then decreased with age. The inducibüity of EROD by 3MC was low 
in young animals but increased with age. Benzphetamine N-demethylation was low in the 
control animal at birth but increased with age and was not induced by 3MC. In the foetal 
Hver, EROD was the only activity present at higher levels than in the maternal Hver. The 
authors concluded that C Y PlA l activity may be the predominant hepatic form in the foetuses 
and neonate but CYP2B1/2B2 becomes a major form as the animal develops. Total CYP450 
levels in control animals were low at birth but increased rapidly reaching adult levels in 
about four weeks post birth. 3MC administration caused a sHght increase in total P450 
content, which was statisticahy significant only in the 8 week old animals.
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Effects of Age and Dose of BHT on P450 Isoenzyme Profile. Foetuses.
The results of the foetal Hver samples (time point 1) wHl be considered fuHy before the 
results from the other time points are discussed.
The results of this study with BHT showed that no total P450 activity could be detected in 
the Hvers from the foetuses at the 20th day of gestation. Both in this study and in the earHer 
study (Robens Institute, 1993), no EROD activity could be detected despite modifications to 
the homogenisation buffer in the second study so that it was identical to that used by Lum 
et al (1985). Pentoxyresorufin-o-depentylase (PROD) activity was used to monitor 
CYP2B1/2B2 activity in this study instead of Benzphetamine-N-demethylase which was used 
in the earHer study, as it was shown that PROD was a much more specific assay for these 
isoforms. Again, no PROD activity could be detected in the foetal Hvers and similarly no 
Benzphetamine-N-demethylase activity could be detected m the earHer study. The difference 
in results between the experiment of Lum et al (1985) and those obtained here could be 
explained by the fact that in this experiment the majority of foetuses were 20th day of 
gestation whilst the foetuses in Lum’s experiment were 21/22 days of gestation. The 
appearance of cytochrome P450 mediated xenobiotic biotransformation in foetal Hver has 
been correlated with the development of the smooth endoplasmic reticulum which does not 
appear in foetal Hver of most laboratory rodents untü the end of gestation (Manson, 1986). 
These results would indicate that at the estimated 20th day of gestation, C Y PlA l and 
CYP2B1/2B2 are not expressed but by the end of gestation, 24-48 hours later, the activity 
of C Y PlA l may be detectable. SDS-PAGE of the Hvers from 20th day of gestation foetuses 
showed that two bands, with molecular weights in the range of the cytochrome P450s were 
present. They corresponded with bands seen in phenobarbitone (PB) induced Hvers and were 
present in aU of the experimental samples through out the animals development. However,
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there were obviously bands missing from the foetal livers, which could be clearly detected 
in the positive PB treated animal as well as in the older animal. It is not clear whether or not 
these "missing" bands correspond to the CYPIA and CYP2B isoforms. However, from the 
lack of detectable enzyme activity and from the lack of bands on SDSPAGE compared to the 
positive control sample, it is possible to say that BHT does not appear to induce either 
C Y PlA l or CYP2B1/2B2 isoforms in the liver of the 20th day of gestation foetuses in this 
study.
Detectable P450 Activities in Foetal Liver.
Confirmation that xenobiotic detoxification systems do exist in foetal liver is obtained by the 
measurement of Glutathione S-transferase (GST) and the measurement in some animals of 
Epoxide Hydrolase. GST activity shows a slight, non significant decrease in the high dose 
group foetuses whilst no clear picture can be obtained from the Epoxide Hydrolase results 
as there was considerable variability in activity between samples from the same dose group. 
One cytochrome P450 isoform that was detectable in the foetal Hver was that associated with 
Ethyhnorphine N-demethylase (END) activity. This activity has been shown to be associated 
with the CYP3A famüy, the hepatic levels of which are known to be strictly regulated by the 
pituitary, through growth hormone (Lemoine et al, 1988).
Effect of BHT Feeding on Levels of CYP3A in the Foetus.
The results showed that Ethylmorphine-N-Demethylase (END) activity was detectable in the 
foetal Hvers at day 20 of gestation and that foetuses from the high dose group had 
approximately only 33 % of END activity present in the control animals. This would suggest 
that there was an inhibition of CYP3A expression in the foetuses from BHT fed dams, 
indicating that BHT and/or its metabohtes may have reached the foetuses in high enough 
concentrations to cause this inhibition. Alternatively, since high growth hormone levels have
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been associated with decreased expression of CYP3A and therefore decreased ethyhnorphine- 
N-demethylase activity, then this apparent inhibition may due to high levels of growth 
hormone, either foetal or maternal. Low levels of growth hormone have been associated with 
increased expression of CYP3A protein in rat hver (Lemoine et al, 1988). Barnett et al 
(1993) have also shown that Streptozotocin treatment of male rats, which rendered them 
diabetic, resulted in an increase in END activity and also an increase in CYP3A protein, as 
measured by immunoblot analysis. It is also of interest to note that insulin-dependent diabetes 
is characterised by low circulating levels of growth hormone, due to impaired release, and 
also by increased CYP3A protein levels (Barnett et al 1993). This activity was monitored as 
an indirect measurement of growth hormone because of the failure of the pups bom to and 
suckled by dams receiving 500mg/kg b.wt./day BHT to gain weight.
No suggestion that the animals were diabetic should be taken from the previous text as none 
of the classical signs associated with diabetes, i.e. hyperphagia or polydipsia were noted in 
this study. The only "symptom" that both diabetes and BHT treatment had in common was 
depressed body weight gain. It was felt that perhaps monitoring this activity would give some 
indication as to why these animals failed to develop as quickly as age matched controls and 
also what effect BHT had on this activity and this family of cytochromes.
Evidence has been pubhshed regarding the unexpected suppressing effect of growth hormone 
on the expression of phenobarbitone inducible P450s (Yamazoe et al, 1987). Since BHT has 
been shown to induce a similar profile of CYP450 isoenzymes to phenobarbitone, then it 
could be postulated that the inhibition of END activity found in this study and the associated 
inhibition of the CYP3A isoform, may indeed be due to high growth hormone levels. The 
results would suggest that the foetuses from high dose BHT fed dams had higher levels of 
growth hormone at day 20 of gestation than age-matched control foetuses. Dannan et al
173
(1983) have shown that the induction of CYP3A is commonly coordinately induced with the 
CYP2B1 isoform. If this is the case, then it would be further confirmation that the lack of 
detectable PROD activity in this study at time point 1 was a true result, as there was no 
measurable induction of either CYP2B1/2B2 proteins on SDSPAGE or in the enzyme activity 
(END) associated with the CYP3A family.
Effects of Age and  Dose of BHT on CYP450 Isoenzyme Profiles. W eanling to Aged R at. 
Examination of the induction by BHT of total cytochrome P450 and the C Y PlA l and 
CYP2B1/2B2 isoforms at time points 2-7 showed that total cytochrome P450 was 
significantly increased in a dose dependant manner at 21 days post partum. At 4 weeks and 
6 months post weaning there was no difference from control values in any of the dose 
groups, whilst at 11, 16 and 22 months post weaning there was a statistically significant 
induction of total cytochrome P450 m the high dose group animals only.
DevelopmentaUy, the control values of this activity did not alter with age once adult levels 
had been reached, a finding consistent with other workers (Horbach et al 1992, Baird et al 
1975, Kato et al 1968) but in contrast with others (Me Martin et al 1980). Ethoxyresorufm-o- 
deethylase (EROD) activity showed dose dependant significant increases at 21 days post 
partum and 4 weeks post weaning. At 6 months post weaning only the mid dose group had 
increased EROD activity, whilst 11, 16 and 22 months post weaning only the high dose 
groups had increased EROD levels over controls. This activity tended towards a decline with 
age, again a finding confirmed by other workers (Lum et al 1985). Pentoxyresorufin-o- 
deethylase (PROD) activity showed dose related, statistically significant increases at all time 
points.
In this study this activity also tended to decrease in the older uninduced animal (16 months 
post weaning and older) but as in the experiment of Lum, PROD appeared to be the major
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form in the mature animal. Unlike EROD activity, PROD activity did not become less 
inducible in the older animal, in fact greatest percentage of induction over basal levels was 
seen in the 22 months post weaning animals (time point 7). Epoxide hydrolase also showed 
dose related increases in activity at all time points, confirming BHT’s ability to induce 
enzymes of xenobiotic metabolism. The control levels of epoxide hydrolase exhibited a 
plateaux in activity from 11 months post weaning up to 22 months post weaning. 
SDSPAGE showed that BHT treatment resulted in darker staining bands with apparent 
molecular weights in the range of the CYP450s, from 21 days post partum to termination 
indicating an increase in protein levels of some of the various P450s. These bands had 
similar but not identical molecular weights to the major bands induced in the phenobarbitone 
positive control sample. It is not clear whether the differences are due to either the induction 
of different CYP450s by both compounds or shghtly different migration times of the proteins 
in the gel matrix due to inconsistencies in the gel itself. However, it can be concluded that 
chronic BHT feeding results in the long term induction of enzymes involved in xenobiotic 
metabolism and in particular, due to the thousands of fold induction seen in PROD activity, 
appears to fall into the class of chemicals that induce CYP2B1/2B2 isoforms of the 
cytochrome-dependant mixed function oxidases i.e. Phenobarbitone type of inducers. This 
induction is confirmed ultrastructuraHy by proliferation of the s.e.r. and also enlargement of 
the centrilobular hepatocytes in the high dose group animals (as seen by e.m. examination). 
Although induction of EROD activity was also found, it was not of the same magnatutide as 
PROD nor that expected from a 3MC type of inducer. Thus, the isoenzyme profile of 
CYP450s in the ageing animal is similar to that seen in the weanling animal, with PROD 
being the dominant isoenzyme induced. There was no evidence of a decrease in the function 
of the cytochromes examined with age, as suggested by Me Martin et al (1980), nor was
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there a shift to the isoform that is associated with the metabolism of carcinogens to their 
ultimate carcinogenic form, i.e. the C Y PlA l isoform. Electron microscope examination of 
Hver sections taken at each developmental stage did not reveal any signs of progressive 
hepatocyte damage as seen by Powell et al, (1984) which would rule out the presence of 
reactive metabohtes of BHT in the Hver.
Effects of Age and BHT on CYP3A Activity (from weanling to mature animal).
Ethyhnorphine N-demethylase (END) activity was measured at time points 2, 3, 4 and 7 in 
the control and high dose group animals. At weaning (time point 2), END activity was 
significantly increased in the BHT treated animals, 375% of control values. This would 
indicate that at this time point BHT treatment induced the CYP3A family associated with this 
N-demethylation of ethyhnorphine. This would also suggest that these animals possibly had 
low growth hormone levels, since low growth hormone levels have been associated with an 
increased expression of CYP3A activity (Lemoine et al, 1988).
It can not be confirmed from this study, whether or not the observed increase in 
ethyhnorphine N-demethylase activity is soley due to BHT induction of the CYP3A family 
or is in conjunction with low circulating growth hormone levels. Indeed the proposed low 
growth hormone levels may be as a consequence of BHT’s induction of hepatic metaboHsm 
and hence increased inactivation and clearance of growth hormone. What can be said is that 
BHT or its metabohtes appear to be reaching these animals via the maternal mHk as this is 
the only route of exposure to the compound at this time, just prior to the animals being 
weaned onto the BHT diets.
The possibiHty also exists that the effect on growth hormone levels may be as a consequence 
of maternal suckling i.e the dams may not be responding to the stimulus for mHk let down 
from the pups or may not be producing enough quaHty mHk, and so the pups have a reduced
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growth rate and reduced growth hormone levels due to malnutrition. It could be that the milk 
of the 500mg/kg b.wt/day BHT dose group dams contained high concentrations of BHT that 
altered directly or indirectly the levels of growth hormone. It seems unlikely that toxic levels 
of BHT were passed in the mük, as it has been shown that although some BHT does 
accumulate in the body fat (Tye et al 1965) and hence could be passed into mük, most BHT 
is eliminated within 4 days, leaving approximately only 10% in the tissues (Daniel et al 
1967). However, it can not be categoricaUy stated that the concentration of BHT in the mük 
from the high dose group dams was not high enough to cause these changes, or indeed that 
any BHT was in the mük as it was not possible to obtain enough mük to analyse for BHT 
content. Since the PROD activities are significantly increased in a dose dependant manner 
in the animals at time point 2, then it can be concluded that some BHT must have passed to 
the pups either during in utero exposure or be present in the milk. Olsen et al (1986) and 
Meyer and Hanson (1980) both confirm that BHT is secreted in rat mük.
By 4 weeks post weaning the BHT fed animals had decreased END levels compared to 
controls (71%), a decrease that was also found at 6 months (81%) and 22 months (76%) post 
weaning. Again if the premise is true about low END activity indicating high growth 
hormone levels, then this would confirm that from 4 months post weaning onwards these 
BHT fed animals have possibly higher growth hormone levels than age matched controls. It 
could be suggested that the levels seen in these older animals at this time point are those 
expected in younger animals, i.e. there has been a delay/shift in development in the treated 
animals. This could partiaUy explain the longevity found in Olsen’s study (1986).
BHT in the diets at 4 weeks post partum, 6 months and 22 months post weaning did not 
induce the CYP3A isoform as would have been expected, possibly due to either an 
antagonistic effect by high growth hormone levels at these time points or a switching from
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one isoform to another. DevelopmentaUy, this CYP450 isoenzyme appears to reach a peak 
4 weeks post weaning (time point 3) in the control animal and does not alter greatly from 6 
months to 22 months post weaning.
AU liver biochemistry results obtained are consistent with the treatment of a liver microsomal 
enzyme inducer (Powell et al, 1986, Botham et al 1970, Gübert et al 1969, Gübert & 
Golberg 1965) and there does not appear to be any difference in the pattern of isoenzyme 
induction with one or two generation exposure. None of the previous studies have examined 
CYP3A induction by BHT, thus it is not posible to comment on any differences between one 
and two generation exposure. Hepatic enlargement and increased mixed function oxidase 
enzyme activity are generally regarded as an adaptive response, but if maintained throughout 
the lifespan of the animal may contribute to the development of tumours (Grasso and Hinton, 
1991). In the rat, tumour development of this sort is usually a "late" phenomenon, only 
appearing in the aged animal (100-152 weeks of treatment). The tumours observed in Olsen’s 
study only appeared after 115 weeks of treatment, in a population of animals with an 
increased life expectancy.
In this study, no tumours were observed but nodules and AHF were seen from 11 months 
post weaning. These lesions were mainly found at termination of the study in the high dose 
group. A second possible explanation for tumour development in the study of Olsen may he 
m the retardation of weight gain in the pups from dams fed 500mg/kg body weight/day BHT. 
Thus, since none of the biochemical results of the F I generation can fuUy account for this 
retardation, the hver biochemistry of the Fo dams wUl be reviewed.
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Effects of Dose of BHT on Livers of NuUiparous Females and Pregnant Dams.
A comparison of liver biochemical parameters was carried out between three groups of 
females. Group 1 consisted of animals that had undergone lactation and had been fed 
500mg/kg body weight/day BHT prior to and through out pregnancy and lactation. Group 
2 consisted of animals that had not become pregnant (nuUiparous) and had also been fed 
500mg/kg body weight/day BHT for the same length of time as group 1. Group 3 consisted 
of animals that had been fed 500mg/kg body weight/day BHT through out pregnancy and 
lactation then fed control diet for 14 days after the end of lactation (termed reversed group). 
Each group had its own corresponding control group of females fed diets that did not contain 
added BHT. The results from group 1 and group 2 animals will be compared with each other 
in order to clarify the effects of both BHT feeding and BHT feeding in conjunction with 
pregnancy and lactation. The results from group 3 animals wül then be discussed as these 
serve to illustrate the point that the effects produced by BHT are essentially reversible. 
Throughout the gestational period both group 1 dams (control and BHT treated) had similar 
food consumption and body weights, the BHT fed dams having slightly higher body weights. 
It is worth noting that those BHT fed dams sacrificed at day 20 of gestation (time point 1 of 
main study) had increased Hver weights compared to controls, the greatest increase being 
seen in the 500mg/kg body weight group. There was also a dose related trend towards 
increased Hver; body weight ratios which would indicate that dietary administration of BHT 
resulted in hepatomegaly during gestation.
Effects on Bodv Weights and Liver Weights.
The results showed that group 1 animals (lactating) had increased body weights compared 
to group 2 animals (non-lactating) and that although no significant difference was noted, 
those animals fed a nominal 500mg/kg body weight/day BHT had higher terminal body
179
weights than their corresponding controls. There was a statistically significant increase in 
liver weight in both lactating BHT treated dams and in non-lactating BHT treated females 
over their controls. Those aniipals that had been pregnant had greater liver weights than those 
that had not. Thus it would appear that BHT treatment produces hepatomegaly and BHT 
treatment plus pregnancy/lactation results in greater hepatomegaly than BHT treatment alone. 
A similar pattern was seen in the liver:body weight ratios.
Effects of BHT Dose on Liver Biochemistry.
As in the F I generation animal various biochemical parameters were assessed in the Fo dams 
and nuUiparous females as indicators of hepatotoxicity and inducers of xenobiotic 
metabolism. The results showed that there was a statistically significant loss m G6Pase 
activity in those dams that had been fed BHT and undergone lactation (group 1 animals) 
when compared to their non BHT fed control dams and also when compared to both the 
control and BHT fed non-lactating animals (group 2). Those animals fed BHT but not having 
become pregnant also showed a decrease in G6Pase activity compared to their controls. 
These results would indicate that BHT treatment alone causes a depletion in G6Pase activity 
but BHT treatment plus lactation results in an exacerbation of this loss to values less than 
50% of controls. This would strongly suggest that the Hvers of these BHT fed dams were 
stressed, and also that carbohydrate metaboHsm was significantly decreased. Electron 
microscope examination of the Hvers showed a loss of glycogen in the BHT/lactatmg dams 
compared to lactating controls. If these alterations in G6Pase and glycogen stores were also 
present at the start of lactation then it would be possible to see a Hnk between decreased 
carbohydrate metaboHsm in the dams and under nourished pups i.e. reduced maternal free 
glucose available to the foetus.
Total Glutathione levels were statisticahy and significantly reduced in those dams that had
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been fed BHT and that had undergone lactation. The control group for these dams (i.e. 
control diet plus lactation) showed decreased GSH levels compared to both the BHT fed 
nuUiparous females (group 2), and their control diet fed nuUiparous controls. These results 
would indicate that lactation depletes the GSH pool whUst lactation in combination with BHT 
feeding dramaticaUy reduces the levels of this protective mechanism even further. Both the 
G6Pase and GSH results clearly show that the Uvers of these dams are under considerable 
metaboHc stress by the end of lactation and probably had been since the onset of lactation. 
Effects of BHT Dose on Xenobiotic M etabolism,
In terms of induction of enzymes involved in xenobiotic metaboHsm it is clear that BHT 
treated animals (groups 1 and 2) had significantly increased GST activities compared to their 
controls. Lactation produced a further increase in this activity which would indicate that both 
exogenous (BHT) and endogenous ( e.g.steroid hormones) factors induced the GST(s) 
responsible for conjugating them with glutathione, the levels of which were significantly 
decreased in the group 1 animals. The effect that BHT and lactation had on the cytochrome 
P450 dependent mixed function oxidases was monitored by measuring total P450, 
Ethoxyresorufin-o-deethylase and Pentoxyresorufin-o-depentylase activities. The results 
showed that BHT feeding produced statisticaHy significant increases m the amounts of total 
cytochrome P450 in the Hvers of both lactating and non-lactating animals compared to their 
controls (a two fold induction). However, the results would suggest that lactation has a sHght 
inhibitory effect on total P450 activity as those dams that had undergone lactation had lower 
values (group 1) than those animals that had not (group 2/nulHparous). The induction seen 
in both BHT fed groups is consistent with the proliferation of the smooth e.r. as seen at the 
e.m. level and also with the known action of BHT as an inducer of specific forms of the 
m.f.os. This specificity is seen m the induction profiles of C Y PlA l (as measured by EROD
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activity) and CYP2B1/2B2 (as measured by PROD activity). The results showed that BHT 
fed animals (groups 1 and 2 ) had lower EROD activities than their corresponding controls 
and that animals that had under gone lactation had 2 to 3 fold lower activity than those 
nuUiparous females. Again this would suggest that lactation had an inhibitory effect on the 
expression of C Y PlA l protein and hence lower EROD values. It is generally beUeved that 
the rates of most phase I and n  reactions are decreased during pregnancy in rats and that the 
decreased levels of monooxygenase activity can be attributed to decreased enzyme levels as 
well as to competitive inhibition by circulating steroids (Casarett and Doull, 1986). The 
results of this study partially confirm this. A quite different picture was seen with PROD 
activity which showed that BHT feeding resulted in thousands of fold induction in this 
activity and hence in the CYP2B1/2B2 isoforms. When BHT and lactation were considered 
together there was a further induction of PROD activity (two fold higher than BHT alone) 
which would suggest that lactation had a synergistic effect with BHT on the induction of this 
isoenzyme of P450.
Reversibility of Hepatic Changes.
The livers from those dams that had been fed diets containing a nominal 500mg/kg body 
weight/day BHT prior to and throughout pregnancy and lactation and then received control 
diet for 14 days post end of lactation (reversed group 3), were examined biochemically. 
There was no significant difference in body weight between "reversed" dams and their age- 
matched controls. These previously BHT fed dams did have increased liver weights and 
liver;body weight ratios compared to their controls, but these were not statistically 
significant. This increase was due to both pregnancy/lactation and the additional burden of 
BHT metabolism, a work load hypertrophy. Both sets of dams in this group had Uver weights 
and Uver:body weight ratios that were lower than those m group 1 dams (i.e. lactating
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controls and lactating BHT fed dams) but higher than group 2 females (i.e. non-lactating 
controls and non-lactating BHT fed females). This would indicate that the livers of the 
"reversed" and control dams ,were remodelling after the removal of BHT in the reversed 
dams and the demands of lactation in both groups of dams.
Glucose-6-phosphatase activity was, as in other BHT treated groups, lower than controls 
(85%) in the "reversed" dams. The controls had activities similar to control animals in 
groups 1 and 2, indicating that lactation alone had no effect on G6Pase activity. The 
"reversed" dams had the highest G6Pase activity of all treated groups, indicating that removal 
of both "stresses" resulted in the "normalisation" of the hver by 14 days post removal. 
Total glutathione (GSH) levels were slightly lower than controls (94%) but were not 
significantly different. These group 3 animals had the highest GSH levels of any group, the 
controls almost double the controls of groups 1 and 2. This would suggest that 14 days after 
the end of lactation the hvers of these dams were more metabohcaUy capable of removing 
the higher than normal levels of endogenous factors from the circulation. 
Glutathione-s-transferase levels were stiU induced in these "reversed" dams, 14 days after 
the removal of BHT from the diet at the end of lactation. This increase was not significant 
nor as great as BHT treated dams and females of groups 1 and 2. Again this would indicate 
that at this time, the hvers of the previously treated dams were now remodelhng to the 
reduced need to remove BHT and endogenous factors associated with lactation. The activity 
of GST m the reversed dams was similar to that measured in the non-lactating BHT treated 
dams of group 2, which would suggest that BHT was the prominent factor involved in 
induction. Total CYP450 levels showed a non-significant reduction (86%) in the reversed 
dams compared to controls, 14 days post lactation. This result suggests that the induction 
seen in both lactating and non-lactating BHT treated animals was due to BHT, as removal
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of BHT from the diet results in a decrease in activity. It also confirms the slight inhibitory 
effect by lactation on CYP450 levels. EROD activity showed no difference from control 
values, both of which were similar to group 1 levels (i.e. lactating BHT treated and lactating 
control fed dams). Similarly, PROD activity showed a return to control levels in the reversed 
dams, these being higher than both the control groups from groups 1 or 2.
Thus, it would appear that the induction of phase I and n  metabolism by BHT can be seen 
to reverse in the livers of the previously lactating animal by day 14 after removal. However, 
moderate damage is still present as indicated by a reduced G6Pase activity.
Possible Adverse Effects on Milk Production.
All of the previous biochemical and histological data indicates that during the lactational 
period, the livers of dams fed 500mg/kg body weight/ day BHT were under considerable 
metabolic stress. This would greatly affect the carbohydrate metaboHsm and hence the 
production of milk by the dams. In the rat, sugars and proteins are synthesised in the 
mammary gland from circulating glucose and amino-acids, so their production is Hkely to be 
affected only by locaUy acting toxins or malnutrition. It is quite conceivable however, that 
because of the metaboHc overload to the Hver, amino-acids may be required to sustain the 
Hver ceHs rather than be diverted to the mammary gland. Furthermore, the Hver produces 
approximately 50% of the fat content in the m ük under normal physiological conditions. In 
adverse situations, such as metaboHc overload, this amount of fat may be greatly reduced. 
There is thus considerable , albeit indirect, evidence that the weight deficit at weaning of the 
pups bom to BHT-treated dams is due to malnutrition and that this event could be partiaUy 
responsible for the development of tumours in the aged animal in Olsen’s study. For 
example, transient choHne deficiency in early life has been shown to increase Hver cancer
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in rats (Ghoshal et al, 1987). There is also evidence to suggest that food restriction results 
in depressed secretion of growth hormone (Armario et al 1987) which would correlate weU 
with the growth hormone results found in the weanling and the proposed mechanism of 
malnutrition.
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CONCLUSIONS.
It would appear that there are two, possibly three, contributing factors to the tumour 
development observed in the Olsen study (1986). The first one is the severe malnutrition 
during lactation brought about as a consequence of the conflicting demands on the dams’ 
hver to maintain its functionality under the conditions of pregnancy and BHT metabolism and 
also to produce milk of good nutritional quality for her pups. Faced with this dilemma, the 
physiological needs of the dam outweighed the demands for quality mük production, the mük 
that was produced not being adequate to maintain the growth rate of the pups in Une with 
those of the control pups.
The second factor is the chronic induction of the hepatic enzymes of the xenobiotic system 
with associated hepatomegaly and proliferation of the smooth endoplasmic reticulum. Many 
chemicals have been shown to result in neoplastic changes upon chronic administration whüst 
being devoid of genotoxic activity. As outlined in the introduction of this thesis, their 
mechanism of action has been shown to involve the sustained induction of enzymes of 
xenobiotic metabolism, proliferation of the smooth endoplasmic reticulum, and a work load 
hypertrophy progressing to hyperplasia via mitogenesis. This hyperplasia may or may not be 
associated with signs of overt hepatotoxicity which initiates rounds of ceU death and 
regeneration. This process may lead to neoplastic changes or tumours. A weU documented 
example of this mode of non-genotoxic carcinogenesis is seen with phenobarbitone. It would 
appear from the biochemistry and histology results that BHT may be acting m a simüar 
manner.
The third factor, which was less evident in this study than m Olsen’s was the longevity of 
the BHT fed animals. Again it is recognised that tumour production and ageing are related
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phenomena. BHT would appear to be a non-genotoxic promoter of carcinogenesis in the 
second generation rat exposed to high doses o f the chemical in utero and subsequently 
through out the majority of its,lifespan. Its action as an inducer of the enzymes of the hepatic 
xenobiotic system coupled with the early life stress of malnutrition probably accounts for, 
and could have been predicted to result in, the increased incidence of adenomas and 
carcinomas in the aged animal m the study conducted by Olsen.
Currently BHT is being re-evaluated with respect to the temporary acceptable daily intake 
(ADI) set by the Joint Expert Committee on Food Additives (JECFA) in 1991 at 0.125mg/kg 
body weight/day (approximately equivalent to 8.75mg/adult). Based on the biochemical and 
histopathological changes in the liver, the histopathology of the kidneys, thyroids and 
adrenals, a no observable adverse effect level (NOAEL) of 25mg/kg body weight/day BHT 
was established. Applying a safety factor of 100, an ADI of 0.25mg/kg body weight for BHT 
would seem a more realistic figure (double the current ADI).
With regard to the reported hepatocarcinogenic action of BHT seen in the second generation 
rat, it seems uhhkely that any carcinogenic risk exists to man, since the conditions under 
which the tumours were produced (i.e. chronic administration of high doses of BHT) are 
unhl^ey to occur.
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APPENDIX 1
A SUMMARY OF THE FINDINGS FR O M  A DOSE RANGING EXPERIM ENT FO R 
A TW O GENERATION STUDY ON TH E EFFECTS O F DIETARYADM INISTRATION 
O F BHT TO RATS.
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ATMS OF STUDY
To determine the maximum dietary dose of butylated hydroxytoluene (BHT) tolerated 
by female rats exposed prior to and throughout pregnancy, and by pups similarly exposed 
in utero and until weaning. ^
ANIMALS and DIETARY ADMINISTRATION OF BHT and MATING.
Eight, eight week old male and sixty-four, four week old female Wistar albino rats , 
purchased from Bantin and Kingman Ltd. (HuU, U .K.) and of defined microbial status, 
were examined upon receipt and assigned to treatment groups and weighed. Four 
treatment groups were set up, each comprised three males and sixteen females. After a 
three week acclimatisation period the groups received the following diets:
Group A : Unadulterated CRM diet ( Controls )
Group B : CRM diet containing BHT to ensure an intake of 500mg/kg b.wt./day.
Group C : CRM diet containing BHT to ensure an intake of 750mg/kg b.wt./day.
Group D : CRM diet containing BHT to ensure an intake of lOOOmg/kg b.wt./day.
Rats were weighed weekly and food consumption measured on a weekly basis. The 
dietary concentration of BHT required was calculated using data obtained for the 
previous week. After three weeks , one treated male was allowed access to eight females 
that had been exposed to the same level o f BHT. When palpation confirmed that a 
female rat was pregnant, the animal was housed singly, whilst still being exposed to the 
same level of BHT as previously.
RESULTS
1. Effects of BHT on weight gain, Food Consumption and General Condition prior to
Confirmation of Pregnancy.
The food consumption of the treated female animals was consistently higher than control 
animals from the fourth week of the study onwards. BHT had no statistically significant 
effects on body weight gain although a dose related trend towards reduced body weights 
was noted.(Data not presented). Males exhibited both a fall in food consumption and 
body weight gain during the first week o f dosing, however these changes did return to 
control levels. It was felt that this was not a toxic effect of BHT, but reflected the fact 
that older animals have an aversion to changes in diet palatability. AH animals remained 
in good health through out the study.
2. Mating Success of BHT Treated Male and Female Rats.
It was noted that successful mating occurred less frequently in rats treated with 
lOOOmg/kg b.wt. of BHT than in the other experimental groups.
3. Observations of Pregnant Female Rats.
There were no differences in the health or behaviour of BHT treated females when 
compared to controls. The weight gain during pregnancy followed the expected pattern 
except in those rats treated with 750 and lOOOmg/kg b.wt. BHT, where there appeared 
to be some inhibition of the weight gain normally shown in the last weeks of pregnancy. 
The concentration of BHT in the diet was not adjusted during pregnancy.
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4. Number and Condition of Pups at Birth.
There was no statistically significant differences between litter number or litter weight 
when pups bom to control dams were compared with pups bom  from sires and dams 
treated with BHT. There did appear to be a dose related trend towards reduced litter 
size and a reduced average vjeight of pups was noted in the pups from the dams treated 
with 750mg/kg of BHT.
5. Condition of Rats During Lactation.
Both control dams and low and mid dose group dams remained in good health through 
out lactation, but the high dose group dams were markedly lighter than aU other groups. 
Pup development appeared to be retarded in all dose groups compared to controls and 
some high dose animals were cold to the touch in the third week of life. Food 
consumption rose in aU groups during lactation, this increase being less marked in the 
treated groups. There was also noted a dose related inhibition of weight gain during 
pregnancy.
7. Condition of Rats at Weaning.
The only differences noted between the dams at the end of weaning were the lighter 
body weights of the high dose group dams which at autopsy showed little fat around the 
body wall, kidneys and adrenals as would be expected in the lactating animal.
The pups of control dams were well developed. Pups from dams treated with the lowest 
dose of BHT were markedly stunted in their growth but their fur condition was good and 
they were active and exploratory. Pups from both mid and high dose treated dams were 
severely stunted, showed poor fur condition and were markedly less active than pups 
from other groups. No malformations were noted in any group but pups in the mid and 
high dose groups showed a disproportionate development of the head as compared with 
the rest of the body. This is expected when growth is inhibited to the extent found in this 
study. No cross fostering was carried out to increase the litter number to eight, and in 
some cases pups died after reduction of the litters to eight. It was noted that in the BHT 
treated animals, where the litter size was less than eight, the average pup weight was 
generally considerably greater.
CONCLUSIONS
The results indicate that administration of BHT at doses up to lOOOmg/kg body 
weight/day has no effect on the overall health of either adult male or adult female rats, 
although there was marked hepatomegaly in the dams. More matings were required in 
the lOOOmg/kg dose group animals to achieve the desired number o f pregnancies. No 
similar effect was found when test males (lOOOmg/kg) were mated with control females, 
suggesting that at lOOOmg/kg/day BHT has an effect on the receptiveness or fertility of 
female rats. The pregnancies of control and 500mg/kg b.wt/day dosed animals proceeded 
normally but the two higher dose groups showed a reduced weight gain in the last week 
of pregnancy. As there was only a small, statistically insignificant reduction in overall 
litter weight it would appear likely that the effect on maternal weight gain reflected 
reduced fat deposition or some similar effect.
All doses of BHT caused a marked inhibition of the post-natal weight gain of pups. 
Three weeks after birth the pups of dams receiving the two higher doses of BHT were 
emaciated and some pups from high dosed dams were killed on humamtanan grounds. 
The effect appeared to be associated with poor mhk production rather than BHT
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toxicity, firstly because generally pups of smaller than normal litters were significantly 
heavier than those in the normally sized litters and secondly, because the pups showed 
no increase in liver w e ig h t, even on a body weight basis. As the dams remained healthy 
and were not significantly lighter in weight than controls, except the lOOOmg/kg dose 
group, it was concluded that the postulated reduction in m hk production is due to some 
specific effect of BHT rather than to an overall effect on the dams condition. The livers 
of the dams were greatly enlarged, being over two-times the weight, on a body weight 
basis, o f non-lactating rats of this age. This liver enlargement is known to be associated 
with induction of microsomal drug metabolising enzymes and in the pregnant and 
lactating rat further enlargement is believed to be due to the increased synthesis of 
serum lipoproteins needed to support m hk formation. It is possible that the livers of 
BHT treated dams are unable to meet the simultaneous demands for synthesis of the
smooth endoplasmic reticulum, for drug metabolising enzymes, as weU as rough
endoplasmic reticulum, for apolipoprotein synthesis, and that as a result lipid cannot be 
exported to the mammary glands at the speed needed to maintain pup growth.
The pups o f dams treated with 750 or lOOOmg/kg/day BHT seem to be permanently 
damaged and would be quite inappropriate to use these doses. The reduction of pup
weight in  rats treated with 500mg/kg/day of BHT in our study is almost identical to that
found by Olsen et al (1986) and we would recommend that this dose be used in the main 
experiment.
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APPENDIX 2
PREPARATION OF TISSUES FOR LIGHT and ELECTRON 
MICROSCOPE EXAMINATION.
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METHODS
A. LIGHT MICROSCOPY SAMPLES
1. Samples are removed from the 10% neutral buffered formalin after a period of 
approximately one week and placed into a plastic processing cassette. The cassettes are 
then placed into the stainless steel basket which is then placed into the reaction chamber 
of the "Histokinet. "
2. The samples are gradually taken from one chamber to the next, through various 
increasing
concentrations of alcohols, industrial methylated spirit (IMS) and finally into xylene.
3. The cassettes are removed from the Histokinet and embedded into hot paraffin wax.
4. The paraffin wax blocks are cooled down on the ice tray of the embedding station. 
Sections of approximately 5 microns are then cut from them using a microtome.
5. The sections are then floated out on a warm water bath and allowed to flatten.
6. The sections are then picked up onto a microscope slide, dried in an oven and are 
stained with haematoxyhn and eosin.
B. ELECTRON MICROSCOPY SAMPLES
1. Samples taken at autopsy were placed in 4% gluteraldehyde with O.IM cacodylate 
buffer: H N 03, ph 7.4 for 4-6 hours.
2. At the end of fixation time the tissue is washed in cacodylate buffer (O.IM) for at least 
1 hour and no more than 18 hours.
3. The tissues are then counterfixed in 2% buffered osmic acid/O.lM cacodylate NH03, 
ph 7.4 for two hours at room temperature. Approximately 1ml is required to fix material 
from 1 slice of Hver. For larger amounts of tissue increase in proportion.
4. Dehydrate by using the following solutions. Each solution should be left in contact 
with the tissue for at least 10 minutes.
25 % v/v Ethanol x2 changes
50% \7v
75% v/v
90% Wv
100% \Vv
Tissues can now be left overnight if required.
Propylene oxide/Absolute ethanol 1:1 x l change
Propylene oxide x2 changes
1 9 3
5. The tissue blocks are then covered with a 1:1 mixture of propylene oxide and Epon 
812 resin. This is left for periods ranging from 20 minutes to four hours depending on 
the resin type.
6. Small blocks of tissue are transferred using a plastic pasteur pipette to resin tilled 
capsules. 2-3 blocks per capsule is sufficient. The surface of the resin should be stirred 
slightly to ensure blocks do not float.
7. Polymerise resin for 48 hours at 60o or if  tissues had been left in the propylene 
oxide/Epon mix for 2 hours, then polymerisation should be carried out for 12 hours. 
The samples can then be processed for mounting on grids for electron microscope 
analysis, a technique not carried out by the author.
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APPENDIX 3
THE PREPARATION OF UNFIXED FROZEN SECTIONS 
FOR HISTOCHEMICAU EXAMINATION AND TWO EXAMPLES 
OF ENZYME ACTIVTTIES MONITORED.
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SUMMARY
Tissue sections are rapidly frozen in hexane cooled by immersion in a Cardice/ethanol 
freezing mixture. Sections are cut in a cryostat and transferred to slides. The preparation 
methods are optimised for histochemical localisation of enzyme activities.
METHOD
1. A chilling bath is prepared by the addition of small chips of sohd carbon dioxide to 
ethanol. The temperature must be monitored to ensure a constant temperature of-70oc.
2. A beaker containing 30-50ml of hexane is inserted into the bath, preferably through 
a close-fitting space in the lid. The temperature of the hexane should reach at least -65oc 
before it is used.
3. The tissue is cut into approximately 1cm cube in size, and dropped into the hexane 
without sticking to the sides of the glass beaker.
4. The specimen is left in the hexane for at least 30 secs and no longer than 2 mins prior 
to transfer into an appropriately precooled, labelled tube using cooled forceps.
5. Samples can either be stored at -80oc for several days or mounted into the cryostat 
and cut.
6. Sections of 8-lOu are cut and mounted onto microscope slides prior to histochemical 
staining.
STAINING FOR GAMMA-GLUTAMYLTRANSPEPTIDASE ACTIVITY
1.The sections of tissue as prepared above are immersed in CopHn jars containing 50mls 
of O.IM Tris-HCl, pH 7.2, 2.5ml of a 4mg/ml suspension of N-(y-L-glutamyl)-l- 
Naphthylamide monohydrate in acetone, 2.5ml of a 20mg/ml aqueous glycylglycine 
solution and 75mg of Fast Garnet GBC salt.
2. Blanks are also set up for each slide by omitting the N-(y-L-glutamyl)-l-naphthylamide 
monohydrate.
3. Incubation should be carried out at room temperature for 30 minutes.
4. The slides are then removed from the jars and rinsed in distilled water.
5. The nuclei may be counterstained with haematotoxylin.
6. The slides are then washed in distilled water for 5 mins prior to mounting in a suitable 
mountant (Aquamount).
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STAINING FOR GLUCOSE 6-PHOSPHATASE ACTIVITY.
1. The sections of tissue prepared as above are immersed in Coplin jars containing 50mls 
of 0.2MTris maleate buffer, pH 6.7,50mls of 0.125 % w/v of glucose-6-phosphate, 7.5mls 
of a 2% w/v solution of lead nitrate and 17.5mls of distilled water.
2. Mounted, unfixed cryostat sections are placed into the incubating medium at 37®c for 
5-20 minutes.
3. The slides are washed in distilled water for 2 minutes, 2 changes.
4. Sections are immersed in 1 % ammonium sulphide solution for 2 minutes.
5. A further wash in distilled water follows step 4.
6. Sections are fixed in 10% formaldehyde for 15-30 minutes.
7. A final wash in distilled water preceeds mounting of sections in glycerin jeUy.
8. Control sections for both acid and alkaline phosphatases should be employed as both 
may be demonstrated by this technique.
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APPENDIX 4
DEMONSTRATION OF BROMODEOXYURIDINE (BrDU) 
IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE
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The following is a summary of the method used by other workers and should not be 
assumed to be complete.
1. 4um thick sections of the, appropriate tissue are cut and mounted on poly-l-lysine 
coated slides at 60oc for 1 hour and dried down.
2. The slides are deparafinised and hydrated as follows :
2x zylene washes, 5 min per wash.
Ix 100% IMS (Industrial Methylated Spirit), 1 min per wash.
1x90% IMS, 1 min per wash.
1x70% IMS, 1 min per wash.
3. Endogenous peroxidase is blocked by incubating the slides in 0.3% hydrogen peroxide 
in absolute methanol at 20oc for 30 mins. This is followed by a 5 min wash under 
running tap water and a dip in distilled water.
4. The samples are then digested with Trypsin at 37oc for 30 mins, followed by a 5 min 
wash under running tap water.
5. The slides are then placed in 4M HCl for 15 mins at 60oc to hydrolyse the tissue. This 
is also followed by a 5 min wash under running tap water.
6. A further wash in O.IM Tris buffered saline, pH 7.6 for 5 mins preceeds removal of 
the slides which are left to drain on humidity racks.
7. The first antibody coupling is carried out using a 1:30 dilution of a mouse monoclonal 
antibody against BrDU. Tris buffered sahne is used. Incubation is allowed to proceed for 
1 hour at room temperature before 2x 3 mins washes in TBS.
8. The second antibody, a biotinylated rabbit anti-mouse antibody is diluted 1:300 with 
TBS and added to the slides for 1 hour at room temperature. 2x 3 min washes in TBS 
follow removal of the second antibody.
9. A third antibody which is linked to the chromatogen horse radish peroxidase enzyme 
is then incubated with the slides at room temperature for 1 hour. 2x 3 min washes then 
follow using TBS.
10. The substrate used to visualise this antibody complex is 3 ,3’ diaminobenzidine (1 
lOmg tablet/15mis of Tris buffer. 12uls of fresh hydrogen peroxide, 30%, is also added. 
Incubation occurs for 15 to 30 mins at room temperature. A final wash in tap water 
removes any unbound substrate.
11. The slides are then dehydrated through increasing concentrations of IMS (70%- 
100%), Imin/wash, followed by two washes in 100% Zylene, 2 mins/wash. The slides are 
mounted with DPX mountant and are ready to be scored for brown staining nuclei under 
the hght microscope.
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ADDENDUM
It should be noted that, a calculation error was found in the biochemistry results from 
animals at time point 4. As this did not come to light until after the tables and figures 
etc. had been prepared for binding it was felt that a note should be made of this error.
The Total Cytochrome P450 activity for three out of the five control livers assayed 
exhibited higher than expected values upon recalculation. The mean value obtained was 
1.24 ±  0.18nmoles/mg microsomal protein, which is almost double that activity expected 
for animals of this age i.e. 0 .70+  0.08.
These results were considered to be a biological variation and a statistical aberration but 
have been incorporated into the Robens Institute Report (1994).
The following figures and tables differ from the result presented in the Robens Institute 
Report (1994): Figures 26a, 26b, 27a, 27b, 28a, 28b and table 22.
No change to the overall pattern of enzyme induction or indeed to the conclusions drawn 
in this thesis resulted from this calculation error.
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